WO1999004794A1 - Cyclic amine modulators of chemokine receptor activity - Google Patents

Cyclic amine modulators of chemokine receptor activity Download PDF

Info

Publication number
WO1999004794A1
WO1999004794A1 PCT/US1998/014990 US9814990W WO9904794A1 WO 1999004794 A1 WO1999004794 A1 WO 1999004794A1 US 9814990 W US9814990 W US 9814990W WO 9904794 A1 WO9904794 A1 WO 9904794A1
Authority
WO
WIPO (PCT)
Prior art keywords
methylbenzenesulfonamide
phenyl
alkyl
substituted
phenylpiperidin
Prior art date
Application number
PCT/US1998/014990
Other languages
French (fr)
Inventor
Charles G. Caldwell
Paul E. Finke
Malcolm Maccoss
Laura C. Meurer
Sander G. Mills
Bryan Oates
Original Assignee
Merck & Co., Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9800958.2A external-priority patent/GB9800958D0/en
Application filed by Merck & Co., Inc. filed Critical Merck & Co., Inc.
Priority to CA002296314A priority Critical patent/CA2296314A1/en
Priority to EP98936920A priority patent/EP1003514A4/en
Priority to JP50994999A priority patent/JP2002510327A/en
Priority to AU85760/98A priority patent/AU8576098A/en
Publication of WO1999004794A1 publication Critical patent/WO1999004794A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/10—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms
    • C07D211/14—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
    • C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • C07D211/52—Oxygen atoms attached in position 4 having an aryl radical as the second substituent in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56—Nitrogen atoms
    • C07D211/58—Nitrogen atoms attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Definitions

  • Chemokines are chemotactic cytokines that are released by a wide variety of cells to attract macrophages, T cells, eosinophils, basophils and neutrophils to sites of inflammation (reviewed in Schall, Cvtokine. 3, 165-183 (1991) and Murphy, Rev. Immun.. 12, 593-633 (1994)).
  • the -chemokines such as interleukin-8 (IL-8), neutrophil-activating protein-2 (NAP-2) and melanoma growth stimulatory activity protein (MGSA) are chemotactic primarily for neutrophils, whereas ⁇ -chemokines, such as RANTES, MlP-l ⁇ , MlP-l ⁇ , monocyte chemotactic protein-1 (MCP-1), MCP-2, MCP-3 and eotaxin are chemotactic for macrophages, T-cells, eosinophils and basophils (Deng, et al., Nature. 381. 661-666 (1996)).
  • IL-8 interleukin-8
  • NAP-2 neutrophil-activating protein-2
  • MGSA melanoma growth stimulatory activity protein
  • ⁇ -chemokines such as RANTES, MlP-l ⁇ , MlP-l ⁇ , monocyte chemotactic protein-1 (MCP-1), MCP-2, MCP-3 and eo
  • chemokines bind specific cell-surface receptors belonging to the family of G-protein-coupled seven-transmembrane- domain proteins (reviewed in Horuk, Trends Pharm. Sci., 15. 159-165 (1994)) which are termed "chemokine receptors.” On binding their cognate ligands, chemokine receptors transduce an intracellular signal though the associated trimeric G protein, resulting in a rapid increase in intracellular calcium concentration.
  • CCR-1 or "CKR-1" or "CC-CKR-1”
  • MlP-l ⁇ , MlP-l ⁇ , MCP-3, RANTES a human chemokine receptor that bind or respond to ⁇ -chemokines with the following characteristic pattern: CCR-1 (or "CKR-1" or "CC-CKR-1") [MlP-l ⁇ , MlP-l ⁇ , MCP-3, RANTES] (Ben-Barruch, et al., J. Biol. Chem.. 270. 22123-22128 (1995); Beote, et al, Cell.
  • CCR- 2A and CCR-2B (or "CKR-2A7"CKR-2A” or “CC-CKR-2A”/"CC-CKR- 2A") [MCP-1, MCP-3, MCP-4]; CCR-3 (or “CKR-3” or "CC-CKR-3") [eotaxin, RANTES, MCP-3] (Combadiere, et al., J. Biol. Chem.. 270. 16491-16494 (1995); CCR-4 (or "CKR-4" or "CC-CKR-4") [MlP-l ⁇ , RANTES, MCP-1] (Power, et al., J. Biol. Chem.. 270.
  • ⁇ -chemokines include eotaxin, MIP ("macrophage inflammatory protein”), MCP ("monocyte chemoattractant protein”) and RANTES ("regulation-upon-activation, normal T expressed and secreted").
  • Chemokine receptors such as CCR-1, CCR-2, CCR-2A, CCR-2B, CCR-3, CCR-4, CCR-5, CXCR-3, CXCR-4, have been implicated as being important mediators of inflammatory and immunoregulatory disorders and diseases, including asthma and allergic diseases, as well as autoimmune pathologies such as rheumatoid arthritis and atherosclerosis. Accordingly, agents which modulate chemokine receptors would be useful in such disorders and diseases.
  • HIV-1 human immunodeficiency virus
  • LAV human immunodeficiency virus
  • HTLV-III human immunodeficiency virus
  • Certain compounds have been demonstrated to inhibit the replication of HIV, including soluble CD4 protein and synthetic derivatives (Smith, et al., Science, 238, 1704-1707 (1987)), dextran sulfate, the dyes Direct Yellow 50, Evans Blue, and certain azo dyes (U.S. Patent No. 5,468,469). Some of these antiviral agents have been shown to act by blocking the binding of gpl20, the coat protein of HIV, to its target, the CD4 gyycoprotein of the cell.
  • the principal cofactor for entry mediated by the envelope glycoproteins of primary macrophage-trophic strains of HIV-1 is CCR5, a receptor for the ⁇ - chemokines RANTES, MlP-l ⁇ and MlP-l ⁇ (Deng, et al., Nature. 381. 661-666 (1996)). HIV attaches to the CD4 molecule on cells through a region of its envelope protein, gpl20. It is believed that the CD-4 binding site on the gpl20 of Hr interacts with the CD4 molecule on the cell surface, and undergoes conformational changes which allow it to bind to another cell-surface receptor, such as CCR5 and/or CXCR-4.
  • peptides eotaxin, RANTES, MlP-l ⁇ , MlP-l ⁇ , MCP-1, and MCP-3 are known to bind to chemokine receptors.
  • the inhibitors of HIV-1 replication present in supernatants of CD8+ T cells have been characterized as the ⁇ -chemokines RANTES, MlP-l ⁇ and MlP-l ⁇ .
  • PCT Patent Publication WO 97/10211 and EPO Patent Publication EP 0,673,928 disclose certain piperidines as tachykinin antagonists.
  • the present invention is directed to compounds which are modulators of chemokine receptor activity and are useful in the prevention or treatment of certain inflammatory and immunoregulatory disorders and diseases, including asthma and allergic diseases, as well as autoimmune pathologies such as rheumatoid arthritis and atherosclerosis.
  • the invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which chemokine receptors are involved.
  • the present invention is further concerned with compounds which inhibit the entry of human immunodeficiency virus (HIV) into target cells and are of value in the prevention of infection by HPv 7 , the treatment of infection by HIV and the prevention and/or treatment of the resulting acquired immune deficiency syndrome (AIDS).
  • HIV human immunodeficiency virus
  • the present invention also relates to pharmaceutical compositions containing the compounds and to a method of use of the present compounds and other agents for the prevention and treatment of AIDS and viral infection by HIV.
  • the present invention is directed to compounds of formula I:
  • R1 is selected from a group consisting of: linear or branched Cl-8 alkyl, linear or branched C2-8 alkenyl, wherein the Cl-8 alkyl or C2-8 alkenyl is optionally mono, di, tri or tetra substituted, where the substituents are independently selected from: (a) hydroxy,
  • heteroaryl wherein heteroaryl is selected from the group consisting of:
  • R4 and R ⁇ are independently selected from hydrogen, Cl-10 linear or branched alkyl, and C ⁇ -6 alkyl substituted with C3-8 cycloalkyl
  • heteroaryl is selected from the group consisting of: (1') benzimidazolyl,
  • 35 B ⁇ is selected from the group consisting of: (1) hydrogen,
  • R 6 and R 7 may be joined together to form a 5-, 6-, or 7- membered monocyclic saturated ring containing 1 or 2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, and in which the ring is unsubstituted or mono or di-substituted, the substituents independently selected from: (1) hydroxy,
  • n is an integer selected from 0, 1 and 2 and pharmaceutically acceptable salts thereof.
  • Preferred compounds of the present invention include those of formula la:
  • R1 is selected from a group consisting of:
  • R 7 is Cl-6 alkyl, benzyl or phenyl which is unsubsituted or substituted with halo, CF3, Ci-3alkyl, or Ci-3alkoxy,
  • heteroaryl is selected from the group consisting of:
  • R2 is selected from the group consisting of:
  • R3 is selected from the group consisting of: (1) Ar,
  • R4 is selected from hydrogen, Cl-10 linear or branched alkyl, and C ⁇ -6 alkyl substituted with C3-8 cycloalkyl,
  • (o) CH 2 -heteroaryl, with the heteroaryl is selected from the group consisting of: (1') imidazolyl, (2') oxazolyl,
  • n is an integer selected from 0, 1 and 2, with the proviso that the sum of m + n is 2; and pharmaceutically acceptable salts thereof.
  • More preferred compounds of the present invention include those of formula lb:
  • Rl, R2 and R ⁇ are as defined herein; and pharmaceutically acceptable salts thereof.
  • R ⁇ is Ar, m is 1, n is 1, and R ⁇ is C5 alkyl which bears a group selected from: -NR 6 R 7 , -NR 6 COR 7 , -NR 6 CO2R 7 , or -NR ⁇ CONHR 7 , then R 1 does not bear a substituent which is 2,3-dichlorophenyl.
  • pi bears at least one substituent which is selected from:
  • R1 is selected from the group consisting of:
  • R1 is selected from the group consisting of: C4, C5, or C6 linear alkyl, which is substituted, where the substituents are independently selected from:
  • ! is C4 linear alkyl, which is substituted, where the substituents are independently selected from: (a) phenyl,
  • B is selected from the group consisting of: (a) phenyl, and (b) di or tri-substituted phenyl, wherein the substituents on phenyl are independently selected from: chloro, methyl, phenyl, Ci-3alkoxy, and CF3;
  • R" is Cl-3 alkyl, unsubstituted or substituted with cyclohexyl
  • RlO is selected from the group consisting of:
  • RU and Rl2 are independently selected from the group consisting of:
  • R1 is selected from the group consisting of:
  • R1 is selected from the group consisting of:
  • R2 is selected from the group consisting of:
  • R2 is selected from the group consisting of:
  • R2 is hydrogen
  • R3 is selected from the group consisting of: (1) Ar,
  • R3 is selected from the group consisting of:
  • R 4 is selected from hydrogen, Cl-10 linear or branched alkyl, and C ⁇ -6 alkyl substituted with C3-8 cycloalkyl, and
  • Ar is selected from the group consisting of: (1) phenyl,
  • CH -heteroaryl with the heteroaryl is selected from the group consisting of: (10 imidazolyl,
  • Ar is selected from: phenyl, mono substituted phenyl or di-substituted phenyl, wherein the substituents are selected from the group consisting of:
  • heteroaryl selected from the group consisting of:
  • R3 is selected from:
  • R is selected from hydrogen, Ci-6 linear or branched alkyl, and CH 2 substituted with
  • R3 is: -N(R4)-CO-O-(CH 2 )-phenyl, wherein R is selected from hydrogen and Ci-6 alkyl.
  • R 3 is:
  • n is an integer selected from 0, 1 and 2 with the proviso that the sum of m + n is 2.
  • n is 1.
  • halo as used herein are intended to include chloro, fluoro, bromo and iodo.
  • Cl-6, as in Ci-6alkyl is defined to identify the group as having 1, 2, 3, 4, 5, or 6 carbons, such that Cl-6alkyl specifically includes methyl, ethyl, propyl, butyl, pentyl, hexyl, and cyclohexyl.
  • Preferred compounds of the present invention include the compounds of the formula:
  • Specific compounds within the present invention include a compound which selected from the group consisting of:
  • the subject compounds are useful in a method of modulating chemokine receptor activity in a patient in need of such modulation comprising the administration of an effective amount of the compound.
  • the present invention is directed to the use of the foregoing spiro-substituted azacycles as modulators of chemokine receptor activity.
  • these compounds are useful as modulators of the chemokine receptors, including CCR-1, CCR-2, CCR-2A, CCR-2B, CCR- 3, CCR-4, CCR-5, CXCR-3, and/or CXCR-4.
  • the utility of the compounds in accordance with the present invention as modulators of chemokine receptor activity may be demonstrated by methodology known in the art, such as the assay for CCR-1 and/or CCR-5 binding as disclosed by Van Riper, et al., J. Exp. Med.. 177. 851-856 (1993), and the assay for CCR-2 and/or CCR-3 binding as disclosed by Daugherty, et al., J. Exp. Med.. 183. 2349-2354 (1996).
  • Cell lines for expressing the receptor of interest include those naturally expressing the receptor, such as EOL-3 or THP-1, or a cell engineered to express a recombinant receptor, such as CHO, RBL-2H3, HEK-293.
  • a CCR3 transfected AML14.3D10 cell line has been placed on restricted deposit with American Type Culture Collection in Rockville, Maryland as ATCC No. CRL-12079, on April 5, 1996.
  • the utility of the compounds in accordance with the present invention as inhibitors of the spread of HIV infection in cells may be demonstrated by methodology known in the art, such as the HIV quantitation assay disclosed by Nunberg, et al., J. Virology. 65 (9), 4887-4892 (1991).
  • the compounds of the following examples had activity in binding to either the CCR-5 receptor or the CCR-3 receptor in the aforementioned assays, generally with an IC50 of less than about 10 ⁇ M. Such a result is indicative of the intrinsic activity of the compounds in use as modulators of chemokine receptor activity.
  • Mammalian chemokine receptors provide a target for interfering with or promoting eosinophil and/or lymphocyte function in a mammal, such as a human.
  • Compounds which inhibit or promote chemokine receptor function are particularly useful for modulating eosinophil and/or lymphocyte function for therapeutic purposes. Accordingly, the present invention is directed to compounds which are useful in the prevention and/or treatment of a wide variety of inflammatory and immunoregulatory disorders and diseases, including asthma and allergic diseases, as well as autoimmune pathologies such as rheumatoid arthritis and atherosclerosis.
  • an instant compound which inhibits one or more functions of a mammalian chemokine receptor may be administered to inhibit (i.e., reduce or prevent) inflammation.
  • a mammalian chemokine receptor e.g., a human chemokine receptor
  • one or more inflammatory processes such as leukocyte emigration, chemotaxis, exocytosis (e.g., of enzymes, histamine) or inflammatory mediator release, is inhibited.
  • eosinophilic infiltration to inflammatory sites e.g., in asthma
  • inflammatory sites e.g., in asthma
  • an instant compound which promotes one or more functions of a mammalian chemokine receptor is administered to stimulate (induce or enhance) an inflammatory response, such as leukocyte emigration, chemotaxis, exocytosis (e.g., of enzymes, histamine) or inflammatory mediator release, resulting in the beneficial stimulation of inflammatory processes.
  • an inflammatory response such as leukocyte emigration, chemotaxis, exocytosis (e.g., of enzymes, histamine) or inflammatory mediator release, resulting in the beneficial stimulation of inflammatory processes.
  • eosinophils can be recruited to combat parasitic infections.
  • primates such as humans, a variety of other mammals can be treated according to the method of the present invention.
  • mammals including, but not limited to, cows, sheep, goats, horses, dogs, cats, guinea pigs, rats or other bovine, ovine, equine, canine, feline, rodent or murine species can be treated.
  • the method can also be practiced in other species, such as avian species (e.g., chickens).
  • the disease or condition is one in which the actions of eosinophils and/or lymphocytes are to be inhibited or promoted, in order to modulate the inflammatory response.
  • Diseases or conditions of humans or other species which can be treated with inhibitors of chemokine receptor function include, but are not limited to: inflammatory or allergic diseases and conditions, including respiratory allergic diseases such as asthma, allergic rhinitis, hypersensitivity lung diseases, hypersensitivity pneumonitis, eosinophilic pneumonias (e.g., Loeffler's syndrome, chronic eosinophilic pneumonia), delayed-type hypersentitivity, interstitial lung diseases (ILD) (e.g., idiopathic pulmonary fibrosis, or ILD associated with rheumatoid arthritis, systemic lupus erythematosus, ankylosing spondylitis, systemic sclerosis, Sjogren's syndrome, polymyositis or dermatomyositis); systemic anaphylaxis or hypersensitivity responses, drug allergies (e.g., to penicillin, cephalosporins), insect sting allergies; autoimmune diseases, such as rheumatoid arthritis
  • Other diseases or conditions in which undesirable inflammatory responses are to be inhibited can be treated, including, but not limited to, reperfusion injury, atherosclerosis, certain hematologic malignancies, cytokine-induced toxicity (e.g., septic shock, endotoxic shock), polymyositis, dermatomyositis.
  • Immunosuppression such as that in individuals with immunodeficiency syndromes such as AIDS, individuals undergoing radiation therapy, chemotherapy, therapy for autoimmune disease or other drug therapy (e.g., corticosteroid therapy), which causes immunosuppression; immunosuppression due congenital deficiency in receptor function or other causes; and infectious diseases, such as parasitic diseases, including, but not limited to helminth infections, such as nematodes (round worms); (Trichuriasis, Enterobiasis, Ascariasis, Hookworm, Strongyloidiasis, Trichinosis, f ⁇ lariasis); trematodes (flukes) (Schistosomiasis, Clonorchiasis), cestodes (tape worms) (Echinococcosis, Taeniasis saginata, Cysticercosis);
  • helminth infections such as nematodes (round worms); (Trichuriasis, Enterobias
  • the compounds of the present invention are accordingly useful in the prevention and treatment of a wide variety of inflammatory and immunoregulatory disorders and diseases.
  • the instant invention may be used to evaluate putative specific agonists or antagonists of chemokine receptors, including CCR-1, CCR-2, CCR-2A, CCR-2B, CCR-3, CCR-4, CCR-5, CXCR-3, and CXCR-4.
  • the present invention is directed to the use of these compounds in the preparation and execution of screening assays for compounds which modulate the activity of chemokine receptors.
  • the compounds of this invention are useful for isolating receptor mutants, which are excellent screening tools for more potent compounds.
  • the compounds of this invention are useful in establishing or determining the binding site of other compounds to chemokine receptors, e.g., by competitive inhibition.
  • the compounds of the instant invention are also useful for the evaluation of putative specific modulators of the chemokine receptors, including CCR-1, CCR-2, CCR-2A, CCR-2B, CCR-3, CCR-4, CCR-5, CXCR-3, and CXCR-4.
  • putative specific modulators of the chemokine receptors including CCR-1, CCR-2, CCR-2A, CCR-2B, CCR-3, CCR-4, CCR-5, CXCR-3, and CXCR-4.
  • thorough evaluation of specific agonists and antagonists of the above chemokine receptors has been hampered by the lack of availability of non-peptidyl (metabolically resistant) compounds with high binding affinity for these receptors.
  • the present invention is further directed to a method for the manufacture of a medicament for modulating chemokine receptor activity in humans and animals comprising combining
  • the present invention is further directed to the use of these compounds in the prevention or treatment of infection by a retrovirus, in particular, the human immunodeficiency virus (HIV) and the treatment of, and delaying of the onset of consequent pathological conditions such as AIDS.
  • Treating AIDS or preventing or treating infection by HIV is defined as including, but not limited to, treating a wide range of states of HIV infection: AIDS, ARC (AIDS related complex), both symptomatic and asymptomatic, and actual or potential exposure to HIV.
  • the compounds of this invention are useful in treating infection by HIV after suspected past exposure to HIV by, e.g., blood transfusion, organ transplant, exchange of body fluids, bites, accidental needle stick, or exposure to patient blood during surgery.
  • a subject compound may be used in a method of inhibiting the binding of a human immunodeficiency virus to a chemokine receptor, such as CCR-5 and/or CXCR-4, of a target cell, which comprises contacting the target cell with an amount of the compound which is effective at inhibiting the binding of the virus to the chemokine receptor.
  • a chemokine receptor such as CCR-5 and/or CXCR-4
  • the subject treated in the methods above is a mammal, preferably a human being, male or female, in whom modulation of chemokine receptor activity is desired.
  • Modulation as used herein is intended to encompass antagonism, agonism, partial antagonism and/or partial agonism.
  • therapeutically effective amount means the amount of the subject compound that will elicit the biological or medical response of a tissue, system, animal or human that is being sought by the researcher, veterinarian, medical doctor or other clinician.
  • composition as used herein is intended to encompass a product comprising the specified ingredients in the specified amounts, as well as any product which results, directly or indirectly, from combination of the specified ingredients in the specified amounts.
  • pharmaceutically acceptable it is meant the carrier, diluent or excipient must be compatible with the other ingredients of the formulation and not deleterious to the recipient thereof.
  • administering a should be understood to mean providing a compound of the invention or a prodrug of a compound of the invention to the individual in need of treatment.
  • Combined therapy to modulate chemokine receptor activity and thereby prevent and treat inflammatory and immunoregulatory disorders and diseases, including asthma and allergic diseases, as well as autoimmune pathologies such as rheumatoid arthritis and atherosclerosis, and those pathologies noted above is illustrated by the combination of the compounds of this invention and other compounds which are known for such utilities.
  • the present compounds may be used in conjunction with an antiinflammatory or analgesic agent such as an opiate agonist, a lipoxygenase inhibitor, such as an inhibitor of 5-lipoxygenase, a cyclooxygenase inhibitor, such as a cyclooxygenase-2 inhibitor, an interleukin inhibitor, such as an interleukin-1 inhibitor, an NMDA antagonist, an inhibitor of nitric oxide or an inhibitor of the synthesis of nitric oxide, a non-steroidal antiinflammatory agent, or a cytokine- suppressing antiinflammatory agent, for example with a compound such as acetaminophen, asprin, codiene, fentanyl, ibuprofen, indomethacin, ketorolac, morphine, naproxen, phenacetin, piroxicam, a steroidal analgesic, sufentanyl, sunlindac, tenidap, and the like.
  • the instant compounds may be administered with a pain reliever; a potentiator such as caffeine, an H2-antagonist, simethicone, aluminum or magnesium hydroxide; a decongestant such as phenyl ephrine, phenylpropanolamine, pseudophedrine, oxymetazoline, ephinephrine, naphazoline, xylometazoline, propylhexedrine, or levo- desoxy-ephedrine; an antiitussive such as codeine, hydrocodone, caramiphen, carbetapentane, or dextramethorphan; a diuretic; and a sedating or non-sedating antihistamine.
  • a pain reliever such as caffeine, an H2-antagonist, simethicone, aluminum or magnesium hydroxide
  • a decongestant such as phenyl ephrine, phenylpropanolamine, pseudophedrine, oxymetazoline,
  • the present invention is further directed to combinations of the present compounds with one or more agents useful in the prevention or treatment of AIDS.
  • the compounds of this invention may be effectively administered, whether at periods of pre-exposure and/or post-exposure, in combination with effective amounts of the AIDS antivirals, immunomodulators, anti-infectives, or vaccines known to those of ordinary skill in the art.
  • Drug Name Manufacturer Indication 097 Hoechst/Bayer HIV infection, AIDS, ARC (non-nucleoside reverse transcriptase inhibitor)
  • Cidofovir Gilead Science CMV retinitis, herpes, papillomavirus
  • Virazole Viratek/ICN asymptomatic HIV Ribavirin (Costa Mesa, CA) positive, LAS, ARC
  • Isethionate (IM & IV) (Rosemont, IL)
  • combinations of the compounds of this invention with AIDS antivirals, immunomodulators, anti-infectives or vaccines is not limited to the list in the above Table, but includes in principle any combination with any pharmaceutical composition useful for the treatment of AIDS.
  • Preferred combinations are simultaneous or alternating treatments of with a compound of the present invention and an inhibitor of HrV protease and/or a non-nucleoside inhibitor of HIV reverse transcriptase.
  • An optional fourth component in the combination is a nucleoside inhibitor of HIV reverse transcriptase, such as AZT, 3TC, ddC or ddl.
  • a preferred inhibitor of HIV protease is indinavir, which is the sulfate salt of N-(2(R)-hydroxy-l(S)-indanyl)-2(R)-phenylmethyl-4-(S)- hydroxy-5-(l-(4-(3-pyridyl-methyl)-2(S)-N'-(t-butylcarbo-xamido)- piperazinyl))-pentaneamide ethanolate, and is synthesized according to U.S. 5,413,999.
  • Indinavir is generally administered at a dosage of 800 mg three times a day.
  • Other preferred inhibitors of HrV protease include nelfinavir and ritonavir.
  • Preferred non-nucleoside inhibitors of HIV reverse transcriptase include (-) 6-chloro-4(S)-cyclopropylethynyl- 4(S)-trifluoromethyl-l,4-dihydro-2H-3,l-benzoxazin-2-one, which may be prepared by methods disclosed in EP 0,582,455.
  • the preparation of ddC, ddl and AZT are also described in EPO 0,484,071. These combinations may have unexpected effects on limiting the spread and degree of infection of HrV.
  • Preferred combinations with the compounds of the present invention include the following (1) indinavir, with efavirenz or (-) 6-chloro-4(S)-cyclopropylethynyl-4(S)-trifluoromethyl-l,4-dihydro-2H- 3,l-benzoxazin-2-one, and, optionally, AZT and/or 3TC and or ddl and/or ddC; (2) indinavir, and any of AZT and/or ddl and/or ddC.
  • the compound of the present invention and other active agents may be administered separately or in conjunction.
  • the administration of one element may be prior to, concurrent to, or subsequent to the administration of other agent(s).
  • the compounds of the present invention may be administered by oral, parenteral (e.g., intramuscular, intraperitoneal, intravenous, ICV, intracisternal injection or infusion, subcutaneous injection, or implant), by inhalation spray, nasal, vaginal, rectal, sublingual, or topical routes of administration and may be formulated, alone or together, in suitable dosage unit formulations containing conventional non-toxic pharmaceutically acceptable carriers, adjuvants and vehicles appropriate for each route of administration.
  • parenteral e.g., intramuscular, intraperitoneal, intravenous, ICV, intracisternal injection or infusion, subcutaneous injection, or implant
  • inhalation spray nasal, vaginal, rectal, sublingual, or topical routes of administration
  • nasal, vaginal, rectal, sublingual, or topical routes of administration may be formulated, alone or together, in suitable dosage unit formulations containing conventional non-toxic pharmaceutically acceptable carriers, adjuvants and vehicles appropriate for each route of administration.
  • the compounds of the invention are effective for
  • compositions for the administration of the compounds of this invention may conveniently be presented in dosage unit form and may be prepared by any of the methods well known in the art of pharmacy. All methods include the step of bringing the active ingredient into association with the carrier which constitutes one or more accessory ingredients.
  • the pharmaceutical compositions are prepared by uniformly and intimately bringing the active ingredient into association with a liquid carrier or a finely divided solid carrier or both, and then, if necessary, shaping the product into the desired formulation.
  • the active object compound is included in an amount sufficient to produce the desired effect upon the process or condition of diseases.
  • composition is intended to encompass a product comprising the specified ingredients in the specified amounts, as well as any product which results, directly or indirectly, from combination of the specified ingredients in the specified amounts.
  • compositions containing the active ingredient may be in a form suitable for oral use, for example, as tablets, troches, lozenges, aqueous or oily suspensions, dispersible powders or granules, emulsions, hard or soft capsules, or syrups or elixirs.
  • Compositions intended for oral use may be prepared according to any method known to the art for the manufacture of pharmaceutical compositions and such compositions may contain one or more agents selected from the group consisting of sweetening agents, flavoring agents, coloring agents and preserving agents in order to provide pharmaceutically elegant and palatable preparations. Tablets contain the active ingredient in admixture with non-toxic pharmaceutically acceptable excipients which are suitable for the manufacture of tablets.
  • excipients may be for example, inert diluents, such as calcium carbonate, sodium carbonate, lactose, calcium phosphate or sodium phosphate; granulating and disintegrating agents, for example, corn starch, or alginic acid; binding agents, for example starch, gelatin or acacia, and lubricating agents, for example magnesium stearate, stearic acid or talc.
  • the tablets may be uncoated or they may be coated by known techniques to delay disintegration and absorption in the gastrointestinal tract and thereby provide a sustained action over a longer period.
  • a time delay material such as glyceryl monostearate or glyceryl distearate may be employed. They may also be coated by the techniques described in the U.S. Patents 4,256,108; 4,166,452; and 4,265,874 to form osmotic therapeutic tablets for control release.
  • Formulations for oral use may also be presented as hard gelatin capsules wherein the active ingredient is mixed with an inert solid diluent, for example, calcium carbonate, calcium phosphate or kaolin, or as soft gelatin capsules wherein the active ingredient is mixed with water or an oil medium, for example peanut oil, liquid paraffin, or olive oil.
  • an inert solid diluent for example, calcium carbonate, calcium phosphate or kaolin
  • water or an oil medium for example peanut oil, liquid paraffin, or olive oil.
  • Aqueous suspensions contain the active materials in admixture with excipients suitable for the manufacture of aqueous suspensions.
  • excipients are suspending agents, for example sodium carboxymethylcellulose, methylcellulose, hydroxy- propylmethylcellulose, sodium alginate, polyvinyl- pyrrolidone, gum tragacanth and gum acacia; dispersing or wetting agents may be a naturally-occurring phosphatide, for example lecithin, or condensation products of an alkylene oxide with fatty acids, for example polyoxyethylene stearate, or condensation products of ethylene oxide with long chain aliphatic alcohols, for example heptadecaethyleneoxycetanol, or condensation products of ethylene oxide with partial esters derived from fatty acids and a hexitol such as polyoxyethylene sorbitol monooleate, or condensation products of ethylene oxide with partial esters derived from fatty acids and hexitol anhydrides, for example polyethylene sorbitan mono
  • the aqueous suspensions may also contain one or more preservatives, for example ethyl, or n-propyl, p-hydroxybenzoate, one or more coloring agents, one or more flavoring agents, and one or more sweetening agents, such as sucrose or saccharin.
  • preservatives for example ethyl, or n-propyl, p-hydroxybenzoate
  • coloring agents for example ethyl, or n-propyl, p-hydroxybenzoate
  • coloring agents for example ethyl, or n-propyl, p-hydroxybenzoate
  • flavoring agents for example ethyl, or n-propyl, p-hydroxybenzoate
  • sweetening agents such as sucrose or saccharin.
  • Oily suspensions may be formulated by suspending the active ingredient in a vegetable oil, for example arachis oil, olive oil, sesame oil or coconut oil, or in a mineral oil such as liquid paraffin.
  • the oily suspensions may contain a thickening agent, for example beeswax, hard paraffin or cetyl alcohol.
  • Sweetening agents such as those set forth above, and flavoring agents may be added to provide a palatable oral preparation.
  • These compositions may be preserved by the addition of an anti-oxidant such as ascorbic acid.
  • Dispersible powders and granules suitable for preparation of an aqueous suspension by the addition of water provide the active ingredient in admixture with a dispersing or wetting agent, suspending agent and one or more preservatives. Suitable dispersing or wetting agents and suspending agents are exemplified by those already mentioned above. Additional excipients, for example sweetening, flavoring and coloring agents, may also be present.
  • the pharmaceutical compositions of the invention may also be in the form of oil-in-water emulsions.
  • the oily phase may be a vegetable oil, for example olive oil or arachis oil, or a mineral oil, for example liquid paraffin or mixtures of these.
  • Suitable emulsifying agents may be naturally- occurring gums, for example gum acacia or gum tragacanth, naturally-occurring phosphatides, for example soy bean, lecithin, and esters or partial esters derived from fatty acids and hexitol anhydrides, for example sorbitan monooleate, and condensation products of the said partial esters with ethylene oxide, for example polyoxyethylene sorbitan monooleate.
  • the emulsions may also contain sweetening and flavoring agents.
  • Syrups and elixirs may be formulated with sweetening agents, for example glycerol, propylene glycol, sorbitol or sucrose. Such formulations may also contain a demulcent, a preservative and flavoring and coloring agents.
  • sweetening agents for example glycerol, propylene glycol, sorbitol or sucrose.
  • Such formulations may also contain a demulcent, a preservative and flavoring and coloring agents.
  • the pharmaceutical compositions may be in the form of a sterile injectable aqueous or oleagenous suspension.
  • This suspension may be formulated according to the known art using those suitable dispersing or wetting agents and suspending agents which have been mentioned above.
  • the sterile injectable preparation may also be a sterile injectable solution or suspension in a non-toxic parenterally-acceptable diluent or solvent, for example as a solution in 1,3-butane diol.
  • the acceptable vehicles and solvents that may be employed are water, Ringer's solution and isotonic sodium chloride solution.
  • sterile, fixed oils are conventionally employed as a solvent or suspending medium.
  • any bland fixed oil may be employed including synthetic mono- or diglycerides.
  • fatty acids such as oleic acid find use in the preparation of injectables.
  • the compounds of the present invention may also be administered in the form of suppositories for rectal administration of the drug.
  • These compositions can be prepared by mixing the drug with a suitable non-irritating excipient which is solid at ordinary temperatures but liquid at the rectal temperature and will therefore melt in the rectum to release the drug.
  • a suitable non-irritating excipient which is solid at ordinary temperatures but liquid at the rectal temperature and will therefore melt in the rectum to release the drug.
  • Such materials are cocoa butter and polyethylene glycols.
  • topical application For topical use, creams, ointments, jellies, solutions or suspensions, etc., containing the compounds of The present invention are employed. (For purposes of this application, topical application shall include mouth washes and gargles.)
  • compositions and method of the present invention may further comprise other therapeutically active compounds as noted herein which are usually applied in the treatment of the above mentioned pathological conditions.
  • an appropriate dosage level will generally be about 0.01 to 500 mg per kg patient body weight per day which can be administered in single or multiple doses.
  • the dosage level will be about 0.1 to about 250 mg/kg per day; more preferably about 0.5 to about 100 mg/kg per day.
  • a suitable dosage level may be about 0.01 to 250 mg/kg per day, about 0.05 to 100 mg/kg per day, or about 0.1 to 50 mg/kg per day. Within this range the dosage may be 0.05 to 0.5, 0.5 to 5 or 5 to 50 mg/kg per day.
  • compositions are preferably provided in the form of tablets containing 1.0 to 1000 milligrams of the active ingredient, particularly 1.0, 5.0, 10.0, 15.0. 20.0, 25.0, 50.0, 75.0, 100.0, 150.0, 200.0, 250.0, 300.0, 400.0, 500.0, 600.0, 750.0, 800.0, 900.0, and 1000.0 milligrams of the active ingredient for the symptomatic adjustment of the dosage to the patient to be treated.
  • the compounds may be administered on a regimen of 1 to 4 times per day, preferably once or twice per day.
  • the compounds of the present invention are prepared by alkylating heterocycle I under appropriate conditions to provide compound II (Scheme 1).
  • the required starting materials for preparing heterocycle I are available commercially or can be prepared using the methods given below.
  • heterocycle I is combined with the appropriate aldehyde and the intermediate imine or iminium species is reduced to the tertiary amine chemically (e.g. using sodium cyanoborohydride, sodium borohydride, or sodium triacetoxyborohydride) or catalytically (e.g. using hydrogen and palladium on carbon or Raney nickel catalyst) (Scheme 1).
  • the aldehyde needed for this reaction can be prepared by methods generally known in the chemical literature; for the purposes of the present invention one preparation of a representative aldehyde is described in Hale, J.J.; Finke, P.E.; MacCoss, M. Bioorganic & Medicinal Chemistry Letters 1993,3, 319-322.
  • heterocycle I can be alkylated with an alkyl halide or alkyl sulfonate ester (with or without an added base to neutralize the mineral acid or sulfonic acid by-product) to give the desired compound (Scheme 1).
  • the alkyl halide or alkyl sulfonate needed for this reaction can be prepared by methods generally known in the chemical literature; for the purposes of the present invention an aldehyde, prepared as described above, can be reduced to an alcohol with sodium borohydride, diisobutylaluminum hydride or lithium aluminum hydride, and the product alcohol converted to either the alkyl halide using methods described in March J. "Advanced Organic Chemistry", 4th ed., John
  • I can be acylated to give a tertiary amide; subsequent reduction with a strong reducing agent (e.g. diborane; borane in THF; borane dimethylsulfide, or lithium aluminum hydride) will give the desired compound (Scheme 1).
  • a strong reducing agent e.g. diborane; borane in THF; borane dimethylsulfide, or lithium aluminum hydride
  • the acylating agent needed for this reaction can be prepared by methods generally known in the chemical literature; for the purposes of the present invention an aldehyde, prepared as described above, can be oxidized using such commonly used reagents as permanganate in acid or silver oxide, and the resulting acid activated as an acid chloride or mixed anhydride which can be used to acylate I.
  • the product amide can in and of itself be a chemokine receptor modulator or can be reduced as noted above to give the tertiary amine.
  • compound II may be further modified in subsequent reactions, as illustrated below.
  • compounds of interest can be prepared by activating the hydroxyl groups of l,4-dihydroxy-2-butyne, for example by treatment with triphenyl- phosphine dibromide in acetonitrile, to give l,4-dibromo-2-butyne (Scheme 2).
  • Palladium-catalysed hydrostannylation preferentially forms the 3- tributylstannyl olefin IV.
  • the minor product from this reaction can also isolated and carried through the sequence described below.
  • Compound IV can be converted to the corresponding 3-aryl derivative V by treatment with an aryl bromide (wherein Rx, Ry and Rz are substituents on the phenyl or heteroaryl as defined herein) in the presence of a suitable palladium catalyst at or above room temperature.
  • Suitable catalysts include palladium acetate and triphenylphosphine, bis(triphenylphosphine) palladium (II) chloride, or palladium (0) bis(dibenzylidineacetone) in the presence of triphenylphosphine or tri-2- furylphosphine.
  • Suitable solvents include 1,4-dioxane, DMF, and N- methyl pyrrolidinone.
  • a base such as potassium carbonate or potassium phosphate may also be employed.
  • Compound V may be employed as a chemokine receptor modulator itself or it can be reduced to saturated derivative VI by standard conditions, for example catalytic hydrogenation with palladium on carbon or with palladium hydroxide in the presence of a mild acid such as acetic acid.
  • the allyl acid VII (prepared, for example, as described in Hale et al; see above) can be converted into the N-methyl-N-methoxy amide VIII, which is then treated with an alkyl or aryl metal reagent, for example methylhthium or butyllithium, to provide the ketone IX (Scheme 3).
  • the ketone can be converted into an imine which can then be reduced to secondary amine X chemically, (e.g using sodium cyanoborohydride or sodium borohydride), or catalytically (e.g. using hydrogen and palladium on carbon or Raney nickel catalyst). Acylation under standard conditions, for example with an acid chloride, provides the corresponding amide.
  • amine X can be sulfonylated, for example with a alkyl or aryl sulfonyl chloride or an alkyl or aryl sulfonic anhydride, to give (for aryl substituted sulfonylating reagents) sulfonamide XL
  • the allyl group in XI can be oxidatively cleaved to aldehyde XII with osmium tetroxide followed by sodium periodate or with ozone at low temperature. Reductive amination of aldehyde XII with azacycle I can then be carried out under the conditions described above to give the desired product XIII.
  • oxazolidinone imide XV is prepared from acid XIV, by formation of the corresponding acid chloride (by treatment with oxalyl chloride or thionyl chloride) and addition of N- lithio 2(S)-benzyl oxazolidinone.
  • the enolate azidation can be accomplished by a variety of methods, such as the procedure of Evans, D. A.; et. al. J. Am. Chem. Soc. 1990, 112, 4011-4030.
  • Reduction of the oxazolidinone moiety of XVI can be carried out by a variety of metal hydride reagents (e.g.
  • Acid VII can be homologated under Arndt-Eistert conditions to give the chain-extended acid XrV, which can be derivatized under standard acylating conditions with, for example, an aniline derivative, to give the amide XXI.
  • Oxidative cleavage of the olefin with osmium tetroxide or ozone then provides aldehyde XXII as an intermediate suitable for coupling as described earlier.
  • ketone derivatives are prepared by an extension of the chemistry given above, as shown in Scheme 6.
  • An Arndt-Eistert chain extension of acid XIV provides heptenoic acid XXIII, which after conversion into N-methoxy-N-methyl amide XXIV, can be reacted with an aryl organometallic reagent, such as an aryl magnesium bromide, to provide ketone XXV. Routine oxidative cleavage then gives the desired aldehyde XXVI, which can be coupled with an appropriate amine as described above.
  • Alcohol containing compounds are prepared according to procedures given in Scheme 7. Formation of the N-methyl-N-methoxy amide of acid VII followed by oxidative cleavage of the olefin provides intermediate aldehyde XXVII. Coupling with an appropriate amine provides amide XXVIII. Addition of an organometallic reagent to compound XXVIII provides illustrated ketone XXLX. Treatment with a hydride reducing agent, such as sodium borohydride, then yields the desired alcohol XXX.
  • a hydride reducing agent such as sodium borohydride
  • allyl acid VII can be reduced to alcohol XXXI with, for example, lithium aluminum hydride.
  • This alcohol can be alkylated by a Williamson ether synthesis, by deprotonation with a strong base such as sodium hydride or sodium hexamethyldisilazide followed by reaction with a benzyl halide such as benzyl bromide.
  • the resulting ether XXXrV can be processed through the oxidative cleavage steps described earlier to provide aldehyde XXXV.
  • This aldehyde can then be coupled with an appropriate amine under reductive amination conditions to give XXXVI.
  • reduction of XXXV to the corresponding alcohol followed by conversion to the bromide allows for alkylation with an amine to provide XXXVI.
  • CBZ-protected piperidine XLV can be allowed to react with oxalyl chloride and then sodium azide, to provide the corresponding acyl azide, which can then be thermally rearranged to isocyanate XLVI (Scheme 11).
  • Compound XLVI can be treated with an alcohol ROH or an amine RR'NH to form carbamate XLVII or urea XLVIII, respectively, each of which can be deprotected with hydrogen in the presence of palladium on carbon to secondary amines XLLX or L.
  • a suitable base such as sodium hydride, lithium hexamethyldisilazide or potassium t-butoxide
  • Step A (R,S)-N-(2-Phenylpent-4-en-l-yl)-N-methylbenzene- sulfonamide
  • reaction mixture was diluted with methylene chloride and washed with water containing 20 mL of 2 N HC1. The aqueous layer was reextracted with methylene chloride and the organic layers were washed with brine, combined, dried over sodium sulfate and concentrated in vacuo. The residue was purified by flash column chromatography (FCC) eluting with 5% ethyl acetate/hexanes to afford 3.2 g of the title compound.
  • FCC flash column chromatography
  • Step B (R,S)-N-(2-Phenyl-4-oxobut-l-yl)-N-methylbenzene- sulfonamide
  • a solution of 1.0 g (3.2 mmol) of (R,S)-N-(2-phenylpent-4- en-l-yl)-N-methylbenzenesulfonamide from Step A in 7 mL of acetone, 3.5 mL of t-butanol and 3.5 mL of water was added 413 mg (3.5 mmol) of N-methylmorpholine-N-oxide followed by 0.14 mL of 4% osmium tetroxide in water.
  • the reaction was stirred at rt for 16 h and was then quenched with aqueous sodium bisulfite and concentrated in vacuo.
  • the residue was diluted with water and extracted twice with ether.
  • the ether layers were each washed with brine, combined, dried over sodium sulfate and concentrated in vacuo.
  • the residue was purified by FCC eluting with 5% methanol in methylene chloride to afford the diol intermediate.
  • the above product was taken up in 10 mL of THF and 755 mg (3.5 mmole) of sodium periodate in 3 mL of water was added. The mixture was stirred at rt for 3 h, poured into water and extracted twice with ether.
  • Step C (R,S)-N-[2-Phenyl-4-(4-phenylpiperidin-l-yl)but-l-yl]-N- methylbenzenesulfonamide hydrochioride salt
  • Step A N-[4-(4-Phenylpiperidin-l-yl)but-2-yn-l-yl]-N- methylbenzenesulfonamide To a suspension of triphenylphosphine dibromide at 0 C
  • a solution of the sodium salt of N-methylbenzenesulfonamide in 50 mL of DMF was prepared at 0 C under nitrogen by portionwise addition of 3.2 g (80 mmol) of 60% sodium hydride over 0.5 h and then stirred with cooling for 0.5 h.
  • This salt solution was added via canula over 15 min with cooling to the above dibromide solution.
  • 18.0 g (110 mmol) of 4-phenylpiperidine was added and the reaction was stirred a further 2 h at rt.
  • the reaction was diluted with water and extracted three times with ether. The ether layers were each washed with a portion of brine, dried over sodium sulfate, combined and concentrated in vacuo.
  • Step B N-[4-(4-Phenylpiperidin-l-yl)-2-tributylstannylbut-2-en-l-yl]-
  • N-[4-(4-phenyl-piperidin- l-yl)but-2-yn- 1-yl] -N-methylbenzenesulfonamide from Step A in 75 mL of
  • the mixture was heated at 70 C for 24 h, cooled, treated with aqueous sodium fluoride for 10 min, and partitioned between water and ether. The water layer was reextracted with ether and each organic layer was washed with brine, dried over sodium sulfate, combined and concentrated in vacuo. The residue was purified by FCC eluting with 25- 50% ethyl acetate/hexanes to give 57 mg of product contaminated with stannane biproduct. The product was further purified by prep TLC (50% ethyl acetate/hexanes) to afford 53 mg of title compound.
  • Step D (R,S)-N-[4-(4-Phenylpiperidin-l-yl)-2-(3-methylphenyl)-but-l- yl] -N-methylbenzenesulfonamide

Abstract

The present invention is directed to cyclic amines of formula (I), (wherein R?1, R2, R3¿, m and n are defined herein) which are useful as modulators of chemokine receptor activity. In particular, these compounds are useful as modulators of the chemokine receptors CCR-1, CCR-2, CCR-2A, CCR-2B, CCR-3, CCR-4, CCR-5, CXCR-3, and/or CXCR-4.

Description

TITLE OF THE INVENTION
CYCLIC AMINE MODULATORS OF CHEMOKINE RECEPTOR
ACTIVITY
BACKGROUND OF THE INVENTION
Chemokines are chemotactic cytokines that are released by a wide variety of cells to attract macrophages, T cells, eosinophils, basophils and neutrophils to sites of inflammation (reviewed in Schall, Cvtokine. 3, 165-183 (1991) and Murphy, Rev. Immun.. 12, 593-633 (1994)). There are two classes of chemokines, C-X-C (cc) and C-C (β), depending on whether the first two cysteines are separated by a single amino acid (C-X-C) or are adjacent (C-C). The -chemokines, such as interleukin-8 (IL-8), neutrophil-activating protein-2 (NAP-2) and melanoma growth stimulatory activity protein (MGSA) are chemotactic primarily for neutrophils, whereas β-chemokines, such as RANTES, MlP-lα, MlP-lβ , monocyte chemotactic protein-1 (MCP-1), MCP-2, MCP-3 and eotaxin are chemotactic for macrophages, T-cells, eosinophils and basophils (Deng, et al., Nature. 381. 661-666 (1996)).
The chemokines bind specific cell-surface receptors belonging to the family of G-protein-coupled seven-transmembrane- domain proteins (reviewed in Horuk, Trends Pharm. Sci., 15. 159-165 (1994)) which are termed "chemokine receptors." On binding their cognate ligands, chemokine receptors transduce an intracellular signal though the associated trimeric G protein, resulting in a rapid increase in intracellular calcium concentration. There are at least seven human chemokine receptors that bind or respond to β-chemokines with the following characteristic pattern: CCR-1 (or "CKR-1" or "CC-CKR-1") [MlP-lα, MlP-lβ, MCP-3, RANTES] (Ben-Barruch, et al., J. Biol. Chem.. 270. 22123-22128 (1995); Beote, et al, Cell. 72, 415-425 (1993)); CCR- 2A and CCR-2B (or "CKR-2A7"CKR-2A" or "CC-CKR-2A"/"CC-CKR- 2A") [MCP-1, MCP-3, MCP-4]; CCR-3 (or "CKR-3" or "CC-CKR-3") [eotaxin, RANTES, MCP-3] (Combadiere, et al., J. Biol. Chem.. 270. 16491-16494 (1995); CCR-4 (or "CKR-4" or "CC-CKR-4") [MlP-lα, RANTES, MCP-1] (Power, et al., J. Biol. Chem.. 270. 19495-19500 (1995)); CCR-5 (or "CKR-5" or "CC-CKR-5") [MlP-lα, RANTES, MlP-lβ] (Sanson, et al., Biochemistry. 35, 3362-3367 (1996)); and the Duffy blood- group antigen [RANTES, MCP-1] (Chaudhun, et al., J. Biol. Chem.. 269. 7835-7838 (1994)). The β-chemokines include eotaxin, MIP ("macrophage inflammatory protein"), MCP ("monocyte chemoattractant protein") and RANTES ("regulation-upon-activation, normal T expressed and secreted").
Chemokine receptors, such as CCR-1, CCR-2, CCR-2A, CCR-2B, CCR-3, CCR-4, CCR-5, CXCR-3, CXCR-4, have been implicated as being important mediators of inflammatory and immunoregulatory disorders and diseases, including asthma and allergic diseases, as well as autoimmune pathologies such as rheumatoid arthritis and atherosclerosis. Accordingly, agents which modulate chemokine receptors would be useful in such disorders and diseases.
A retrovirus designated human immunodeficiency virus (HIV-1) is the etiological agent of the complex disease that includes progressive destruction of the immune system (acquired immune deficiency syndrome; AIDS) and degeneration of the central and peripheral nervous system. This virus was previously known as LAV, HTLV-III, or ARV. Certain compounds have been demonstrated to inhibit the replication of HIV, including soluble CD4 protein and synthetic derivatives (Smith, et al., Science, 238, 1704-1707 (1987)), dextran sulfate, the dyes Direct Yellow 50, Evans Blue, and certain azo dyes (U.S. Patent No. 5,468,469). Some of these antiviral agents have been shown to act by blocking the binding of gpl20, the coat protein of HIV, to its target, the CD4 gyycoprotein of the cell.
Entry of HIV-1 into a target cell requires cell-surface CD4 and additional host cell cofactors. Fusin has been identified as a cofactor required for infection with virus adapted for growth in transformed T- cells, however, fusin does not promote entry of macrophagetropic viruses which are believed to be the key pathogenic strains of HIV in vivo. It has recently been recognized that for efficient entry into target cells, human immunodeficiency viruses require the chemokine receptors CCR-5 and CXCR-4, as well as the primary receptor CD4 (Levy, N. Engl. J. Med.. 335(20). 1528-1530 (Nov. 14 1996). The principal cofactor for entry mediated by the envelope glycoproteins of primary macrophage-trophic strains of HIV-1 is CCR5, a receptor for the β- chemokines RANTES, MlP-lα and MlP-lβ (Deng, et al., Nature. 381. 661-666 (1996)). HIV attaches to the CD4 molecule on cells through a region of its envelope protein, gpl20. It is believed that the CD-4 binding site on the gpl20 of Hr interacts with the CD4 molecule on the cell surface, and undergoes conformational changes which allow it to bind to another cell-surface receptor, such as CCR5 and/or CXCR-4. This brings the viral envelope closer to the cell surface and allows interaction between gp41 on the viral envelope and a fusion domain on the cell surface, fusion with the cell membrane, and entry of the viral core into the cell. It has been shown that β-chemokine ligands prevent HPV-l from fusing with the cell (Dragic, et al., Nature. 381. 667-673 (1996)). It has further been demonstrated that a complex of gpl20 and soluble CD4 interacts specifically with CCR-5 and inhibits the binding of the natural CCR-5 ligands MlP-lα and MlP-lβ (Wu, et al., Nature. 384. 179-183 (1996); Trkola, et al., Nature. 384. 184-187 (1996)).
Humans who are homozygous for mutant CCR-5 receptors which do not serve as co-receptors for HIV-1 in vitro apper to be unusually resistant to HIV-1 infection and are not immunocompromised by the presence of this genetic variant (Nature. 382. 722-725 (1996)). Absence of CCR-5 appears to confer protection from HΓV-1 infection (Nature. 382. 668-669 (1996)). Other chemokine receptors may be used by some strains of HTV-l or may be favored by non-sexual routes of transmission. Although most HIV- 1 isolates studied to date utilize CCR-5 or fusin, some can use both as well as the related CCR-2B and CCR-3 as co-receptors (Nature Medicine. 2(11), 1240-1243 (1996)). Nevertheless, drugs targeting chemokine receptors may not be unduly compromised by the genetic diversity of HTV-l (Zhang, et al., Nature. 383. 768 (1996)). Accordingly, an agent which could block chemokine receptors in humans who possess normal chemokine receptors should prevent infection in healthy individuals and slow or halt viral progression in infected patients. By focusing on the host's cellular immune response to HIV infection, better therapies towards all subtypes of HrV may be provided. These results indicate that inhibition of chemokine receptors presents a viable method for the prevention or treatment of infection by HrV and the prevention or treatment of AIDS. The peptides eotaxin, RANTES, MlP-lα, MlP-lβ, MCP-1, and MCP-3 are known to bind to chemokine receptors. As noted above, the inhibitors of HIV-1 replication present in supernatants of CD8+ T cells have been characterized as the β-chemokines RANTES, MlP-lα and MlP-lβ. PCT Patent Publication WO 97/10211 and EPO Patent Publication EP 0,673,928 disclose certain piperidines as tachykinin antagonists.
SUMMARY OF THE INVENTION
The present invention is directed to compounds which are modulators of chemokine receptor activity and are useful in the prevention or treatment of certain inflammatory and immunoregulatory disorders and diseases, including asthma and allergic diseases, as well as autoimmune pathologies such as rheumatoid arthritis and atherosclerosis. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which chemokine receptors are involved.
The present invention is further concerned with compounds which inhibit the entry of human immunodeficiency virus (HIV) into target cells and are of value in the prevention of infection by HPv7, the treatment of infection by HIV and the prevention and/or treatment of the resulting acquired immune deficiency syndrome (AIDS). The present invention also relates to pharmaceutical compositions containing the compounds and to a method of use of the present compounds and other agents for the prevention and treatment of AIDS and viral infection by HIV.
DETAILED DESCRIPTION OF THE INVENTION
The present invention is directed to compounds of formula I:
Figure imgf000007_0001
I
wherein: R1 is selected from a group consisting of: linear or branched Cl-8 alkyl, linear or branched C2-8 alkenyl, wherein the Cl-8 alkyl or C2-8 alkenyl is optionally mono, di, tri or tetra substituted, where the substituents are independently selected from: (a) hydroxy,
(b) oxo,
(c) cyano,
(d) halogen which is selected from F, Cl, Br, and I,
(e) trifluoromethyl, (f) phenyl
(g) mono, di or tri-substituted phenyl, where the substituents are independently selected from: (1') phenyl, (2') hydroxy, (3') Ci-3alkyl,
(4') cyano,
(5') halogen,
(6') trifluoromethyl,
Figure imgf000007_0002
(9*) -NR6CONHR7,
(10') -NR6S(O)jR7, wherein j is 1 or 2,
(11') -CONR6R7,
(12') -COR6, (13') -CO2R6,
(14') -OR6, (15') -S(O)kR6, wherein k is 0, 1 or 2,
(h) Ci-6 alkyl, unsubstituted or substituted with hydroxy,
(i) -NR6R7,
Figure imgf000008_0001
(1) -NR6CONHR7,
Figure imgf000008_0002
(n) -CONR6R7,
(o) -COR6, (p) -CO2R6,
(q) -OCOR6,
(r) -CN, (s) -OR6, (t) -S(O)kR6, (u) -NR6CO-heteroaryl,
(v) -NR6S(O)j-heteroaryl, and
(w) heteroaryl, wherein heteroaryl is selected from the group consisting of:
(1') benzimidazolyl, (2') benzofuranyl,
(3') benzoxazolyl,
(4') furanyl,
(51) imidazolyl,
(6') indolyl, (7') isooxazolyl,
(8') isothiazolyl,
(91) oxadiazolyl,
(10') oxazolyl,
(11') pyrazinyl, (12') pyrazolyl,
(13') pyridyl,
(14') pyrimidyl,
(15') pyrrolyl,
(16') quinolyl, (17') tetrazolyl,
(18') thiadiazolyl,
(19') thiazolyl,
(20') thienyl, and
(21') triazolyl, wherein the heteroaryl is unsubstituted or mono di or tri- substituted, where the substituents are independently selected from:
(a") phenyl,
(b") hydroxy,
(c") oxo,
(d") cyano,
(e") halogen, and
(f) trifluoromethyl;
elected from the group consisting of:
(1) hydrogen,
(2) hydroxy,
(3) Cl-6 : alkyl,
(4) substituted Cl-6 alkyl, where the substituents are independently selected from:
(a) phenyl,
(b) hydroxy,
(c) oxo,
(d) halogen,
(e) trifluoromethyl,
(f) -N(R4)(R5)J wherein R4 and R^ are independently selected from hydrogen, Cl-10 linear or branched alkyl, and Cθ-6 alkyl substituted with C3-8 cycloalkyl
(g) -N(R4)-CO-O-(R5), and
(h) -N(R4')-CO-N(R )(R5), wherein R4' is selected from the definitions of R4,
(5) -O-Ci-6 alkyl, and
(6) phenyl; elected from the group consisting of:
(1) Ar,
(2) -N(R4)-CO-O-(Ci-6 alkyl)-Ar,
(3) -N(R4)-CO-O-R7,
(4) -(Cl-6 alkyl)-Ar,
(5) -(Cl-6 alkyl)-O-(Ci-6 alkyl)-Ar, and
(6) -(Cl-6 alkyl)-O-(Ci-6 alkyl)-Ar;
selecti ed from the group consisting of:
(1) phenyl,
(2) pyridyl,
(3) pyrimidyl,
(4) naphthyl,
(5) furyl,
(6) pyrryl,
(7) thienyl,
(8) isothiazolyl,
(9) imidazolyl,
(10) benzimidazolyl,
(11) tetrazolyl,
(12) pyrazinyl,
(13) quinolyl,
(14) isoquinolyl,
(15) benzofuryl,
(16) isobenzofuryl,
(I7) benzothienyl,
(18) pyrazolyl,
(19) indolyl,
(20) isoindolyl,
(21) purinyl,
(22) isoxazolyl,
(23) thiazolyl,
(24) oxazolyl,
(25) triazinyl, and (26) benzthiazolyl,
(27) benzoxazolyl,
(28) imidazopyrazinyl,
(29) triazolopyrazinyl, (30) naphthyridinyl,
(31) furopyridinyl,
(32) thiopyranopyrimidyl and the 5-oxide and 5-dioxide thereof,
(33) pyridazinyl,
(34) quinazolinyl, (35) pteridinyl,
(36) triazolopyrimidyl,
(37) triazolopyrazinyl,
(38) thiapurinyl,
(39) oxapurinyl, and (40) deazapurinyl, wherein Ar items (1) to (40) are unsubstituted or mono or di-substituted, where the substituents are independently selected from:
(a) Cl-3 alkyl, unsubstituted or substituted with a substituent selected from: (1') oxo,
(2') hydroxy,
(3") -OR7,
(4') phenyl,
(5') trifluoromethyl, and (6') phenyl or mono, di or tri-substituted phenyl, where the substituents are independently selected from: hydroxy, cyano, halogen, and trifluoromethyl ,
(b) halogen, (c) -OCi-6 alkyl,
(d) trifluoromethyl,
(e) hydroxy,
(f) -N02,
(g) -(CH2)pS(O)k-(Ci-6 alkyl), wherein p is 0, 1 or 2, (h) -(CH2)pS(O)j-NH2, (i) -(CH2)pS(O)j-NH(Ci-6 alkyl), (j) -(CH2)pS(O)j-NHR6 (k) -(CH2)pS(O)j-NR6-(Ci-6 alkyl), (1) -(CH2)pCONH2, (m) -(CH2)pCONH-(Ci-6 alkyl),
(n) -(CH2)pCONHR6, (o) -(CH2)pCONR6R7, (p) -(CH2)pCO2H, (q) -(CH2)pCO2-(Ci-6 alkyl),
Figure imgf000012_0001
(s) -(CH2)pNH-C(O)-Ci_6alkyl, (t) -(CH2)pNH-C(O)-NH2, (u) -(CH2)pNH-C(O)-NHCi-6alkyl, (v) -(CH2)pNH-C(O)-N(Cι-6 alkyl)2, (w) -(CH2)pNH-S(O)k-Ci-6alkyl,
(x) -(CH2)pN(Ci-3alkyl)-C(O)-N(diCi-6 alkyl), (y) -(CH2)p-heteroaryl, -C(O)-heteroaryl or
-(CH2)p-O-heteroaryl , wherein the heteroaryl is selected from the group consisting of: (1') benzimidazolyl,
(2') benzofuranyl,
(31) benzoxazolyl,
(4') furanyl,
(5') imidazolyl, (6') indolyl,
(7') isooxazolyl,
(8') isothiazolyl,
(9') oxadiazolyl,
(10') oxazolyl, (11') pyrazinyl,
(12') pyrazolyl,
(13') pyridyl or oxopyridyl,
(14') pyrimidyl,
(15') pyrrolyl, (16') quinolyl,
(17') tetrazolyl,
(18') thiadiazolyl,
(19') thiazolyl,
(20') thienyl, and
(21') triazolyl, wherein the heteroaryl group of items (1') to (21') is unsubstituted, or mono, di or tri-substituted, where the substituents are selected from:
10 (a') hydrogen,
(b') Cl-6 alkyl, branched or unbranched, unsubstituted or mono or di-substituted, where the substituents are selected from hydrogen and hydroxy,
15 (c') hydroxy,
(d') oxo,
(e') -OR6,
(f) halogen,
(g') trifluoromethyl,
20 (h') nitro,
(i') cyano,
(] ') -NHR6,
(k') -NR6R7,
(D -NHCOR6,
25 (m1) -NR6COR7,
(n') -NHCO2R6,
Figure imgf000013_0001
(P') -NHS(0)jR6,
(q') -NR6S(O)jR7,
30 (r') -CONRβR7,
(s') -COR6,
(f) -CO2R6, and
(u1) -S(O)jR6;
35 Bβ is selected from the group consisting of: (1) hydrogen,
(2) Cl-6 alkyl,
(3) substituted Cl-6 alkyl, where the substituents are independently selected from:
(a) phenyl,
(b) hydroxy,
(c) oxo,
(d) cyano,
(e) halogen,
(f) trifluoromethyl, and
(g) C5-8 cycloalkyl,
(4) phenyl,
(5) mono, di or tri-substituted phenyl, where the substituents are independently selected from:
(a) hydroxy,
(b) Ci-3alkyl,
(c) cyano,
(d) halogen, and
(e) trifluoromethyl;
selected from the group consisting of:
(1) hydrogen,
(2) Cl-6 alkyl or C5-8 cycloalkyl,
(3) substituted Cl-6 alkyl or C5-8 cycloalkyl, where the substituents are independently selected from:
(a) phenyl,
(b) mono, di or tri-substituted phenyl, where the substituent is independently selected from: (1') hydroxy, (2') Ci-3alkyl,
(3') cyano,
(4') halogen,
(5') trifluoromethyl, and
(6') Ci-3alkyloxy, (b) hydroxy, (c) oxo,
(d) cyano,
(e) halogen, and
(f) trifluoromethyl ,
(4) phenyl,
(5) mono, di or tri-substituted phenyl, where the substituents are independently selected from:
(a) hydroxy,
(b) Ci-3alkyl,
(c) cyano,
(d) halogen, and
(e) trifluoromethyl;
or R6 and R7 may be joined together to form a 5-, 6-, or 7- membered monocyclic saturated ring containing 1 or 2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, and in which the ring is unsubstituted or mono or di-substituted, the substituents independently selected from: (1) hydroxy,
(2) oxo,
(3) cyano,
(4) halogen,
(5) trifluoromethyl, m is an integer selected from 0, 1 and 2, n is an integer selected from 0, 1 and 2, and pharmaceutically acceptable salts thereof.
Preferred compounds of the present invention include those of formula la:
Figure imgf000015_0001
la wherein: R1 is selected from a group consisting of:
C3, C4, C5, Cβ, C7, or Cδ linear or branched alkyl, which is unsubstituted or mono, di or tri-substituted, where the substituents are independently selected from:
(a) hydroxy,
(b) Cl or F,
(c) phenyl, (d) mono, di or tri-substituted phenyl, where the substituents are independently selected from: (1') phenyl, (2') hydroxy, (3') Ci-3alkyl, (4') cyano,
(51) halogen, and (6') trifluoromethyl,
(e) Cl-6 alkyl, unsubstituted or substituted with hydroxy,
(f) -NR6CO-R7, wherein R6 is hydrogen or Ci-3 alkyl, unsubstituted or substituted with C5-8 cycloalkyl, and
R7 is Cl-6 alkyl, benzyl or phenyl which is unsubsituted or substituted with halo, CF3, Ci-3alkyl, or Ci-3alkoxy,
(g) -COR6, (h) -OR6,
(i) -NR6S(O)j-R7, where j is 1 or 2,
(j) -NR6S(O)j-heteroaryl, wherein heteroaryl is selected from the group consisting of:
(l1) benzimidazolyl, (2*) benzofuranyl,
(3') benzoxazolyl,
(4') furanyl,
(5') imidazolyl,
(6') indolyl, (7') isooxazolyl, (8') isothiazolyl,
(9') oxadiazolyl,
(10') oxazolyl,
(ID pyrazinyl,
(12') pyrazolyl,
(13') pyridyl,
(14') pyrimidyl,
(15') pyrrolyl,
(16') quinolyl, d7' tetrazolyl,
(is1 thiadiazolyl,
(i9*: thiazolyl,
(20r thienyl, and
(2r ) triazolyl, wherein the heteroaryl is unsubstituted or mono di or tri substitute d, where the substituents are independently selected ft •om:
(a') phenyl,
(b') hydroxy,
(c') oxo,
(d') cyano,
(e') halogen, and
(f) trifluoromethyl;
R2 is selected from the group consisting of:
(1) hydrogen
(2) hydroxy,
(3) Cl-6 alkyl
(4) -O-Ci-6 alkyl,
(5) phenyl,
(6) -N(CH3)-CO-N(H)(CH3),
(7) -N(H)-CO- ■O-CH3, and
(8) -CO-CH3;
R3 is selected from the group consisting of: (1) Ar,
(2) -(Cl-6 alkyl)-Ar,
(3) -(Cl-6 alkyl)-O-(Ci-6 alkyl)-Ar, and
(4) -N(R4)-CO-O-(Cl-6 alkyl)-Ar, wherein R4 is selected from hydrogen, Cl-10 linear or branched alkyl, and Cθ-6 alkyl substituted with C3-8 cycloalkyl,
(5) -N(R4)-CO-O-R7;
elected from the group consisting of: (1) phenyl,
(2) pyrazinyl,
(3) pyrazolyl,
(4) pyridyl,
(5) pyrimidyl, and (6) thienyl, wherein the Ar is unsubstituted or mono or di-substituted, and the substituents are independently selected from:
(a) C1-3 alkyl, unsubstituted or substituted with
(1') oxo, (2') hydroxy,
(3') -OR7, (4') phenyl, and (5') trifluoromethyl,
(b) halogen, (c) -OC1-6 alkyl,
(d) trifluoromethyl,
(e) -NO2,
(f) CONR6-(Cl-2 alkyl),
(g) CO2H, (h) CO2-(Cl-2 alkyl),
(i) CH2NR6-(Cι-2 alkyl),
(j) CH2NH-C(O)-Ci-3alkyl,
(k) CH2NH-C(O)NH2,
(1) CH2NH-C(O)NHCi-3alkyl, (m) CH2NH-C(O)N-diCl-3 alkyl), (n) CH NH-S(O)j-Ci-3alkyl,
(o) CH2-heteroaryl, with the heteroaryl is selected from the group consisting of: (1') imidazolyl, (2') oxazolyl,
(3') pyridyl, (4') tetrazolyl, (5') triazolyl, and the heteroaryl is unsubstituted, mono, di or tri- substituted, where the substituents selected from:
(a') hydrogen, (b') Cl-6 alkyl, branched or unbranched, unsubstituted or mono or di-substituted, the substituents being selected from hydrogen and hydroxy;
m is an integer selected from 0, 1 and 2, n is an integer selected from 0, 1 and 2, with the proviso that the sum of m + n is 2; and pharmaceutically acceptable salts thereof.
More preferred compounds of the present invention include those of formula lb:
Figure imgf000019_0001
lb
wherein:
Rl, R2 and R^ are as defined herein; and pharmaceutically acceptable salts thereof.
In the present invention it is preferred that elected from the group consisting of:
C3, C4, C5? Cβ, C7, or C8 linear or branched alkyl, which is unsubstituted or mono, di or tri-substituted, where the substituents are independently selected from: (a) hydroxy,
(b) Cl or F,
(c) phenyl,
(d) mono, di or tri-substituted phenyl, where the substituents are independently selected from: (1') phenyl,
(2') hydroxy, (3') Ci_3alkyl,
(4') cyano, (5') halogen, and (6') trifluoromethyl,
(e) Cl-6 alkyl, unsubstituted or substituted with hydroxy,
(f) -NR6CO-R7, wherein R6 is hydrogen or Cl-3 alkyl, unsubstituted or substituted with C5-8 cycloalkyl, and R7 is Cl-6 alkyl, benzyl or phenyl which is unsubsituted or substituted with halo, CF3, Ci-3alkyl, or Ci-3alkoxy,
(g) -COR6, (h) -OR6,
(i) -NRβS(O)j-R7, where j is 1 or 2, (j) -NR6S(O)j-heteroaryl, wherein heteroaryl is selected from the group consisting of:
(1') benzimidazolyl,
(2') benzofuranyl,
(31) benzoxazolyl, (4') furanyl,
(5') imidazolyl,
(6') indolyl,
(7') isooxazolyl,
(8') isothiazolyl, (9') oxadiazolyl,
(10') oxazolyl,
(ID pyrazinyl,
(12') pyrazolyl,
(13') pyridyl,
(14') pyrimidyl,
(15') pyrrolyl,
(16') quinolyl,
(ID tetrazolyl,
(18') thiadiazolyl,
(19') thiazolyl,
(20') thienyl, and
(21') triazolyl, wherein the heteroaryl is unsubstituted or mono di or tri substituted , where the substituents are independently selected from:
(a') phenyl,
(b') hydroxy,
(c') oxo,
(d1) cyano,
(e') halogen, and
(f) trifluoromethyl.
In the present invention it is preferred that if R^ is Ar, m is 1, n is 1, and R^ is C5 alkyl which bears a group selected from: -NR6R7, -NR6COR7, -NR6CO2R7, or -NR^CONHR7, then R1 does not bear a substituent which is 2,3-dichlorophenyl.
In the present invention it is preferred that pi bears at least one substituent which is selected from:
(a) -NR6CO-R7, wherein R6 is Ci-3 alkyl, unsubstituted or substituted with cyclohexyl, and R7 is Cl-6 alkyl, benzyl or phenyl which is unsubsituted or substituted with halo, CF3, Ci-3alkyl, or Ci-3alkoxy, and (b) -NR6S(O)j-R7, where j is 1 or 2. In the present invention it is more preferred that R1 is selected from the group consisting of:
C4, C5, C6, C7 or Cδ linear or branched alkyl, which is mono, di- or tri-substituted, where the substituents are independently selected from:
(a) hydroxy,
(b) Cl or F,
(c) phenyl, (d) mono, di or tri-substituted phenyl, where the substituents are independently selected from:
(1') hydroxy,
(20 methyl or ethyl,
(30 Cl or F, and (40 trifluoromethyl,
(e) Cl-6 alkyl, unsubstituted or substituted with hydroxy,
(f) -NR6CO-R7, wherein R6 is Ci-3 alkyl, unsubstituted or substituted with cyclohexyl, and R7 is Cl-6 alkyl, benzyl or phenyl which is unsubsituted or substituted with halo, CF3, Ci-3alkyl, or Ci-3alkoxy,
(g) -NR6S(O)j-R7, where j is 1 or 2.
In the present invention it is still more preferred that R1 is selected from the group consisting of: C4, C5, or C6 linear alkyl, which is substituted, where the substituents are independently selected from:
(a) phenyl,
(b) mono, di or tri-substituted phenyl, where the substituents are independently selected from: (10 hydroxy,
(20 methyl or ethyl, (30 Cl or F, and (40 trifluoromethyl,
(c) Cl-6 alkyl, unsubstituted or substituted with hydroxy, (d) -NR6CO-R7, wherein R6 is methyl, unsubstituted or substituted with cyclohexyl, and R7 is phenyl which is unsubstituted or substituted with Cl, F, CF3, Ci- 3alkyl or Ci-3alkoxy, and (e) -NR6S(O)j-R7, where j is 1 or 2.
In the present invention it is still more preferred that ! is C4 linear alkyl, which is substituted, where the substituents are independently selected from: (a) phenyl,
(b) mono, di or tri-substituted phenyl, where the substituents are independently selected from: (10 hydroxy,
(20 methyl or ethyl, (30 Cl or F, and
(40 trifluoromethyl,
(c) Cl-6 alkyl, unsubstituted or substituted with hydroxy, and
(d) -NR6S(O)j-R7, where R6 is methyl, unsubstituted or substituted with cyclohexyl, and R7 is phenyl which is unsubstituted or substituted with Cl, F, CF3, Ci- 3alkyl or Ci-3alkoxy, and j is 1 or 2.
In the present invention it is even more preferred that Rl IS:
Figure imgf000023_0001
wherein:
B is selected from the group consisting of: (a) phenyl, and (b) di or tri-substituted phenyl, wherein the substituents on phenyl are independently selected from: chloro, methyl, phenyl, Ci-3alkoxy, and CF3;
R" is Cl-3 alkyl, unsubstituted or substituted with cyclohexyl;
RlO is selected from the group consisting of:
(1) hydrogen, and
(2) Cl-6 alkyl, unsubstituted or substituted with hydroxy;
RU and Rl2 are independently selected from the group consisting of:
(1) hydrogen,
(2) hydroxy,
(3) methyl or ethyl,
(4) Cl or F, and
(5) trifluoromethyl.
In the present invention it is highly preferred that R1 is selected from the group consisting of:
Figure imgf000024_0001
Figure imgf000024_0002
In the present invention it is most preferred that R1 is selected from the group consisting of:
Figure imgf000025_0001
Figure imgf000025_0002
In the present invention it is preferred that R2 is selected from the group consisting of:
(1) hydrogen,
(2) hydroxy,
(3) Ci-6 alkyl,
(4) -O-Ci-6 alkyl,
(5) phenyl,
(6) -N(CH3)-CO-N(H)(CH3),
(7) -N(H)-CO-O-CH3, and
(8) -CO-CH3.
In the present invention it is more preferred that R2 is selected from the group consisting of:
(1) hydrogen,
(2) hydroxy, and
(3) phenyl.
In the present invention it is most preferred that
R2 is hydrogen.
In the present invention it is preferred that R3 is selected from the group consisting of: (1) Ar,
(2) -(Cl-6 alkyl)-Ar,
(3) -(Cl-6 alkyl)-O-(Ci-6 alkyl)-Ar, and
(4) -N(R )-CO-O-(Cl-6 alkyl)-Ar, wherein R is selected from hydrogen, Cl-10 linear or branched alkyl, and Cθ-6 alkyl substituted with C3-8 cycloalkyl,
(5) -N(R4)-C0-0-R7.
In the present invention it is more preferred that R3 is selected from the group consisting of:
(1) Ar,
(2) -(Cl-6 alkyl)-Ar,
(3) -N(R4)-CO-O-(Ci-6 alkyl)-Ar, wherein R4 is selected from hydrogen, Cl-10 linear or branched alkyl, and Cθ-6 alkyl substituted with C3-8 cycloalkyl, and
(4) -N(R4)-C0-0-R7.
In the present invention it is preferred that Ar is selected from the group consisting of: (1) phenyl,
(2) pyrazinyl,
(3) pyrazolyl,
(4) pyridyl,
(5) pyrimidyl, and (6) thienyl, wherein the Ar is unsubstituted or mono or di-substituted, and substituents are independently selected from:
(a) C1-3 alkyl, unsubstituted or substituted with
(10 oxo, (20 hydroxy,
(30 -OR7, (40 phenyl, and (50 trifluoromethyl,
(b) CONR6-(Ci-2 alkyl), (c) CO2H, (d) C02-(Cι-2 alkyl),
(e) CH2NR6-(Cι-2 alkyl),
(f) CH2NH-C(O)-Ci-3alkyl, (h) CH NH-C(O)NH2, (i) CH2NH-C(O)NHCι_3alkyl,
(j) CH2NH-C(O)N-diCι-3 alkyl), (k) CH2NH-S(O)j-Ci_3alkyl,
(1) CH -heteroaryl, with the heteroaryl is selected from the group consisting of: (10 imidazolyl,
(20 oxazolyl, (30 pyridyl, (40 tetrazolyl, (50 triazolyl, and the heteroaryl is unsubstituted, mono, di or tri- substituted, where the substituents selected from: (a') hydrogen, (b') Cl-6 alkyl, branched or unbranched, unsubstituted or mono or di-substituted, the substituents being selected from hydrogen and hydroxy.
In the present invention it is more preferred that Ar is selected from: phenyl, mono substituted phenyl or di-substituted phenyl, wherein the substituents are selected from the group consisting of:
(a) Cl-3 alkyl, unsubstituted or substituted with
(10 oxo, (20 hydroxy, or
(30 -OR6, wherein R6 is hydrogen or Cl-3 alkyl,
(b) -CH2NR6-(Cι-2 alkyl),
(c) -CH2NH-C(O)-Ci-3alkyl,
(d) -CH2NH-C(O)NH2, (i) -CH2NH-C(O)NHCi-3alkyl, (j) -CH2NH-C(O)N-diCi-3 alkyl), (k) -CH2NH-S(O)j-Ci-3alkyl,
(1) -CH -heteroaryl, where heteroaryl is selected from the group consisting of:
(10 imidazolyl, (20 oxazolyl, (30 pyridyl, (40 tetrazolyl, (50 triazolyl, and where heteroaryl is unsubstituted, mono, di or tri substituted, where the substituents are independently selected from:
(a') hydrogen, (b1) Cl-6 alkyl, branched or unbranched, unsubstituted or mono or disubstituted, where the substituents are selected from: hydrogen and hydroxy.
In the present invention it is more preferred that
R3 is selected from:
(1) phenyl, and
(2) -N(R4)-CO-O-(Ci-6 alkyD-phenyl, wherein R is selected from hydrogen, Ci-io linear or branched alkyl, and Cθ-6 alkyl substituted with C3-8 cycloalkyl.
In the present invention it is even more preferred that
R3 IS:
-N(R4)-CO-O-(CH2)-phenyl, wherein R is selected from hydrogen, Ci-6 linear or branched alkyl, and CH2 substituted with
C3-8 cycloalkyl.
In the present invention it is still more preferred that
R3 is: -N(R4)-CO-O-(CH2)-phenyl, wherein R is selected from hydrogen and Ci-6 alkyl.
In the present invention it is most preferred that R3 is:
-N(CH2CH3)-CO-O-(CH2)-phenyl.
In the present invention it is preferred that m is an integer selected from 0, 1 and 2, n is an integer selected from 0, 1 and 2, with the proviso that the sum of m + n is 2.
In the present invention it is more preferred that m is 1, and n is 1.
As appreciated by those of skill in the art, halo as used herein are intended to include chloro, fluoro, bromo and iodo. Similarly, Cl-6, as in Ci-6alkyl is defined to identify the group as having 1, 2, 3, 4, 5, or 6 carbons, such that Cl-6alkyl specifically includes methyl, ethyl, propyl, butyl, pentyl, hexyl, and cyclohexyl.
Exemplifying the invention is the use of the compounds disclosed in the Examples and herein.
Preferred compounds of the present invention include the compounds of the formula:
Figure imgf000030_0001
wherein:
R a Rb hydrogen
chloro
hydrogen
chloro
hydrogen
chloro
hydrogen
chloro
Figure imgf000030_0002
and pharmaceutically acceptable salts thereof. Specific compounds within the present invention include a compound which selected from the group consisting of:
Figure imgf000031_0001
Figure imgf000032_0001
Figure imgf000033_0001
Figure imgf000033_0002
Figure imgf000033_0003
Figure imgf000033_0004
31-
Figure imgf000034_0001
Figure imgf000035_0001
Figure imgf000035_0002
Figure imgf000035_0003
Figure imgf000036_0001
Figure imgf000036_0002
Figure imgf000036_0003
Figure imgf000037_0001
Figure imgf000037_0002
Figure imgf000037_0003
Figure imgf000038_0001
Cl
Figure imgf000038_0002
Figure imgf000038_0003
Figure imgf000039_0001
Figure imgf000039_0002
Figure imgf000039_0003
Figure imgf000039_0004
Figure imgf000040_0001
Figure imgf000040_0002
Figure imgf000041_0001
Figure imgf000041_0002
Figure imgf000041_0003
Figure imgf000042_0001
Figure imgf000042_0002
Figure imgf000042_0003
Figure imgf000043_0001
Figure imgf000043_0002
Figure imgf000043_0003
Figure imgf000044_0001
Figure imgf000044_0002
Figure imgf000044_0003
Figure imgf000045_0001
Figure imgf000045_0002
Figure imgf000045_0003
Figure imgf000045_0004
Figure imgf000046_0001
Figure imgf000046_0002
Figure imgf000046_0003
Figure imgf000047_0001
Figure imgf000047_0002
Figure imgf000047_0003
Figure imgf000048_0001
Figure imgf000048_0002
46-
Figure imgf000049_0001
Figure imgf000049_0002
Figure imgf000050_0001
48-
Figure imgf000051_0001
49
Figure imgf000052_0001
Figure imgf000052_0002
Figure imgf000052_0003
50-
Figure imgf000053_0001
Figure imgf000053_0002
Figure imgf000054_0001
Figure imgf000054_0002
Figure imgf000054_0003
Figure imgf000054_0004
Figure imgf000055_0001
Figure imgf000055_0002
Figure imgf000055_0003
Figure imgf000055_0004
Figure imgf000056_0001
Figure imgf000056_0002
Figure imgf000056_0003
Figure imgf000056_0004
Figure imgf000057_0001
Figure imgf000057_0002
Figure imgf000057_0003
Figure imgf000057_0004
Figure imgf000058_0001
Figure imgf000058_0002
Figure imgf000058_0003
Figure imgf000058_0004
Figure imgf000059_0001
Figure imgf000059_0002
57
Figure imgf000060_0001
Figure imgf000060_0002
Figure imgf000060_0003
Figure imgf000060_0004
Figure imgf000061_0001
Figure imgf000061_0002
Figure imgf000061_0003
-59-
Figure imgf000062_0001
Figure imgf000062_0002
Figure imgf000062_0003
60
Figure imgf000063_0001
Figure imgf000063_0002
Figure imgf000064_0001
Figure imgf000064_0002
Figure imgf000064_0003
-62-
Figure imgf000065_0001
Figure imgf000065_0002
Figure imgf000065_0003
Figure imgf000066_0001
Figure imgf000066_0002
Figure imgf000066_0003
Figure imgf000067_0001
Figure imgf000068_0001
Figure imgf000068_0002
Figure imgf000068_0003
-66
Figure imgf000069_0001
Figure imgf000069_0002
Figure imgf000069_0003
Figure imgf000070_0001
Figure imgf000070_0002
Figure imgf000070_0003
Figure imgf000071_0001
Figure imgf000072_0001
Figure imgf000072_0002
Figure imgf000072_0003
Figure imgf000073_0001
Figure imgf000074_0001
Figure imgf000075_0001
^^
Figure imgf000075_0002
Figure imgf000076_0001
Figure imgf000076_0002
Figure imgf000076_0003
Figure imgf000076_0004
Figure imgf000077_0001
Figure imgf000077_0002
Figure imgf000077_0003
Figure imgf000077_0004
Figure imgf000078_0001
Figure imgf000078_0002
Figure imgf000079_0001
Figure imgf000079_0002
Figure imgf000079_0003
Figure imgf000079_0004
Figure imgf000080_0001
Figure imgf000081_0001
Figure imgf000082_0001
Figure imgf000083_0001
Figure imgf000083_0002
Figure imgf000083_0003
Figure imgf000083_0004
cn
Figure imgf000084_0001
Figure imgf000084_0002
Figure imgf000085_0001
cn
Figure imgf000086_0001
Figure imgf000087_0001
Figure imgf000087_0002
Figure imgf000087_0003
Figure imgf000087_0004
Figure imgf000088_0001
cn
Figure imgf000089_0001
Figure imgf000090_0001
Figure imgf000090_0002
Figure imgf000090_0003
Figure imgf000090_0004
Figure imgf000090_0005
Figure imgf000091_0001
Figure imgf000092_0001
Figure imgf000092_0002
Figure imgf000092_0003
Figure imgf000093_0001
Figure imgf000094_0001
Figure imgf000095_0001
Figure imgf000096_0001
Figure imgf000097_0001
Figure imgf000098_0001
Figure imgf000099_0001
Figure imgf000100_0001
Figure imgf000100_0002
and pharmaceutically acceptable salts thereof.
The subject compounds are useful in a method of modulating chemokine receptor activity in a patient in need of such modulation comprising the administration of an effective amount of the compound.
The present invention is directed to the use of the foregoing spiro-substituted azacycles as modulators of chemokine receptor activity. In particular, these compounds are useful as modulators of the chemokine receptors, including CCR-1, CCR-2, CCR-2A, CCR-2B, CCR- 3, CCR-4, CCR-5, CXCR-3, and/or CXCR-4.
The utility of the compounds in accordance with the present invention as modulators of chemokine receptor activity may be demonstrated by methodology known in the art, such as the assay for CCR-1 and/or CCR-5 binding as disclosed by Van Riper, et al., J. Exp. Med.. 177. 851-856 (1993), and the assay for CCR-2 and/or CCR-3 binding as disclosed by Daugherty, et al., J. Exp. Med.. 183. 2349-2354 (1996). Cell lines for expressing the receptor of interest include those naturally expressing the receptor, such as EOL-3 or THP-1, or a cell engineered to express a recombinant receptor, such as CHO, RBL-2H3, HEK-293. For example, a CCR3 transfected AML14.3D10 cell line has been placed on restricted deposit with American Type Culture Collection in Rockville, Maryland as ATCC No. CRL-12079, on April 5, 1996. The utility of the compounds in accordance with the present invention as inhibitors of the spread of HIV infection in cells may be demonstrated by methodology known in the art, such as the HIV quantitation assay disclosed by Nunberg, et al., J. Virology. 65 (9), 4887-4892 (1991).
In particular, the compounds of the following examples had activity in binding to either the CCR-5 receptor or the CCR-3 receptor in the aforementioned assays, generally with an IC50 of less than about 10 μM. Such a result is indicative of the intrinsic activity of the compounds in use as modulators of chemokine receptor activity.
Mammalian chemokine receptors provide a target for interfering with or promoting eosinophil and/or lymphocyte function in a mammal, such as a human. Compounds which inhibit or promote chemokine receptor function, are particularly useful for modulating eosinophil and/or lymphocyte function for therapeutic purposes. Accordingly, the present invention is directed to compounds which are useful in the prevention and/or treatment of a wide variety of inflammatory and immunoregulatory disorders and diseases, including asthma and allergic diseases, as well as autoimmune pathologies such as rheumatoid arthritis and atherosclerosis.
For example, an instant compound which inhibits one or more functions of a mammalian chemokine receptor (e.g., a human chemokine receptor) may be administered to inhibit (i.e., reduce or prevent) inflammation. As a result, one or more inflammatory processes, such as leukocyte emigration, chemotaxis, exocytosis (e.g., of enzymes, histamine) or inflammatory mediator release, is inhibited. For example, eosinophilic infiltration to inflammatory sites (e.g., in asthma) can be inhibited according to the present method.
Similarly, an instant compound which promotes one or more functions of a mammalian chemokine receptor (e.g., a human chemokine) is administered to stimulate (induce or enhance) an inflammatory response, such as leukocyte emigration, chemotaxis, exocytosis (e.g., of enzymes, histamine) or inflammatory mediator release, resulting in the beneficial stimulation of inflammatory processes. For example, eosinophils can be recruited to combat parasitic infections. In addition to primates, such as humans, a variety of other mammals can be treated according to the method of the present invention. For instance, mammals including, but not limited to, cows, sheep, goats, horses, dogs, cats, guinea pigs, rats or other bovine, ovine, equine, canine, feline, rodent or murine species can be treated. However, the method can also be practiced in other species, such as avian species (e.g., chickens).
Diseases and conditions associated with inflammation and infection can be treated using the method of the present invention. In a preferred embodiment, the disease or condition is one in which the actions of eosinophils and/or lymphocytes are to be inhibited or promoted, in order to modulate the inflammatory response.
Diseases or conditions of humans or other species which can be treated with inhibitors of chemokine receptor function, include, but are not limited to: inflammatory or allergic diseases and conditions, including respiratory allergic diseases such as asthma, allergic rhinitis, hypersensitivity lung diseases, hypersensitivity pneumonitis, eosinophilic pneumonias (e.g., Loeffler's syndrome, chronic eosinophilic pneumonia), delayed-type hypersentitivity, interstitial lung diseases (ILD) (e.g., idiopathic pulmonary fibrosis, or ILD associated with rheumatoid arthritis, systemic lupus erythematosus, ankylosing spondylitis, systemic sclerosis, Sjogren's syndrome, polymyositis or dermatomyositis); systemic anaphylaxis or hypersensitivity responses, drug allergies (e.g., to penicillin, cephalosporins), insect sting allergies; autoimmune diseases, such as rheumatoid arthritis, psoriatic arthritis, multiple sclerosis, systemic lupus erythematosus, myasthenia gravis, juvenile onset diabetes; glomerulonephritis, autoimmune thyroiditis, Behcet's disease; graft rejection (e.g., in transplantation), including allograft rejection or graft-versus-host disease; inflammatory bowel diseases, such as Crohn's disease and ulcerative colitis; spondyloarthropathies; scleroderma; psoriasis (including T-cell mediated psoriasis) and inflammatory dermatoses such an dermatitis, eczema, atopic dermatitis, allergic contact dermatitis, urticaria; vasculitis (e.g., necrotizing, cutaneous, and hypersensitivity vasculitis); eosinphilic myositis, eosinophilic fasciitis; cancers with leukocyte infiltration of the skin or organs. Other diseases or conditions in which undesirable inflammatory responses are to be inhibited can be treated, including, but not limited to, reperfusion injury, atherosclerosis, certain hematologic malignancies, cytokine-induced toxicity (e.g., septic shock, endotoxic shock), polymyositis, dermatomyositis. Diseases or conditions of humans or other species which can be treated with promoters of chemokine receptor function, include, but are not limited to: immunosuppression, such as that in individuals with immunodeficiency syndromes such as AIDS, individuals undergoing radiation therapy, chemotherapy, therapy for autoimmune disease or other drug therapy (e.g., corticosteroid therapy), which causes immunosuppression; immunosuppression due congenital deficiency in receptor function or other causes; and infectious diseases, such as parasitic diseases, including, but not limited to helminth infections, such as nematodes (round worms); (Trichuriasis, Enterobiasis, Ascariasis, Hookworm, Strongyloidiasis, Trichinosis, fϊlariasis); trematodes (flukes) (Schistosomiasis, Clonorchiasis), cestodes (tape worms) (Echinococcosis, Taeniasis saginata, Cysticercosis); visceral worms, visceral larva migrans (e.g., Toxocara), eosinophilic gastroenteritis (e.g., Anisaki spp., Phocanema ssp.), cutaneous larva migrans (Ancylostona braziliense, Ancylostoma caninum) .
The compounds of the present invention are accordingly useful in the prevention and treatment of a wide variety of inflammatory and immunoregulatory disorders and diseases. In another aspect, the instant invention may be used to evaluate putative specific agonists or antagonists of chemokine receptors, including CCR-1, CCR-2, CCR-2A, CCR-2B, CCR-3, CCR-4, CCR-5, CXCR-3, and CXCR-4. Accordingly, the present invention is directed to the use of these compounds in the preparation and execution of screening assays for compounds which modulate the activity of chemokine receptors. For example, the compounds of this invention are useful for isolating receptor mutants, which are excellent screening tools for more potent compounds. Furthermore, the compounds of this invention are useful in establishing or determining the binding site of other compounds to chemokine receptors, e.g., by competitive inhibition. The compounds of the instant invention are also useful for the evaluation of putative specific modulators of the chemokine receptors, including CCR-1, CCR-2, CCR-2A, CCR-2B, CCR-3, CCR-4, CCR-5, CXCR-3, and CXCR-4. As appreciated in the art, thorough evaluation of specific agonists and antagonists of the above chemokine receptors has been hampered by the lack of availability of non-peptidyl (metabolically resistant) compounds with high binding affinity for these receptors. Thus the compounds of this invention are commercial products to be sold for these purposes. The present invention is further directed to a method for the manufacture of a medicament for modulating chemokine receptor activity in humans and animals comprising combining a compound of the present invention with a pharmaceutical carrier or diluent.
The present invention is further directed to the use of these compounds in the prevention or treatment of infection by a retrovirus, in particular, the human immunodeficiency virus (HIV) and the treatment of, and delaying of the onset of consequent pathological conditions such as AIDS. Treating AIDS or preventing or treating infection by HIV is defined as including, but not limited to, treating a wide range of states of HIV infection: AIDS, ARC (AIDS related complex), both symptomatic and asymptomatic, and actual or potential exposure to HIV. For example, the compounds of this invention are useful in treating infection by HIV after suspected past exposure to HIV by, e.g., blood transfusion, organ transplant, exchange of body fluids, bites, accidental needle stick, or exposure to patient blood during surgery.
In a preferred aspect of the present invention, a subject compound may be used in a method of inhibiting the binding of a human immunodeficiency virus to a chemokine receptor, such as CCR-5 and/or CXCR-4, of a target cell, which comprises contacting the target cell with an amount of the compound which is effective at inhibiting the binding of the virus to the chemokine receptor.
The subject treated in the methods above is a mammal, preferably a human being, male or female, in whom modulation of chemokine receptor activity is desired. "Modulation" as used herein is intended to encompass antagonism, agonism, partial antagonism and/or partial agonism. The term "therapeutically effective amount" means the amount of the subject compound that will elicit the biological or medical response of a tissue, system, animal or human that is being sought by the researcher, veterinarian, medical doctor or other clinician.
The term "composition" as used herein is intended to encompass a product comprising the specified ingredients in the specified amounts, as well as any product which results, directly or indirectly, from combination of the specified ingredients in the specified amounts. By "pharmaceutically acceptable" it is meant the carrier, diluent or excipient must be compatible with the other ingredients of the formulation and not deleterious to the recipient thereof.
The terms "administration of and or "administering a" compound should be understood to mean providing a compound of the invention or a prodrug of a compound of the invention to the individual in need of treatment.
Combined therapy to modulate chemokine receptor activity and thereby prevent and treat inflammatory and immunoregulatory disorders and diseases, including asthma and allergic diseases, as well as autoimmune pathologies such as rheumatoid arthritis and atherosclerosis, and those pathologies noted above is illustrated by the combination of the compounds of this invention and other compounds which are known for such utilities. For example, in the treatment or prevention of inflammation, the present compounds may be used in conjunction with an antiinflammatory or analgesic agent such as an opiate agonist, a lipoxygenase inhibitor, such as an inhibitor of 5-lipoxygenase, a cyclooxygenase inhibitor, such as a cyclooxygenase-2 inhibitor, an interleukin inhibitor, such as an interleukin-1 inhibitor, an NMDA antagonist, an inhibitor of nitric oxide or an inhibitor of the synthesis of nitric oxide, a non-steroidal antiinflammatory agent, or a cytokine- suppressing antiinflammatory agent, for example with a compound such as acetaminophen, asprin, codiene, fentanyl, ibuprofen, indomethacin, ketorolac, morphine, naproxen, phenacetin, piroxicam, a steroidal analgesic, sufentanyl, sunlindac, tenidap, and the like. Similarly, the instant compounds may be administered with a pain reliever; a potentiator such as caffeine, an H2-antagonist, simethicone, aluminum or magnesium hydroxide; a decongestant such as phenyl ephrine, phenylpropanolamine, pseudophedrine, oxymetazoline, ephinephrine, naphazoline, xylometazoline, propylhexedrine, or levo- desoxy-ephedrine; an antiitussive such as codeine, hydrocodone, caramiphen, carbetapentane, or dextramethorphan; a diuretic; and a sedating or non-sedating antihistamine. The present invention is further directed to combinations of the present compounds with one or more agents useful in the prevention or treatment of AIDS. For example, the compounds of this invention may be effectively administered, whether at periods of pre-exposure and/or post-exposure, in combination with effective amounts of the AIDS antivirals, immunomodulators, anti-infectives, or vaccines known to those of ordinary skill in the art.
ANTIVIRALS
Drug Name Manufacturer Indication 097 Hoechst/Bayer HIV infection, AIDS, ARC (non-nucleoside reverse transcriptase inhibitor)
141 W94 Glaxo Wellcome HIV infection, AIDS, ARC (protease inhibitor)
1592U89 Glaxo Wellcome HIV infection, AIDS, ARC Acemannan Carrington Labs ARC (Irving, TX)
Acyclovir Burroughs Wellcome HIV infection, AIDS,
ARC, in combination with
AZT
AD-439 Tanox Biosystems HIV infection, AIDS,
ARC
AD-519 Tanox Biosystems HIV infection, AIDS,
ARC
Adefovir dipivoxil Gilead Sciences HIV infection AL-721 Ethigen ARC, PGL
(Los Angeles, CA) HIV positive, AIDS
Alpha Interferon Glaxo Wellcome Kaposi's sarcoma,
HrV in combination w/Retrovir Ansamycin Adria Laboratories ARC LM 427 (Dublin, OH) Erbamont (Stamford, CT)
Antibody which Advanced Biotherapy AIDS, ARC neutralizes pH Concepts labile alpha aberrant (Rockville, MD) Interferon AR177 Aronex Pharm HIV infection, AIDS,
ARC beta-fluoro-ddA Nat'l Cancer Institute AIDS-associated diseases
(-) 6-Chloro-4(S)- Merck HIV infection, cyclopropylethynyl- AIDS, ARC
4(S)-trifluoro- (non-nucleoside methyl- 1 ,4-dihydro- reverse
2H-3,l-benzoxazin- transcriptase
2-one inhibitor)
CI-1012 Warner-Lambert HIV-1 infection
Cidofovir Gilead Science CMV retinitis, herpes, papillomavirus
Curdlan sulfate AJI Pharma USA HIV infection Cytomegalovirus Medlmmune CMV retinitis immune globin Cytovene Syntex sight threatening Ganciclovir CMV peripheral CMV retinitis
Delaviridine Pharmacia-Upjohn HIV infection,
AIDS, ARC
(protease inhibitor)
Dextran Sulfate Ueno Fine Chem. AIDS, ARC, HIV Ind. Ltd. (Osaka, positive asymptomatic Japan) ddC Hoffman-La Roche HIV infection, AIDS,
Dideoxycytidine ARC ddl Bristol-Myers Squibb HrV infection, AIDS,
Dideoxyinosine ARC; combination with AZT/d4T
DMP-450 AVID HIV infection,
(Camden, NJ) AIDS, ARC (protease inhibitor)
EL10 Elan Corp, PLC HIV infection (Gainesville, GA)
Efavirenz, DMP- DuPont-Merck HIV infection,
266 Pharmaceuticals AIDS, ARC
(non-nucleoside reverse transcriptase inhibitor)
Famciclovir Smith Kline herpes zoster, herpes simplex
FTC Emory University HIV infection, AIDS, ARC
(reverse transcriptase inhibitor)
GS 840 Gilead HIV infection, AIDS, ARC (reverse transcriptase inhibitor)
GW 141 Glaxo Welcome HIV infection, AIDS, ARC (protease inhibitor)
GW 1592 Glaxo Welcome HIV infection, AIDS, ARC (reverse transcriptase inhibitor) HBY097 Hoechst Marion HIV infection, Roussel AIDS, ARC
(non-nucleoside reverse transcriptase inhibitor)
Hypericin VIMRx Pharm. HIV infection, AIDS,
ARC
Recombinant Human Triton Biosciences AIDS, Kaposi's Interferon Beta (Almeda, CA) sarcoma, ARC Interferon alfa-n3 Interferon Sciences ARC, AIDS Indinavir Merck HIV infection, AIDS,
ARC, asymptomatic
Hr positive, also in combination with
AZT/ddl/ddC
ISIS 2922 ISIS Pharmaceuticals CMV retinitis KNI-272 Nat'l Cancer Institute HIV-assoc. diseases
Lamivudine, 3TC Glaxo Wellcome HIV infection,
AIDS, ARC
(reverse transcriptase inhibitor); also with AZT
Lobucavir Bristol-Myers Squibb CMV infection Nelfϊnavir Agouron HIV infection,
Pharmaceuticals AIDS, ARC
(protease inhibitor)
Nevirapine Boeheringer HIV infection, Ingleheim AIDS, ARC
(protease inhibitor)
Novapren Novaferon Labs, Inc. HIV inhibitor (Akron, OH) Peptide T Peninsula Labs AIDS
Octapeptide (Belmont, CA)
Sequence
Tris odium Astra Pharm. CMV retinitis, HIV
Phosphonoformate Products, Inc infection, other CMV infections
PNU-140690 Pharmacia Upjohn HIV infection, AIDS, ARC (protease inhibitor)
Probucol Vyrex HIV infection, AIDS RBC-CD4 Sheffield Med. HIV infection, Tech (Houston TX) AIDS, ARC
Ritonavir Abbott HIV infection, AIDS, ARC (protease inhibitor) Saquinavir Hoffmann- HIV infection, LaRoche AIDS, ARC (protease inhibitor)
Stavudine; d4T Bristol-Myers Squibb HIV infection, AIDS,
Didehydrodeoxy- ARC thymidine
Valaciclovir Glaxo Wellcome genital HSV & CMV infections
Virazole Viratek/ICN asymptomatic HIV Ribavirin (Costa Mesa, CA) positive, LAS, ARC
VX-478 Vertex HIV infection, AIDS, ARC
Zalcitabine Hoffmann-La Roche HIV infection, AIDS, ARC, with AZT Zidovudine; AZT Glaxo Wellcome HIV infection, AIDS, ARC, Kaposi's sarcoma, in combination with other therapies
IMMUNO-MODULATORS
Drug Name Manufacturer Indication
AS-101 Wyeth-Ayerst AIDS
Bropirimine Pharmacia Upjohn advanced AIDS
Acemannan Carrington Labs, Inc. AIDS, ARC (Irving, TX)
CL246,738 American Cyanamid AIDS, Kaposi's
Lederle Labs sarcoma
EL10 Elan Corp, PLC HIV infection (Gainesville, GA)
Gamma Interferon Genentech ARC, in combination w/TNF (tumor necrosis factor)
Granulocyte Genetics Institute AIDS
Macrophage Colony Sandoz
Stimulating
Factor
Granulocyte Hoeschst-Roussel AIDS
Macrophage Colony Immunex
Stimulating
Factor
Granulocyte Schering-Plough AIDS, combination
Macrophage Colony w/AZT
Stimulating Factor
HIV Core Particle Rorer seropositive HIV
Immunostimulant IL-2 Cetus AIDS, in combination
Interleukin-2 w/AZT
IL-2 Hoffman-La Roche AIDS, ARC, HIV, in
Interleukin-2 Immunex combination w/AZT
IL-2 Chiron AIDS, increase in CD4
Interleukin-2 cell counts
(aldeslukin)
Immune Globulin Cutter Biological pediatric AIDS, in
Intravenous (Berkeley, CA) combination w/AZT
(human)
IMREG-1 Imreg AIDS, Kaposi's
(New Orleans, LA) sarcoma, ARC, PGL
IMREG-2 Imreg AIDS, Kaposi's
(New Orleans, LA) sarcoma, ARC, PGL
Imuthiol Diethyl Merieux Institute AIDS, ARC
Dithio Carbamate
Alpha-2 Schering Plough Kaposi's sarcoma
Interferon w/AZT, AIDS
Methionine- TNI Pharmaceutical AIDS, ARC
Enkephalin (Chicago, IL)
MTP-PE Ciba-Geigy Corp. Kaposi's sarcoma
Muramyl-Tripeptide
Granulocyte Amgen AIDS, in combination
Colony Stimulating w/AZT
Factor
Remune Immune Response immunotherapeutic
Corp. rCD4 Genentech AIDS, ARC
Recombinant
Soluble Human CD4 rCD4-IgG AIDS, ARC hybrids
Recombinant Biogen AIDS, ARC
Soluble Human CD4 Interferon Hoffman-La Roche Kaposi's sarcoma
Alfa 2a AIDS, ARC, in combination w/AZT
SK&F106528 Smith Kline HIV infection
Soluble T4
Thymopentin Immunobiology HIV infection Research Institute (Annandale, NJ)
Tumor Necrosis Genentech ARC, in combination
Factor; TNF w/gamma Interferon
ANTI-INFECTIVES
Drug Name Manufacturer Indication
Clindamycin with Pharmacia Upjohn PCP
Primaquine
Fluconazole Pfizer cryptococcal meningitis, candidiasis
Pastille Squibb Corp. prevention of
Nystatin Pastille oral candidiasis
Ornidyl Merrell Dow PCP
Eflornithine
Pentamidine LyphoMed PCP treatment
Isethionate (IM & IV) (Rosemont, IL)
Trimethoprim antibacterial
Trimethoprim/sulfa antibacterial
Piritrexim Burroughs Wellcome PCP treatment
Pentamidine Fisons Corporation PCP prophylaxis isethionate for inhalation
Spiramycin Rhone-Poulenc cryptosporidial diarrhea Intraconazole- Janssen Pharm. histoplasmosis; R51211 cryptococcal meningitis
Trimetrexate Warner-Lambert PCP
OTHER
Drug Name Manufacturer Indication
Daunorubicin NeXstar, Sequus Karposi's sarcoma
Recombinant Human Ortho Pharm. Corp. severe anemia Erythropoietin assoc. with AZT therapy
Recombinant Human Serono AIDS-related wasting, Growth Hormone cachexia Megestrol Acetate Bristol-Myers Squibb treatment of anorexia assoc. w/AIDS
Testosterone Alza, Smith Kline AIDS-related wasting Total Enteral Norwich Eaton diarrhea and Nutrition Pharmaceuticals malabsorption related to AIDS
It will be understood that the scope of combinations of the compounds of this invention with AIDS antivirals, immunomodulators, anti-infectives or vaccines is not limited to the list in the above Table, but includes in principle any combination with any pharmaceutical composition useful for the treatment of AIDS. Preferred combinations are simultaneous or alternating treatments of with a compound of the present invention and an inhibitor of HrV protease and/or a non-nucleoside inhibitor of HIV reverse transcriptase. An optional fourth component in the combination is a nucleoside inhibitor of HIV reverse transcriptase, such as AZT, 3TC, ddC or ddl. A preferred inhibitor of HIV protease is indinavir, which is the sulfate salt of N-(2(R)-hydroxy-l(S)-indanyl)-2(R)-phenylmethyl-4-(S)- hydroxy-5-(l-(4-(3-pyridyl-methyl)-2(S)-N'-(t-butylcarbo-xamido)- piperazinyl))-pentaneamide ethanolate, and is synthesized according to U.S. 5,413,999. Indinavir is generally administered at a dosage of 800 mg three times a day. Other preferred inhibitors of HrV protease include nelfinavir and ritonavir. Preferred non-nucleoside inhibitors of HIV reverse transcriptase include (-) 6-chloro-4(S)-cyclopropylethynyl- 4(S)-trifluoromethyl-l,4-dihydro-2H-3,l-benzoxazin-2-one, which may be prepared by methods disclosed in EP 0,582,455. The preparation of ddC, ddl and AZT are also described in EPO 0,484,071. These combinations may have unexpected effects on limiting the spread and degree of infection of HrV. Preferred combinations with the compounds of the present invention include the following (1) indinavir, with efavirenz or (-) 6-chloro-4(S)-cyclopropylethynyl-4(S)-trifluoromethyl-l,4-dihydro-2H- 3,l-benzoxazin-2-one, and, optionally, AZT and/or 3TC and or ddl and/or ddC; (2) indinavir, and any of AZT and/or ddl and/or ddC.
In such combinations the compound of the present invention and other active agents may be administered separately or in conjunction. In addition, the administration of one element may be prior to, concurrent to, or subsequent to the administration of other agent(s).
The compounds of the present invention may be administered by oral, parenteral (e.g., intramuscular, intraperitoneal, intravenous, ICV, intracisternal injection or infusion, subcutaneous injection, or implant), by inhalation spray, nasal, vaginal, rectal, sublingual, or topical routes of administration and may be formulated, alone or together, in suitable dosage unit formulations containing conventional non-toxic pharmaceutically acceptable carriers, adjuvants and vehicles appropriate for each route of administration. In addition to the treatment of warm-blooded animals such as mice, rats, horses, cattle, sheep, dogs, cats, monkeys, etc., the compounds of the invention are effective for use in humans.
The pharmaceutical compositions for the administration of the compounds of this invention may conveniently be presented in dosage unit form and may be prepared by any of the methods well known in the art of pharmacy. All methods include the step of bringing the active ingredient into association with the carrier which constitutes one or more accessory ingredients. In general, the pharmaceutical compositions are prepared by uniformly and intimately bringing the active ingredient into association with a liquid carrier or a finely divided solid carrier or both, and then, if necessary, shaping the product into the desired formulation. In the pharmaceutical composition the active object compound is included in an amount sufficient to produce the desired effect upon the process or condition of diseases. As used herein, the term "composition" is intended to encompass a product comprising the specified ingredients in the specified amounts, as well as any product which results, directly or indirectly, from combination of the specified ingredients in the specified amounts.
The pharmaceutical compositions containing the active ingredient may be in a form suitable for oral use, for example, as tablets, troches, lozenges, aqueous or oily suspensions, dispersible powders or granules, emulsions, hard or soft capsules, or syrups or elixirs. Compositions intended for oral use may be prepared according to any method known to the art for the manufacture of pharmaceutical compositions and such compositions may contain one or more agents selected from the group consisting of sweetening agents, flavoring agents, coloring agents and preserving agents in order to provide pharmaceutically elegant and palatable preparations. Tablets contain the active ingredient in admixture with non-toxic pharmaceutically acceptable excipients which are suitable for the manufacture of tablets. These excipients may be for example, inert diluents, such as calcium carbonate, sodium carbonate, lactose, calcium phosphate or sodium phosphate; granulating and disintegrating agents, for example, corn starch, or alginic acid; binding agents, for example starch, gelatin or acacia, and lubricating agents, for example magnesium stearate, stearic acid or talc. The tablets may be uncoated or they may be coated by known techniques to delay disintegration and absorption in the gastrointestinal tract and thereby provide a sustained action over a longer period. For example, a time delay material such as glyceryl monostearate or glyceryl distearate may be employed. They may also be coated by the techniques described in the U.S. Patents 4,256,108; 4,166,452; and 4,265,874 to form osmotic therapeutic tablets for control release.
Formulations for oral use may also be presented as hard gelatin capsules wherein the active ingredient is mixed with an inert solid diluent, for example, calcium carbonate, calcium phosphate or kaolin, or as soft gelatin capsules wherein the active ingredient is mixed with water or an oil medium, for example peanut oil, liquid paraffin, or olive oil.
Aqueous suspensions contain the active materials in admixture with excipients suitable for the manufacture of aqueous suspensions. Such excipients are suspending agents, for example sodium carboxymethylcellulose, methylcellulose, hydroxy- propylmethylcellulose, sodium alginate, polyvinyl- pyrrolidone, gum tragacanth and gum acacia; dispersing or wetting agents may be a naturally-occurring phosphatide, for example lecithin, or condensation products of an alkylene oxide with fatty acids, for example polyoxyethylene stearate, or condensation products of ethylene oxide with long chain aliphatic alcohols, for example heptadecaethyleneoxycetanol, or condensation products of ethylene oxide with partial esters derived from fatty acids and a hexitol such as polyoxyethylene sorbitol monooleate, or condensation products of ethylene oxide with partial esters derived from fatty acids and hexitol anhydrides, for example polyethylene sorbitan monooleate. The aqueous suspensions may also contain one or more preservatives, for example ethyl, or n-propyl, p-hydroxybenzoate, one or more coloring agents, one or more flavoring agents, and one or more sweetening agents, such as sucrose or saccharin.
Oily suspensions may be formulated by suspending the active ingredient in a vegetable oil, for example arachis oil, olive oil, sesame oil or coconut oil, or in a mineral oil such as liquid paraffin. The oily suspensions may contain a thickening agent, for example beeswax, hard paraffin or cetyl alcohol. Sweetening agents such as those set forth above, and flavoring agents may be added to provide a palatable oral preparation. These compositions may be preserved by the addition of an anti-oxidant such as ascorbic acid. Dispersible powders and granules suitable for preparation of an aqueous suspension by the addition of water provide the active ingredient in admixture with a dispersing or wetting agent, suspending agent and one or more preservatives. Suitable dispersing or wetting agents and suspending agents are exemplified by those already mentioned above. Additional excipients, for example sweetening, flavoring and coloring agents, may also be present.
The pharmaceutical compositions of the invention may also be in the form of oil-in-water emulsions. The oily phase may be a vegetable oil, for example olive oil or arachis oil, or a mineral oil, for example liquid paraffin or mixtures of these. Suitable emulsifying agents may be naturally- occurring gums, for example gum acacia or gum tragacanth, naturally-occurring phosphatides, for example soy bean, lecithin, and esters or partial esters derived from fatty acids and hexitol anhydrides, for example sorbitan monooleate, and condensation products of the said partial esters with ethylene oxide, for example polyoxyethylene sorbitan monooleate. The emulsions may also contain sweetening and flavoring agents.
Syrups and elixirs may be formulated with sweetening agents, for example glycerol, propylene glycol, sorbitol or sucrose. Such formulations may also contain a demulcent, a preservative and flavoring and coloring agents.
The pharmaceutical compositions may be in the form of a sterile injectable aqueous or oleagenous suspension. This suspension may be formulated according to the known art using those suitable dispersing or wetting agents and suspending agents which have been mentioned above. The sterile injectable preparation may also be a sterile injectable solution or suspension in a non-toxic parenterally-acceptable diluent or solvent, for example as a solution in 1,3-butane diol. Among the acceptable vehicles and solvents that may be employed are water, Ringer's solution and isotonic sodium chloride solution. In addition, sterile, fixed oils are conventionally employed as a solvent or suspending medium. For this purpose any bland fixed oil may be employed including synthetic mono- or diglycerides. In addition, fatty acids such as oleic acid find use in the preparation of injectables. The compounds of the present invention may also be administered in the form of suppositories for rectal administration of the drug. These compositions can be prepared by mixing the drug with a suitable non-irritating excipient which is solid at ordinary temperatures but liquid at the rectal temperature and will therefore melt in the rectum to release the drug. Such materials are cocoa butter and polyethylene glycols.
For topical use, creams, ointments, jellies, solutions or suspensions, etc., containing the compounds of The present invention are employed. (For purposes of this application, topical application shall include mouth washes and gargles.)
The pharmaceutical composition and method of the present invention may further comprise other therapeutically active compounds as noted herein which are usually applied in the treatment of the above mentioned pathological conditions.
In the treatment or prevention of conditions which require chemokine receptor modulation an appropriate dosage level will generally be about 0.01 to 500 mg per kg patient body weight per day which can be administered in single or multiple doses. Preferably, the dosage level will be about 0.1 to about 250 mg/kg per day; more preferably about 0.5 to about 100 mg/kg per day. A suitable dosage level may be about 0.01 to 250 mg/kg per day, about 0.05 to 100 mg/kg per day, or about 0.1 to 50 mg/kg per day. Within this range the dosage may be 0.05 to 0.5, 0.5 to 5 or 5 to 50 mg/kg per day. For oral administration, the compositions are preferably provided in the form of tablets containing 1.0 to 1000 milligrams of the active ingredient, particularly 1.0, 5.0, 10.0, 15.0. 20.0, 25.0, 50.0, 75.0, 100.0, 150.0, 200.0, 250.0, 300.0, 400.0, 500.0, 600.0, 750.0, 800.0, 900.0, and 1000.0 milligrams of the active ingredient for the symptomatic adjustment of the dosage to the patient to be treated. The compounds may be administered on a regimen of 1 to 4 times per day, preferably once or twice per day.
It will be understood, however, that the specific dose level and frequency of dosage for any particular patient may be varied and will depend upon a variety of factors including the activity of the specific compound employed, the metabolic stability and length of action of that compound, the age, body weight, general health, sex, diet, mode and time of administration, rate of excretion, drug combination, the severity of the particular condition, and the host undergoing therapy.
Several methods for preparing the compounds of this invention are illustrated in the following Schemes and Examples. Starting materials are made from known procedures or as illustrated.
Several methods for preparing the compounds of this invention are illustrated in the following Schemes and Examples.
SCHEME 1 RCHO, [H]
Figure imgf000121_0001
The compounds of the present invention are prepared by alkylating heterocycle I under appropriate conditions to provide compound II (Scheme 1). The required starting materials for preparing heterocycle I are available commercially or can be prepared using the methods given below.
Thus, heterocycle I is combined with the appropriate aldehyde and the intermediate imine or iminium species is reduced to the tertiary amine chemically (e.g. using sodium cyanoborohydride, sodium borohydride, or sodium triacetoxyborohydride) or catalytically (e.g. using hydrogen and palladium on carbon or Raney nickel catalyst) (Scheme 1). The aldehyde needed for this reaction can be prepared by methods generally known in the chemical literature; for the purposes of the present invention one preparation of a representative aldehyde is described in Hale, J.J.; Finke, P.E.; MacCoss, M. Bioorganic & Medicinal Chemistry Letters 1993,3, 319-322. In an alternative embodiment of the present invention, heterocycle I can be alkylated with an alkyl halide or alkyl sulfonate ester (with or without an added base to neutralize the mineral acid or sulfonic acid by-product) to give the desired compound (Scheme 1). The alkyl halide or alkyl sulfonate needed for this reaction can be prepared by methods generally known in the chemical literature; for the purposes of the present invention an aldehyde, prepared as described above, can be reduced to an alcohol with sodium borohydride, diisobutylaluminum hydride or lithium aluminum hydride, and the product alcohol converted to either the alkyl halide using methods described in March J. "Advanced Organic Chemistry", 4th ed., John
Wiley & Sons, New York, pp. 431-433 (1992), or alkyl sulfonate ester using methods described in March J. "Advanced Organic Chemistry", 4th ed., John Wiley & Sons, New York, p. 498-499 (1992).
In an alternative embodiment of the present invention, I can be acylated to give a tertiary amide; subsequent reduction with a strong reducing agent (e.g. diborane; borane in THF; borane dimethylsulfide, or lithium aluminum hydride) will give the desired compound (Scheme 1). The acylating agent needed for this reaction can be prepared by methods generally known in the chemical literature; for the purposes of the present invention an aldehyde, prepared as described above, can be oxidized using such commonly used reagents as permanganate in acid or silver oxide, and the resulting acid activated as an acid chloride or mixed anhydride which can be used to acylate I. The product amide can in and of itself be a chemokine receptor modulator or can be reduced as noted above to give the tertiary amine.
Optionally, compound II may be further modified in subsequent reactions, as illustrated below. SCHEME 2
HO OH Ph3P-Br2
V Br, Br
_/
CH3CN
Figure imgf000123_0001
In an alternative embodiment of the present invention, compounds of interest can be prepared by activating the hydroxyl groups of l,4-dihydroxy-2-butyne, for example by treatment with triphenyl- phosphine dibromide in acetonitrile, to give l,4-dibromo-2-butyne (Scheme 2). Displacement of one bromide with the sodium salt of an arylsulfonamide (wherein Rs and Rt are substituents on the phenyl or Ar as defined herein), followed by displacement of the other bromide with a suitable cyclic secondary amine, provides the acetylene derivative III. Palladium-catalysed hydrostannylation preferentially forms the 3- tributylstannyl olefin IV. The minor product from this reaction can also isolated and carried through the sequence described below. Compound IV can be converted to the corresponding 3-aryl derivative V by treatment with an aryl bromide (wherein Rx, Ry and Rz are substituents on the phenyl or heteroaryl as defined herein) in the presence of a suitable palladium catalyst at or above room temperature. Suitable catalysts include palladium acetate and triphenylphosphine, bis(triphenylphosphine) palladium (II) chloride, or palladium (0) bis(dibenzylidineacetone) in the presence of triphenylphosphine or tri-2- furylphosphine. Suitable solvents include 1,4-dioxane, DMF, and N- methyl pyrrolidinone. A base such as potassium carbonate or potassium phosphate may also be employed. Compound V may be employed as a chemokine receptor modulator itself or it can be reduced to saturated derivative VI by standard conditions, for example catalytic hydrogenation with palladium on carbon or with palladium hydroxide in the presence of a mild acid such as acetic acid.
SCHEME 3
I RLi, -78°C or
RMgBr, rt
Figure imgf000125_0001
Figure imgf000125_0002
In an alternative embodiment of the present invention, the allyl acid VII (prepared, for example, as described in Hale et al; see above) can be converted into the N-methyl-N-methoxy amide VIII, which is then treated with an alkyl or aryl metal reagent, for example methylhthium or butyllithium, to provide the ketone IX (Scheme 3). The ketone can be converted into an imine which can then be reduced to secondary amine X chemically, (e.g using sodium cyanoborohydride or sodium borohydride), or catalytically (e.g. using hydrogen and palladium on carbon or Raney nickel catalyst). Acylation under standard conditions, for example with an acid chloride, provides the corresponding amide. Alternatively, amine X can be sulfonylated, for example with a alkyl or aryl sulfonyl chloride or an alkyl or aryl sulfonic anhydride, to give (for aryl substituted sulfonylating reagents) sulfonamide XL The allyl group in XI can be oxidatively cleaved to aldehyde XII with osmium tetroxide followed by sodium periodate or with ozone at low temperature. Reductive amination of aldehyde XII with azacycle I can then be carried out under the conditions described above to give the desired product XIII.
SCHEME 4
Figure imgf000127_0001
Preparation of hydroxymethyl derivatives of the target compounds is outlined in Scheme 4. The oxazolidinone imide XV is prepared from acid XIV, by formation of the corresponding acid chloride (by treatment with oxalyl chloride or thionyl chloride) and addition of N- lithio 2(S)-benzyl oxazolidinone. The enolate azidation can be accomplished by a variety of methods, such as the procedure of Evans, D. A.; et. al. J. Am. Chem. Soc. 1990, 112, 4011-4030. Reduction of the oxazolidinone moiety of XVI can be carried out by a variety of metal hydride reagents (e.g. LiBH4 MeOH, LiAlH4, etc.). The azide is then reduced by treatment with PPI13/H2O to provide alcohol XVII. Formation of cyclic carbamate XVIII is accomplished by literature methods; i.e. phosgene, triphosgene or carbonyl diimidazole, followed by N-alkylation with sodium hydride and methyl iodide. The target compounds are prepared by oxidative cleavage of the olefin to the aldehyde followed by reductive amination with an amine salt as described for Scheme 1, to provide XTX. Hydrolysis of the cyclic carbamate under basic conditions (for example, potassium hydroxide in ethanol at elevated temperature) followed by selective amide formation at 0°C by combining with an acylating agent or a sulfonating agent such as an arylsulfonyl chloride gives the corresponding hydroxyamides or hydroxysulfonamides (i.e. XX).
SCHEME 5
Figure imgf000128_0001
Compounds with alternate arrangements of an amide bond are prepared as shown in Scheme 5. Acid VII can be homologated under Arndt-Eistert conditions to give the chain-extended acid XrV, which can be derivatized under standard acylating conditions with, for example, an aniline derivative, to give the amide XXI. Oxidative cleavage of the olefin with osmium tetroxide or ozone then provides aldehyde XXII as an intermediate suitable for coupling as described earlier.
SCHEME 6
Figure imgf000129_0001
In addition, ketone derivatives are prepared by an extension of the chemistry given above, as shown in Scheme 6. An Arndt-Eistert chain extension of acid XIV provides heptenoic acid XXIII, which after conversion into N-methoxy-N-methyl amide XXIV, can be reacted with an aryl organometallic reagent, such as an aryl magnesium bromide, to provide ketone XXV. Routine oxidative cleavage then gives the desired aldehyde XXVI, which can be coupled with an appropriate amine as described above.
SCHEME 7
Figure imgf000130_0001
Alcohol containing compounds are prepared according to procedures given in Scheme 7. Formation of the N-methyl-N-methoxy amide of acid VII followed by oxidative cleavage of the olefin provides intermediate aldehyde XXVII. Coupling with an appropriate amine provides amide XXVIII. Addition of an organometallic reagent to compound XXVIII provides illustrated ketone XXLX. Treatment with a hydride reducing agent, such as sodium borohydride, then yields the desired alcohol XXX.
SCHEME 8
Figure imgf000131_0001
Formation of heterocycle compounds is carried out according to the procedure given in Scheme 8 for substituted imidazoles. Reduction of allyl acid VII with a strong reducing agent such as lithium aluminum hydride provides alcohol XXXI. In situ formation of the trifluoromethanesulfonate ester of the formed alcohol allows for displacement of the triflate with a nucleophile such as 2-phenyl- imidazole, to give imidazole XXXII. Oxidative cleavage under standard conditions provides the aldehyde XXXIII which can then be coupled under the conditions described above to the appropriate amine. SCHEME 9
Figure imgf000132_0001
Compounds with ether substituents are prepared by the route shown in Scheme 9. Thus, allyl acid VII can be reduced to alcohol XXXI with, for example, lithium aluminum hydride. This alcohol can be alkylated by a Williamson ether synthesis, by deprotonation with a strong base such as sodium hydride or sodium hexamethyldisilazide followed by reaction with a benzyl halide such as benzyl bromide. The resulting ether XXXrV can be processed through the oxidative cleavage steps described earlier to provide aldehyde XXXV. This aldehyde can then be coupled with an appropriate amine under reductive amination conditions to give XXXVI. Alternatively, reduction of XXXV to the corresponding alcohol followed by conversion to the bromide allows for alkylation with an amine to provide XXXVI. SCHEME 10
Figure imgf000133_0001
XXXVII XXXVIII
Figure imgf000133_0002
XXXVII
Figure imgf000133_0003
Figure imgf000133_0004
XLI
The substituted amines employed in the preceding Schemes can be obtained commercially in many cases or are prepared by a number of procedures. For example, as shown in Scheme 10, compound XXXVII, the N-t-butoxycarbonyl protected form of isonipecotic acid (4- piperidinecarboxylic acid) can be activated under standard conditions, for example with a carbodiimide, and converted into ester XXXVIII or amide XXXIX. Alternatively, acid XXXVII can be converted into the N- methyl-N-methoxy amide, XL, which upon reaction with organomagnesium and organolithium reagents forms the ketone XLI. The Boc group of XXXVIII, XXXLX and XLI can be removed under acidic conditions to provide secondary amines XLII, XLIII and XLIV, respectively.
SCHEME 11
Figure imgf000134_0001
XLVII
Figure imgf000134_0002
XLVI 11 Alternatively, CBZ-protected piperidine XLV can be allowed to react with oxalyl chloride and then sodium azide, to provide the corresponding acyl azide, which can then be thermally rearranged to isocyanate XLVI (Scheme 11). Compound XLVI can be treated with an alcohol ROH or an amine RR'NH to form carbamate XLVII or urea XLVIII, respectively, each of which can be deprotected with hydrogen in the presence of palladium on carbon to secondary amines XLLX or L.
SCHEME 12
Figure imgf000135_0001
Lll LIV
If the carbamate XLVII has R = -(CH2)XCH2C1, where x = 1-
3, then treatment with a suitable base, such as sodium hydride, lithium hexamethyldisilazide or potassium t-butoxide, can induce cyclization to compound LI (Scheme 12). For other R groups, carbamate XLVII can be treated with an alkylating agent R'X, where R' = primary or secondary alkyl or alkyl-cycloalkyl, while X = bromide, iodide, tosylate, mesylate or trifluoromethanesulfonate, in the presence of a suitable base, such as sodium hydride, lithium hexamethyldisilazide or potassium t-butoxide, to give derivative LII. In each case, removal of the CBZ protecting group under standard conditions provides the secondary amines LIII and LIV. SCHEME 13
Figure imgf000136_0001
XLVIII
Figure imgf000136_0002
LVIII
Additional derivatives of a piperidine with nitrogen functionality at C4 can be carried out as shown in Scheme 13. For example, if the ring nitrogen is protected with a CBZ group, as with isocyanate XLVI, treatment with tert-butyl alcohol in the presence of copper(I) chloride, provides Boc derivative LV. This compound can be selectively deprotected to the free amine LVI. This amine can be acylated with an acid chloride, a chloroformate, an isocyanate, or a carbamyl chloride, to provide compounds LVII, XLVII or XLVIII. Alternatively, amine LVI can be sulfonated with an alkyl or arylsulfonyl chloride, to give sulfonamide LVIII. SCHEME 14
Figure imgf000137_0001
LVI I LIX
Figure imgf000137_0002
XLVII XLIX
Figure imgf000137_0003
XLVIII
Figure imgf000137_0004
LVIII
LX
In each case, removal of the CBZ group under reductive conditions gives the desired secondary amines LLX, XLIX, L, and LX (Scheme 14).
SCHEME 15
Figure imgf000138_0001
Functionalization of the piperidine can also be carried out after it has been coupled with an Nl substituent. For example, as shown in Scheme 15, reductive deprotection of CBZ derivative LV yields secondary amine LXI. Reductive amination with an appropriate aldehyde fragment (as described above) provides piperidine LXII. Removal of the Boc group under acidic conditions then gives primary amine LXIII. This primary amine can then be functionalized by analogy to the chemistry given in Scheme 13. Compound LXI can also be alkylated as described above in Scheme 12, and then carried through the remaining sequence given in Scheme 15. SCHEME 16
Figure imgf000139_0001
Figure imgf000139_0002
DIEA, CHoCN, Δ
Figure imgf000139_0003
A method of preparing a backbone with an alternate spacing from the one described above is given in Scheme 16. Deprotonation of a suitable phenylacetonitrile derivative LXr with sodium hydride followed by addition of allyl bromide provides the allyl nitrile LXV. Reduction to the corresponding aldehyde LXVI is carried out with diisobutylaluminum hydride in THF. Reductive amination with a primary amine followed by sulfonylation then provides sulfonamide LXVII. Selective hydroboration of the terminal position of the olefin, for example with 9-BBN, followed by oxidation with basic hydrogen peroxide, then gives primary alcohol LXVIII. Conversion of this alcohol to the corresponding bromide with triphenylphosphine- dibromide complex followed by alkylation with a cyclic secondary amine then gives the desired product LXIX.
SCHEME 17
Figure imgf000140_0001
Figure imgf000140_0002
Another backbone variation is prepared according to Scheme 17. Epoxidation of a suitably substituted styrene derivative LXX with an oxidizing agent such as mCPBA provides the epoxide LXXI which is converted to the aminoalcohol LXXII by treatment with a primary amine RNH2. Treatment of LXXII with an acylating agent or a sulfonylating agent under mild conditions (as shown for the conversion to compound LXXIII) produces the corresponding neutral alcohol. Activation of the hydroxy group with, for example, methanesulfonyl chloride, followed by treatment with a secondary cyclic amine yields the aminosulfonamide LXXIV.
SCHEME 18
Figure imgf000141_0001
Another backbone variation is prepared according to Scheme 18. Treatment of 3-arylpentane-l,5-dioic acid LXXV with acetic anhydride in toluene provides anhydride LXXVI. Addition of an amine RNH2 yields amidoacid LXXVII, which can be reduced with a strong reducing agent like lithium aluminum hydride to give aminoalcohol LXXVIII. Selective sulfonylation on nitrogen can be accomplished by treatment with a suitable arylsulfonyl chloride, to produce sulfonamide LXXLX. Activation of the hydroxy group with methanesulfonyl chloride in the presence of triethylamine followed by addition of a cyclic secondary amine in isobutyronitrile in the presence of sodium carbonate at elevated temperatures then provides the desired sulfonamidoamine LXXX.
SCHEME 19
Figure imgf000142_0001
Figure imgf000142_0002
LXXXVI
Figure imgf000142_0003
Another backbone variation is prepared according to
Scheme 19. Reduction of 2-arylmalonic acid derivative LXXXI with lithium aluminum hydride provides diol LXXXII, which upon treatment with sodium hydride and t-butyldimethylsilyl chloride in THF produces selectively the monosilyl ether LXXXIII. Exposure of this compound to an N-substituted arylsulfonamide in the presence of DEAD and triphenylphosphine in THF provides the sulfonamide LXXXIV. Removal of the silyl group, for example with tetrabutylammonium fluoride in THF, followed by treatment with methanesulfonyl chloride in ethyl acetate, yields the mesylate LXXXV. Treatment of this mesylate with a cyclic secondary amine then provides the desired product LXXXVI.
SCHEME 20
Figure imgf000143_0001
LXXXVI I
Figure imgf000143_0002
LX LXXXIX
Figure imgf000143_0003
XC Another backbone variation is prepared according to
Scheme 20. Reductive alkylation of the commercially available aldehyde LXXXVII with a suitable primary amine followed by sulfonylation provides sulfonamide LXXXVIII. Treatment of this olefin with osmium tetroxide followed by sodium periodate provides aldehyde LXXXLX. Reductive amination with a cyclic secondary amine then provides the target compound XC.
In some cases the order of carrying out the foregoing reaction schemes may be varied to facilitate the reaction or to avoid unwanted reaction products. The following examples are provided for the purpose of further illustration only and are not intended to be limitations on the disclosed invention.
EXAMPLE 1
(R,S)-N-[2-Phenyl-4-(4-phenylpiperidin-l-yl)but-l-yl]-N-methylbenzene- sulfonamide
Step A: (R,S)-N-(2-Phenylpent-4-en-l-yl)-N-methylbenzene- sulfonamide
A solution of 2.0 g (11.4 mmol) of (R,S)-4-phenyl-5- methylamino-1-pentene (prepared as described by J. Hale et al., Bioorganic and Medicinal Chemistry Letters, 1993, 3, 319-322) and 6.0 mL (34 mmol) of diisopropylethylamine (DIPEA) in 25 mL of methylene chloride was cooled in an ice/ethanol bath. To this was added 2.2 mL (17 mmol) of benzenesulfonyl chloride and after 5 min the ice bath was removed. After stirring for 16 h, the reaction mixture was diluted with methylene chloride and washed with water containing 20 mL of 2 N HC1. The aqueous layer was reextracted with methylene chloride and the organic layers were washed with brine, combined, dried over sodium sulfate and concentrated in vacuo. The residue was purified by flash column chromatography (FCC) eluting with 5% ethyl acetate/hexanes to afford 3.2 g of the title compound. IH NMR (400 MHz, CDCI3): δ 2.38 (p, J = 8, IH), 2.55 (m, IH), 2.57 (s, 3H), 2.94 (m, 2H), 3.41 (m, IH), 4.95 (m, 2H), 5.62 (m, IH), 7.1-7.3 (m, 5H), 7.45 (m, 2H), 7.52 (m, IH), 7.69 (dd, J = 1.5 and 6, 2H).
Step B: (R,S)-N-(2-Phenyl-4-oxobut-l-yl)-N-methylbenzene- sulfonamide To a solution of 1.0 g (3.2 mmol) of (R,S)-N-(2-phenylpent-4- en-l-yl)-N-methylbenzenesulfonamide from Step A in 7 mL of acetone, 3.5 mL of t-butanol and 3.5 mL of water was added 413 mg (3.5 mmol) of N-methylmorpholine-N-oxide followed by 0.14 mL of 4% osmium tetroxide in water. The reaction was stirred at rt for 16 h and was then quenched with aqueous sodium bisulfite and concentrated in vacuo. The residue was diluted with water and extracted twice with ether. The ether layers were each washed with brine, combined, dried over sodium sulfate and concentrated in vacuo. The residue was purified by FCC eluting with 5% methanol in methylene chloride to afford the diol intermediate. The above product was taken up in 10 mL of THF and 755 mg (3.5 mmole) of sodium periodate in 3 mL of water was added. The mixture was stirred at rt for 3 h, poured into water and extracted twice with ether. The ether layers were each washed with brine, combined, dried over sodium sulfate and concentrated in vacuo to afford 940 mg of the title compound. iH NMR (400 MHz, CDCI3): δ 2.62 (s, 3H), 2.75-2.9
(m, 2H), 3.14 (dd, J = 6 and 17, IH), 3.39 (m, IH), 3.55 (m, IH), 7.15-7.35 (2 m, 5H), 7.46 (m, 2H), 7.53 (m, IH), 7.70 (dd, J = 1.5 and 7, 2H), 9.78 (d, J = 1.2, IH).
Step C: (R,S)-N-[2-Phenyl-4-(4-phenylpiperidin-l-yl)but-l-yl]-N- methylbenzenesulfonamide hydrochioride salt
To a solution of 0.020 g (0.063 mmol) of (R,S)-N-(2-phenyl-4- oxobut-l-yl)-N-methylbenzenesulfonamide from Step B in 1.2 mL of THF were added 31 mg (0.19 mmol) of 4-phenylpiperidine, 3 A molecular sieves and 0.011 mL of acetic acid. After stirring the mixture for 20 min, 27 mg (0.126 mmol) of sodium triacetoxy-borohydride was added. After 16 h the mixture was filtered through a pad of celite and the reaction flask and the pad were rinsed with water and ethyl acetate. The layers were separated and the aqueous layer was extracted twice more with ethyl acetate. The organic layers were each washed with brine, combined, dried over sodium sulfate and concentrated in vacuo. The residue was purified by prep TLC using 5% methanol in methylene chloride to isolate 25 mg of the free amine of the title compound as an oil. IH NMR (400 MHz, CDCI3): δ 1.80 (m, 5H), 1.9-2.3 (3 m, 5H), 2.4-2.5 (m, IH), 2.59 (s, 3H), 2.9-3.1 (m, 4H), 3.35-3.45 (m, IH), 7.1-7.3 (m, 10H), 7.4-
7.5 (m, 2H), 7.5-7.6 (m, IH), 7.70 (dd, J = 1.5 and 7.0, 2H). Mass spectrum (NH3/CI): m/z 463 (M+l, 100%). The hydrochioride salt of the title compound was prepared by dissolving the above oil in ether/methanol and addition of 2-3 equivalents of 1 M ethereal HC1. Evaporation of the volatiles and drying in vacuo afforded 26 mg of the title salt as a white solid after trituration with ether.
The following Examples were prepared following the procedure described in Example 1, Step C but using the appropriate substituted amine in the reductive amination.
EXAMPLE 2
(R,S)-N-[2-Phenyl-4-(4-benzylpiperidin-l-yl)but-l-yl]-N- methylbenzenesulfonamide
Mass spectrum (NH3/CI): m z 477 (M+l, 100%).
EXAMPLE 3
(R,S)-N-[2-Phenyl-4-(4-dimethylaminocarbonyl-4-phenylpiperidin-l- yPbut-l-yll-N-methylbenzenesulfonamide
Mass spectrum (NH3/CI): m/z 534 (M+l, 100%).).
EXAMPLE 4
(R,S)-N-[2-Phenyl-4-(4-aminocarbonyl-4-phenylpiperidin-l-yl)but-l-yl]- N-methylbenzenesulfonamide
Mass spectrum (NH3/CI): m/z 506 (M+l), 249 (100%).
EXAMPLE 5
(R,S)-N-[2-Phenyl-4-(4-hydroxymethyl-4-phenylpiperidin-l-yl)but-l-yl]- N-methylbenzenesulfonamide
Mass spectrum (NH3/CI): m/z 493 (M+l, 100%). EXAMPLE 6
(R,S)-N-[2-Phenyl-4-(4-methoxycarbonyl-4-phenylpiperidin-l-yl)but-l- yll -N-methylbenzenesulfonamide
Mass spectrum (NH3/CI): m/z 521 (M+l, 100%).
EXAMPLE 7
(R,S)-N-[2-Phenyl-4-(piperidin-l-yl)but-l-yl]-N-methylbenzene- sulfonamide
Mass spectrum (NH3/CI): m z 387 (M+l, 100%).
EXAMPLE 8
(R,S)-N-[2-Phenyl-4-(4-pentylaminocarbonylpiperidin-l-yl)but-l-yl]-N- methylbenzenesulfonamide
Mass spectrum (NH3/CI): m/z 500 (M+l, 100%).
EXAMPLE 9
(R,S)-N-[2-Phenyl-4-(4-isopropylaminocarbonylpiperidin-l-yl)but-l-yl]- N-methylbenzenesulfonamide
Mass spectrum (NH3/CI): m/z 472 (M+l, 100%).
EXAMPLE 10
(R,S)-N-[2-Phenyl-4-(4-methylaminocarbonylmethylene-4- phenylpiperidin-l-yl)but-l-yn-N-methylbenzenesulfonamide
Mass spectrum (NH3/CI): m/z 534 (M+l, 100%). EXAMPLE 11
(R,S)-N-[2-Phenyl-4-(4-methylaminocarbonyl(methylamino)m phenylpiperidin-l-yPbut-l-yll-N-methylbenzenesulfonamide
Mass spectrum (ESI): m/z 563 (M+l, 100%).
EXAMPLE 12
(R,S)-N-[2-Phenyl-4-(4-methoxycarbonylaminomethylene-4- phenylpiperi din- 1-yl )but-l-yll-N-methylbenzenesulfonamide
Mass spectrum (ESI): m/z 550 (M+l, 100%).
EXAMPLE 13
(R,S)-N-[2-Phenyl-4-(4-methylaminocarbonylaminomethylene-4- phenylpiperidin- 1 -yPbut- 1 -yll -N-methylbenzenesulfonamide
Mass spectrum (ESI): m/z 549 (M+l, 100%).
EXAMPLE 14
(R,S)-N-[2-Phenyl-4-(4-(2-methyl)phenylpiperidin-l-yl)but-l-yl]-N- methylbenzenesulfonamide
Mass spectrum (NHg/CI): m/z 477 (M+l, 100%).
EXAMPLE 15
(R,S)-N- [2-Phenyl-4-(4-morpholinocarbonylpiperi din- l-yl)but- 1-yl] -N- methylbenzenesulfonamide
Mass spectrum (NHg/CI): m/z 500 (M+l, 100%). The following Examples were prepared following the procedure described in Example 1, Step A-C but starting with (R,S)-4-(2- chlorophenyl), (3,5-dichlorophenyl), (2-thienyl), (3-thienyl), or (cyclohexyl)-5-methylamino-l-pentene (prepared as described by J. Hale et al., Bioorganic and Medicinal Chemistry Letters, 1993, 3, 319-322) and using the appropriate substituted piperidine in the reductive amination.
EXAMPLE 16
(R,S)-N-[2-(2-Chlorophenyl)-4-(4-phenylpiperidin-l-yl)but-l-yl]-N- methylbenzenesulfonamide
Mass spectrum (NHg/CI): m/z 497 (M+l, 100%).
EXAMPLE 17
(R,S)-N-[2-(2-Thienyl)-4-(4-phenylpiperidin-l-yl)but-l-yl]-N- methylbenzenesulfonamide
Mass spectrum (ESI): m/z 469 (M+l, 100%).
EXAMPLE 18
(R,S)-N-[2-(3-Thienyl)-4-(4-phenylpiperidin-l-yl)but-l-yl]-N- methylbenzenesulfonamide
Mass spectrum (ESI): m/z 469 (M+l, 100%).
EXAMPLE 19
(R,S)-N-[2-(3-Thienyl)-4-(4-benzylpiperidin-l-yl)but-l-yl]-N- methylbenzenesulfonamide Mass spectrum (ESI): m/z 483 (M+l, 100%).
EXAMPLE 20
(R,S)-N- [2-Cyclohexyl-4-(4-phenylpiperidin- l-yl)but- 1-yl] -N- methylbenzenesulfonamide
Mass spectrum (NH3/CI): m/z 469 (M+l, 100%). EXAMPLE 21
(R,S)-N-[2-(3,5-Dichlorophenyl)-4-(4-phenylpiperidin-l-yl)but-l-yl]-N- methylbenzenesulfonamide hydrochioride salt
Mass spectrum (NH3-CI): m z 531 (M+l, 100%).
EXAMPLE 22
(R,S)-N-[2-(3-Methylphenyl)-4-(4-phenylpiperidin-l-yl)but-l-yl]-N- methylbenzenesulfonamide
Step A: N-[4-(4-Phenylpiperidin-l-yl)but-2-yn-l-yl]-N- methylbenzenesulfonamide To a suspension of triphenylphosphine dibromide at 0 C
(prepared by addition of bromine to 53.5 g (210 mmol) of triphenylphosphine in 200 mL of acetonitrile at 0 C) was added 8.0 g (93 mmol) of 2-butyne-l,4-diol. The reaction was stirred for 10 min, the ice bath was removed, the mixture was stirred for 2 hr, and then concentrated in vacuo. The residue was triturated with ether and filtered to remove the precipitated triphenylphosphine oxide. The filtrate was washed with water and brine, dried over sodium sulfate and concentrated. The residue of crude dibromide was taken up in 50 mL of DMF under nitrogen and cooled in an ice bath. A solution of the sodium salt of N-methylbenzenesulfonamide in 50 mL of DMF was prepared at 0 C under nitrogen by portionwise addition of 3.2 g (80 mmol) of 60% sodium hydride over 0.5 h and then stirred with cooling for 0.5 h. This salt solution was added via canula over 15 min with cooling to the above dibromide solution. After 0.5 h, 18.0 g (110 mmol) of 4-phenylpiperidine was added and the reaction was stirred a further 2 h at rt. The reaction was diluted with water and extracted three times with ether. The ether layers were each washed with a portion of brine, dried over sodium sulfate, combined and concentrated in vacuo. The residue was purified by FCC eluting with 30 to 50% ethyl acetate/hexanes to afford 11.3 g of title compound. IH NMR (400 MHz, CDCI3): δ 1.65-1.85 (m, 4H), 2.07 (dt, J = 3 and 8, 2H), 2.4 (m, IH), 2.78 (br d, J = 11, 2H), 2.84 (s, 3H), 3.09 (t, J = 2, 2H), 4.07 (t, J
= 2, 2H), 7.1-7.3 (2 m, 5H), 7.45-7.6 (m, 3H), 7.82 (dd, J = 1.5 and 7, 2H). Mass spectrum (NH3-CI): m/z 383 (M+l, 100%).
Step B: N-[4-(4-Phenylpiperidin-l-yl)-2-tributylstannylbut-2-en-l-yl]-
N-methylbenzenesulfonamide and N-[4-(4-Phenylpiperidin- l-yl)-3-tributylstannylbut-2-en-l-yl]-N-methylbenzene- sulfonamide To a solution of 11.0 g (29 mmol) of N-[4-(4-phenyl-piperidin- l-yl)but-2-yn- 1-yl] -N-methylbenzenesulfonamide from Step A in 75 mL of
THF under nitrogen was added 400 mg (0.58 mmol) of dichlorobis(triphenylphosρhine)palladium (II) and then 13.7 mL (51 mmol) of tributylstannane was added dropwise via syringe over 0.5 h. After a further 0.5 h, the dark reaction (from precipitated palladium) was concentrated in vacuo. The residue was purified by FCC eluting with 20% ethyl acetate/hexanes to give 2.5 g of the higher Rf 3-stannyl title product. Elution with 30-40% ethyl acetate/hexanes afforded 10.8 g of the lower Rf 2-stannyl title compound. Further elution with 50-70% ethyl acetate/hexanes afforded 3.5 g of recovered starting material, higher Rf product:
IH NMR (400 MHz, CDCI3): δ 0.8-0.9 (m, 6H), 0.87 (t, J = 7, 9H), 1.25-1.35
(m, 6H), 1.35-1.5 (m, 6H), 1.6-1.85 (2 m, 4H), 1.94 (dt, J = 3 and 8, 2H), 2.43 (m, IH), 2.69 (s, 3H), 3.01 (br t, JH.Sn = 25, 2H), 3.78 (d, J = 6, 2H), 5.44 (br ttt, J = 1.5 and 6, JH.Sn = 34, IH), 7.1-7.3 (2 , 5H), 7.5-7.65 ( , 3H), 7.77
(dd, J = 1.5 and 7.0, 2H). Lower Rf product:
IH NMR (400 MHz, CDCI3): δ 0.87 (t, J = 7, 9H), 0.95-1.05 ( , 6H), 1.25-
1.4 (m, 6H), 1.45-1.6 (m, 6H), 1.7-1.85 (m, 4H), 1.92 (dt, J = 3 and 8, 2H), 2.42 (m, IH), 2.48 (s, 3H), 2.96 (m, 2H), 3.74 (br t, JH-Sn = 23, 2H), 5.88 (br tt, J = 6, JH.Sn = 32, IH), 7.1-7.3 (2 m, 5H), 7.5-7.65 (m, 3H), 7.77 (dd, J = 1.5 and 7.0, 2H). Step C: N-[2-(3-Methylphenyl)-4-(4-phenylpiperidin-l-yl)but-2-en-lz yll -N-methylbenzenesulfonamide
To 250 mg (0.37 mmol) of N-[4-(4-phenylpiperidin-l-yl)-2- tributylstannylbut-2-en-l-yl] -N-methylbenzenesulfonamide from Step B in 0.4 mL of N-methylpyrrolidinone under argon was added 77 mg (0.55 mmol) of potassium carbonate, 8 mg (catalytic) of dichlorobis(triphenyl- phosphine)palladium (II) and 0.067 mL (0.55 mmol) of 3-methylbromo- benzene. The mixture was heated at 70 C for 24 h, cooled, treated with aqueous sodium fluoride for 10 min, and partitioned between water and ether. The water layer was reextracted with ether and each organic layer was washed with brine, dried over sodium sulfate, combined and concentrated in vacuo. The residue was purified by FCC eluting with 25- 50% ethyl acetate/hexanes to give 57 mg of product contaminated with stannane biproduct. The product was further purified by prep TLC (50% ethyl acetate/hexanes) to afford 53 mg of title compound.
IH NMR (400 MHz, CDCI3): δ 1.7-1.9 (m, 4H), 2.0-2.2 (m, 2H), 2.32 (s,
3H), 2.6-2.6 (m, IH), 2.50 (s, 3H), 3.05 (m, 2H), 3.20 (m, 2H), 4.12 (s, 2H), 6.11 (br t, J = 7, IH), 7.07 (m, IH), 7.15-7.35 (m, 8H), 7.52 (m, 2H), 7.60 (m, IH), 7.74 (dd, J = 1.5 and 7, 2H).
Step D: (R,S)-N-[4-(4-Phenylpiperidin-l-yl)-2-(3-methylphenyl)-but-l- yl] -N-methylbenzenesulfonamide
A mixture of 46 mg (0.097 mmol) of N-[4-(4-phenylpiperidin- l-yl)-2-(3-methylphenyl)but-2-en-l-yl]-N-methylbenzenesulfonamide from Step C, 12 mg of 20% palladium hydroxide/C (50% water), and 2 drops of acetic acid in 3 mL of methanol was hydrogenated at 40 psi for 24 h. The catalyst was removed by filtration and the filtrate concentrated in vacuo. The residue was purified by prep TLC (50% ethyl acetate/hexanes) to afford 20 mg of title compound. A major biproduct was cleavage of the 4-phenylpiperidine to give N-[2-(3-methylphenyl)but- 1-yl] -N-methylbenzenesulfonamide. IH NMR (400 MHz, CDCI3): δ 1.8-2.0 (m, 5H), 2.1-2.3 (m, 3H), 2.32 (s,
3H), 2.38 (m, IH), 2.51 (m, 2H), 2.61 (s, 3H), 2.88 (m, 2H), 3.21 (m, 2H), 3.32 (dt, J = 3 and 9, IH), 6.96 (br s, 2H), 7.05 (d, J = 8, IH), 7.15-7.3 (m, 6H), 7.46 (m, 2H), 7.54 (m, IH), 7.70 (dd, J = 1.5 and 7, 2H). Mass spectrum (NH3-CI): m z 477 (M+l, 100%).
The following Examples were prepared following the procedure described in Example 22, Steps C-D but using the appropriate substituted bromobenzene in Step C.
EXAMPLE 23
(R,S)-N-[2-(3-Ethylphenyl)-4-(4-phenylpiperidin-l-yl)but-l-yl]-N- methylbenzenesulfonamide hydrochioride salt
Mass spectrum (ESI): m/z 491 (M+l , 100%).
EXAMPLE 24
(R,S)-N-[2-(3-Carboethoxyphenyl)-4-(4-phenylpiperidin-l-yl)but-l-yl]-N- methylbenzenesulfonamide hydrochioride salt
Mass spectrum (ESI): m/z 535 (M+l , 100%).
EXAMPLE 25
(R,S)-N-[2-(3-Fluorophenyl)-4-(4-phenylpiperidin-l-yl)but-l-yl]-N- methylbenzenesulfonamide hydrochioride salt
Mass spectrum (NH3-CI): m z 481 (M+l , 100%).
EXAMPLE 26
(R,S)-N-[2-(3-Methoxyphenyl)-4-(4-phenylpiperidin-l-yl)but-l-yl]-N- methylbenzenesulfonamide hydrochioride salt Mass spectrum (NH3-CI): m/z 493 (M+l, 100%).
EXAMPLE 27 (R,S)-N-[2-(3,4-Difluorophenyl)-4-(4-phenylpiperidin-l-yl)but-l-yl]-N- methylbenzenesulfonamide hydrochioride salt
Mass spectrum (NH3-CI): m/z 499 (M+l, 100%).
EXAMPLE 28
(R,S)-N-[2-(3-Biphenyl)-4-(4-phenylpiperidin-l-yl)but-l-yl]-N- methylbenzenesulfonamide hydrochioride salt
Mass spectrum (NH3-CI): m/z 539 (M+l, 100%).
EXAMPLE 29
(R,S)-N-[2-(3-Pyridyl)-4-(4-phenylpiperidin-l-yl)but-l-yl]-N- methylbenzenesulfonamide hydrochioride salt Mass spectrum (NH3-CI): m/z 464 (M+l, 100%).
EXAMPLE 30
(R,S)-N-[2-(Naphthalen-2-yl)-4-(4-phenylpiperidin-l-yl)but-l-yl]-N- methylbenzenesulfonamide hydrochioride salt
Mass spectrum (NH3-CI): m/z 513 (M+l, 100%).
EXAMPLE 31
(R,S)-N-[2-(4-Methylphenyl)-4-(4-phenylpiperidin-l-yl)but-l-yl]-N- methylbenzenesulfonamide hydrochioride salt
Mass spectrum (NH3-CI): m/z 553 (M+l, 100%).
EXAMPLE 32
(R,S)-N-[2-(2-Pyridyl)-4-(4-phenylpiperidin-l-yl)but-l-yl]-N- methylbenzenesulfonamide hydrochioride salt
Mass spectrum (NH3-CI): m/z 464 (M+l, 100%).
EXAMPLE 33 (R,S)-N-[2-(3-Fluoro-4-methylphenyl)-4-(4-phenylpiperidin-l-yl)but-l- yll -N-methylbenzenesulfonamide hydrochioride salt
Mass spectrum (NH3-CI): m/z 495 (M+l, 100%).
EXAMPLE 34
(R,S)-N-[2-(3,4-Dimethylphenyl)-4-(4-phenylpiperidin-l-yP
N-methylbenzenesulfonamide hydrochioride salt Mass spectrum (NH3-CI): m/z 491 (M+l, 100%).
EXAMPLE 35
(R,S)-N-[2-(3,5-Dimethylphenyl)-4-(4-phenylpiperidin-l-yl)but-l-yl]- N-methylbenzenesulfonamide hydrochioride salt
Mass spectrum (NH3-CI): m/z 491 (M+l, 100%).
EXAMPLE 36
(R,S)-N-[2-(4-Methoxyphenyl)-4-(4-phenylpiperidin-l-yl)but-l-yl]-N- methylbenzenesulfonamide hydrochioride salt
Mass spectrum (ESI): m/z 493 (M+l, 100%).
EXAMPLE 37
(R,S)-N-[2-(3-Trifluoromethylphenyl)-4-(4-phenylpiperidin-l-yl)but-l- yll-N-methylbenzenesulfonamide hydrochioride salt
Mass spectrum (ESI): m/z 531 (M+l, 100%).
EXAMPLE 38
(R,S)-N-[2-(3-Methyl-4-fluorophenyl)-4-(4-phenylpiperidin-l-yl)but-l- yl] -N-methylbenzenesulfonamide hydrochioride salt
Mass spectrum (ESI): m/z 495 (M+l, 100%). EXAMPLE 39
(S)-N-[2-(3-Chlorophenyl)-4-(4-phenylpiperidin-l-yl)but-l-yl]-N- methylbenzenesulfonamide hydrochioride salt
Step A: (S)-N-[2-(3-Chlorophenyl)pent-4-en-l-yl]-N- methylbenzenesulfonamide
A solution of 2.0 g (9.53 mmol) of (S)-4-(3-chorophenyl)-5- methylamino-1-pentene (prepared as described by J. Hale et al., Bioorganic and Medicinal Chemistry Letters, 1993, 3, 319-322) and 5.0 mL (28.6 mmol) of diisopropylethylamine (DIPEA) in 20 mL of methylene chloride was cooled in an ice/ethanol bath. To this was added 1.46 mL (11.4 mmol) of benzenesulfonyl chloride and after 5 min the ice bath was removed. After stirring for 16 h, the reaction mixture was diluted with methylene chloride and washed with water containing 20 mL of 2 N HCl. The aqueous layer was reextracted with methylene chloride and the organic layers were washed with brine, combined, dried over sodium sulfate and concentrated in vacuo. The residue was purified by flash column chromatography (FCC) eluting with 15% ethyl acetate/hexanes to afford 3.44 g of the title compound.
IH NMR (400 MHz, CDCI3): δ 2.38 (p, J = 8, IH), 2.55 (m, IH), 2.59 (s,
3H), 2.94 (m, 2H), 3.37 (m, IH), 4.95 (m, 2H), 5.60 (m, IH), 7.05-7.3 (m, 4H), 7.46 (m, 2H), 7.55 (m, IH), 7.69 (dd, J = 1.5 and 6, 2H).
Step B: (S)-N-[2-(3-Chlorophenyl)-4-oxo-but-l-yl]-N-methylbenzene- sulfonamide
To a solution of 3.33 g (9.53 mmol) of (S)-N-[2-(3- chlorophenyl)pent-4-en- 1-yl] -N-methylbenzenesulfonamide from Step A in 16 mL of acetone, 8 mL of t-butanol and 8 mL of water was added 1.22 g (10.4 mmol) of N-methylmorpholine-N-oxide followed by 0.50 mL of 4% osmium tetroxide in water. The reaction was stirred at rt for 16 h and was then quenched with aqueous sodium sulfite and concentrated in vacuo after 20 min. The residue was diluted with water and extracted twice with ethyl acetate. The organic layers were each washed with brine, combined, dried over sodium sulfate and concentrated in vacuo to afford the crude diol intermediate.
The above product was taken up in 30 mL of THF and 2.45 g (11.4 mmole) of sodium periodate in 10 mL of water was added. The mixture was stirred at rt for 2 h, poured into water and extracted twice with ether. The ether layers were each washed with brine, combined, dried over sodium sulfate and concentrated in vacuo. The residue was purified by FCC (20% ethyl acetate/hexanes) to afford 2.57 g of the title compound. iH NMR (400 MHz, CDCI3): δ 2.63 (s, 3H), 2.75-2.9 (m, 2H), 3.14 (dd, J = 6 and 16, IH), 3.35 (dd, J = 10 and 14, IH), 3.55 (m, IH), 7.15- 7.35 (2 m, 4H), 7.46 (m, 2H), 7.53 (m, IH), 7.70 (dd, J = 1.5 and 7, 2H), 9.78 (s, IH).
Step C: (S)-N-[2-(3-Chlorophenyl)-4-(4-phenylpiperidin-l-yl)but-l-yl]- N-methylbenzenesulfonamide hydrochioride salt
To a solution of 20 mg (0.057 mmol) of (S)-N-[2-(3- chlorophenyl)-4-oxo-but- 1-yl] -N-methylbenzenesulfonamide from Step B in 1.0 mL of THF were added 27 mg (0.17 mmol) of 4-phenylpiperidine, 3 A molecular sieves and 0.010 mL of acetic acid. After stirring the mixture for 20 min, 24 mg (0.113 mmol) of sodium triacetoxyborohydride was added. After 16 h the reaction was quenched with aqueous sodium bicarbonate, the mixture was filtered through a pad of celite and the reaction flask and the pad were rinsed with water and ethyl acetate. The layers were separated and the aqueous layer was extracted twice more with ethyl acetate. The organic layers were each washed with brine, combined, dried over sodium sulfate and concentrated in vacuo. The residue was purified by prep TLC using 2% triethylamine in 5% methanol ethyl acetate to isolate 20 mg of the free amine of the title compound as an oil. IH NMR (400 MHz, CDCI3): δ 1.80 (m, 5H), 1.9-2.3 (3 m, 5H), 2.4-2.5 (m,
IH), 2.61 (s, 3H), 2.9-3.1 (m, 4H), 3.35-3.45 (m, IH), 7.1-7.3 (m, 9H), 7.4-7.5 (m, 2H), 7.5-7.6 (m, IH), 7.70 (dd, J = 1.5 and 7.0, 2H). Mass spectrum (ESI): m/z 497 (M+l, 100%).
The hydrochioride salt of the title compound was prepared by dissolving the above oil in ether/methanol and addition of 2-3 equivalents of 1 M ethereal HCl. Evaporation of the volatiles and drying in vacuo afforded 21 mg of the title salt as a white solid after trituration with ether.
The following Examples were prepared following the procedure described in Example 39, Step C but using the appropriate substituted piperidine in the reductive amination.
EXAMPLE 40
(S)-N-[4-(4-Benzylpiperidin-l-yl)-2-(3-chlorophenyl)but-l-yl]-N- methylbenzenesulfonamide hydrochioride salt
Mass spectrum (ESI): m/z 511 (M+l, 100%).
EXAMPLE 41
(S)-N-[4-(4-(3-Phenylprop-l-yl)piperidin-l-yl)-2-(3-chlorophenyl)but- 1-yl] -N-methylbenzenesulfonamide hydrochioride salt
Mass spectrum (ESI): m/z 539 (M+l, 100%).
EXAMPLE 42
(S)-N-[2-(3-Chlorophenyl)-4-(4-t-butylpiperidin-l-yl)but-l-yl]-N- methylbenzenesulfonamide hydrochioride salt Mass spectrum (NH3-CI): m z 477 (M+l, 100%).
EXAMPLE 43
(S)-N-[2-(3-Chlorophenyl)-4-(4-(cis-octahydro-2H-benzimidazol-2-on-l- yl)piperidin-l-yl)but-l-yl] -N-methylbenzenesulfonamide hydrochioride salt
Mass spectrum (ESI): m/z 559 (M+l, 100%).
EXAMPLE 44 (S)-N-[2-(3-Chlorophenyl)-4-(4-(l,2,3,4-tetrahydro-2H-quinazolin-2-on-l- yl)piperidin-l-yl)but- 1-yl] -N-methylbenzenesulfonamide hydrochioride salt
Mass spectrum (ESI): m/z 567 (M+l, 100%).
EXAMPLE 45
(S)-N-[2-(3-Chlorophenyl)-4-(3-phenylpiperidin-l-yl)but-l-yl]-N- methylbenzenesulfonamide hydrochioride salt Mass spectrum (ESI): m/z 497 (M+l, 100%).
EXAMPLE 46
(S)-N-[2-(3-Chlorophenyl)-4-(4-hydroxy-4-phenylpiperidin-l-yl)but-l-yl]- N-methylbenzenesulfonamide hydrochioride salt
Mass spectrum (NH3-CI): m/z 513 (M+l, 100%).
EXAMPLE 47
(S)-N-[2-(3-Chlorophenyl)-4-(4-(2,3-dihydro-2H-benzimidazol-2-on-l- yl)piperi din- 1-yl )but- 1-yl] -N-methylbenzenesulfonamide hydrochioride salt
Mass spectrum (NH3-CI): m/z 553 (M+l, 100%).
EXAMPLE 48
(S)-N-[2-(3-Chlorophenyl)-4-[4,4-diphenylpiperidin-l-yl]-butyl}-N- methylbenzenesulfonamide hydrochioride salt
Mass spectrum (NH3-CI): m/z 573 (M+l, 100%).
EXAMPLE 49
(S)-N-[4-[4-(4-Chlorophenyl)-4-hydroxypiperidin-l-yl]-2-(3-chlorophenyl)- but-1-yll -N-methylbenzenesulfonamide hydrochioride salt Mass spectrum (NH3-CI): m/z 547 (M+l, 100%). EXAMPLE 50
(S)-N-[4-(4-Acetyl-4-phenylpiperidin-l-yl)-2-(3-chlorophenyl)but-l-yl]-N- methylbenzenesulfonamide hydrochioride salt
Mass spectrum (NH3-CI): m/z 539 (M+l, 100%).
EXAMPLE 51
(S)-N-[4-[4-(4-Chloro-3-trifluoromethylphenyl)-4-hydroxypiperidin-l-yl]-2- (3-chlorophenyl)but- 1-yl] -N-methylbenzenesulfonamide hydrochioride salt
Mass spectrum (NH3-CI): m/z 614 (M+l, 100%).
EXAMPLE 52
(S)-N- [2-(3-Chlorophenyl)-4-[4-(2-methoxycarbonylphenyl)piperi din- 1-yl] - but- 1-yll -N-methylbenzenesulfonamide hydrochioride salt
Mass spectrum (NH3-CI): m/z 555 (M+l, 100%).
EXAMPLE 53
(S)-N-[2-(3-Chlorophenyl)-4-[4-hydroxy-4-(3-trifluoromethyl)pheny idin-1-yll-but-l-yll-N-methylbenzenesulfonamide hydrochioride salt Mass spectrum (NH3-CI): m/z 581 (M+l, 100%).
EXAMPLE 54
(S)-N-[2-(3-Chlorophenyl)-4-[4-(4-fluorophenyl)-4-hydroxypiperidin-l- yl1but-l-vn-N-methylbenzenesulfonamide hydrochioride salt
Mass spectrum (ESI): m/z 531 (M+l, 100%).
EXAMPLE 55
(S)-N-[2-(3-Chlorophenyl)-4-[4-(2-oxo-4H-benzo[d] [l,3]oxazin-l-yl)piper- idin- 1-yll but- 1-yl] -N-methylbenzenesulfonamide hydrochioride salt Mass spectrum (NH3-CI): m/z 568 (M+l, 100%). EXAMPLE 56
(S)-N-[2-(3-Chlorophenyl)-4-[4-(2-oxo-3H-benzo[d] [l,4]oxazin-l-yl)piper- idin-1-ynbut-l-yll-N-methylbenzenesulfonamide hydrochioride salt Mass spectrum (NH3-CI): m/z 568 (M+l, 100%).
EXAMPLE 57
(S)-N-[4-(4-Benzoylpiperidin-l-yl)-2-(3-chlorophenyl)but-l-yl]-N- methylbenzenesulfonamide hydrochioride salt
Mass spectrum (NH3-CI): m/z 525 (M+l, 100%).
EXAMPLE 58
(S)-N-[2-(3-Chlorophenyl)-4-[4-(2-methoxy)phenylpiperidin-l-yl]but-l- yl] -N-methylbenzenesulfonamide hydrochioride salt
Mass spectrum (ESI): m/z 527 (M+l, 100%).
EXAMPLE 59
(S)-N-[2-(3-Chlorophenyl)-4-(4-piperidin-l-ylpiperidin-l-yl)but-l-yl]-N- methylbenzenesulfonamide hydrochioride salt
Mass spectrum (ESI): m/z 504 (M+l, 100%).
The following Examples were prepared using the procedure described in Example 39 but utilizing the appropriate substituted 4- phenyl pentene derivative (prepared as described by J. Hale et al., Bioorganic and Medicinal Chemistry Letters, 1993, 3, 319-322) as the starting material.
EXAMPLE 60
(S)-N-[2-(3,4-Methylenedioxyphenyl)-4-(4-phenylpiperidin-l-yl)but-l- yll-N-methylbenzenesulfonamide hydrochioride salt Mass spectrum (ESI): m/z 507 (M+l, 100%). EXAMPLE 61
(S)-N-[2-(4-Fluorophenyl)-4-(4-phenylpiperidin-l-yl)but-l-yl]-N- methylbenzenesulfonamide hydrochioride salt
Mass spectrum (NH3-CI): m/z 481 (M+l, 100%).
EXAMPLE 62
(S)-N-[2-(3,4-Dichlorophenyl)-4-(4-phenylpiperidin-l-yl)-but-l-yl]-N- ethylbenzenesulfonamide hydrochioride salt
Following essentially the same procedure as described in Example 39 but utilizing (S)-4-(3,4-dichorophenyl)-5-ethylamino-l- pentene (prepared as described by J. Hale et al., Bioorganic and
Medicinal Chemistry Letters, 1993, 3, 319-322) as the starting material, the title compound was prepared.
IH NMR (400 MHz, CDCI3): δ 0.955 (t, J = 8, 3H), 1.5-1.9 (3 m, 5H), 1.9-2.3
(2 m, 5H), 2.4-2.6 (m, IH), 2.8-3.05 (m, 3H), 3.05-3.2 (m, 3H) 3.44 (dd, J = 8 and 13, IH), 7.03 (br d, J = 7, IH), 7.15-7.4 (m, 7H), 7.45 (t, J = 7, 2H), 7.52
(br t, J = 7, IH), 7.70 (dd, J = 1.5 and 7, 2H). Mass spectrum (NH3-CI): m/z 545 (M+l, 100%).
EXAMPLE 63
(R,S)-N-[2-Phenyl-4-(4-phenylpiperidin-l-yl)but-l-yl]-N-methylphenyl- acetamide
The title compound was prepared following the procedure described in Example 1, Steps A-C but substituting phenylacetyl chloride in Step A. Mass spectrum (NH3-CI): m/z 441 (M+l, 100%).
EXAMPLE 64 (R,S)-N-[2-Phenyl-4-[4-acetyl(ethylamino)piperidin-l-yl]but-l-yl]-N- methylbenzenesulfonamide
Step A: (l-Benzyloxycarbonylpiperidin-4-yl)isocyanate To a solution of 9.72 g (34.8 mmol) of l-benzyloxycarbonyl-4- carboxypiperidine in 100 mL of methylene chloride was added 2 drops of DMF and then slowly 3.34 mL (38.3 mmol) of oxalyl chloride. The reaction was stirred at rt for 1 h (gas evolution had stopped) and the volatiles were removed in vacuo followed by evaporation of a portion of toluene.
The above residue was taken up in 100 mL of acetone and slowly added to a solution of 5.66 g (87 mmol) of sodium azide in 25 mL of water and 25 mL of acetone while stirred in an ice bath. The reaction was stirred at 0 °C for 1.5 h and then diluted with ice water and extracted twice with 2x150 mL of toluene. The organic layers were each washed with a portion of brine, dried over sodium sulfate, combined and concentrated to about 100 mL in vacuo with a minimum of heating. The remaining solution was slowly heated to 85 °C for 1.5 h and then concentrated to dryness in vacuo to afford about 9.5 g of crude title product which can be used directly in subsequent reactions.
Step B: l-Benzyloxycarbonyl-4-t-butoxycarbonylaminopiperidine
A solution of 3.2 g (12.3 mmol) of (1-benzyloxycarbonyl- piperidin-4-yl)isocyanate from Step A in 25 mL of DMF was slowly added to a suspension of CuClg in 25 mL of DMF and 12 mL of t-butanol. The reaction was stirred for 24 h and then diluted with water and extracted twice with 1:1 ether:ethyl acetate. The organic layers were each washed with a portion of water and brine, dried over sodium sulfate, combined and concentrated. The residue was purified by FCC eluting with 20% ethyl acetate/hexanes to afford 685 mg of title compound. iH NMR (400 MHz, CDCI3): δ 1.26 (m, 2H), 1.42 (s, 9H), 1.90 (br d, J = 12, 2H), 2.90 (br t,
2H), 3.58 (m, IH), 4.08 (m, 2H), 4.42 (br s, IH), 5.09 (s, 2H), 7.33 (m, 5H).
Step C: l-Benzyloxycarbonyl-4-t-butoxycarbonyl(ethylamino)- piperidine To a solution of 476 mg (1.42 mmol) of l-benzyloxycarbonyl-4- t-butoxycarbonylaminopiperidine and 0.24 mL (2.8 mmol) of ethyl iodide in 10 mL of DMF was added 85 mg (2.1 mmol) of 60% sodium hydride in mineral oil. The reaction was stirred for 16 h and was then poured into water and extracted three times with ether. The organic layers were each washed with a portion of water and brine, dried over sodium sulfate, combined and concentrated. The residue was purified by FCC eluting with 15% ethyl acetate/hexanes to afford 409 mg of title compound. iH NMR (400 MHz, CDCI3): δ 1.06 (t, J = 7, 3H), 1.44 (s, 9H), 1.5-1.7 (2 m, 4H), 2.78 (m, 2H), 3.1 (m, 2H), 4.10 (m, IH), 4.25 (m, 2H), 5.10 (s, 2H), 7.33 (m, 5H).
Step D: 4-t-Butoxycarbonyl( ethylamino )piperidine
A solution of 400 mg (1.1 mmol) of l-benzyloxycarbonyl-4-t- butoxycarbonyl(ethylamino)piperidine from Step C in 4 mL of methanol was hydrogenated with 40 mg of 10% Pd/C under a hydrogen balloon for 16 h. The reaction was filtered and concentrated in vacuo to give the title compound which was used directly in the next step.
Step E: (R,S)-N-[2-Phenyl-4-[4-t-butoxycarbonyl(ethylamino)- piperidin-1-ynbut-l-yll-N-methylbenzenesulfonamide Using essentially the same procedure as Example 1, Step C, 235 mg (1.0 mmol) of 4-t-butoxycarbonyl(ethylamino)piperidine from Step D and 212 mg of (R,S)-N-(2-phenyl-4-oxobut-l-yl)-N- methylbenzenesulfonamide from Example 1, Step B afforded 360 mg of title compound. iH NMR (400 MHz, CDCI3): δ 1.06 (t, J = 7, 3H), 1.43 (s,
9H), 1.5-2.2 (5 m, 10H), 2.56 (s, 3H), 2.90 (m, 4H), 3.10 (m, 2H), 3.38 (m, IH), 3.83 (m, IH), 7.1-7.3 (m, 5H), 7.45 (m, 2H), 7.54 (m, IH). Mass spectrum (ESI): m/z 530 (M+l, 100%).
Step F: (R,S)-N-[2-Phenyl-4-[4-(ethylamino)piperidin-l-yl]but-l-yl]-
N-methylbenzenesulfonamide hydrochioride salt
A solution of 10 mmol of HCl in 10 mL of methanol was prepared by slowly adding 0.70 mL (10 mmol) of acetyl chloride with ice bath cooling. To this was added 251 mg (0.489 mmol) of (R,S)-N-[2- phenyl-4-[4-t-butoxycarbonyl(ethylamino)piperidin-l-yl]but-l-yl]-N- methylbenzenesulfonamide. After stirring at rt for 16 h, the volatiles were removed in vacuo to give the title compound. Mass spectrum (ESI): m/z 430 (M+l, 100%).
Step G: (R,S)-N-[2-Phenyl-4-[4-acetyl(ethylamino)piperidin-l-yl]but
1-yl] -N-methylbenzenesulfonamide hydrochioride salt
To a solution of 45 mg (0.089 mmol) of (R,S)-N-[2-phenyl-4-[4-
(ethylamino)piperidin-l-yl]but-l-yl]-N-methylbenzenesulfonamide hydrochioride salt in 2 mL of methylene chloride at 0 C was added 0.067 mL (0.38 mmol) of DIPEA and 0.014 mL (0.19 mmol) of acetyl chloride.
The reaction was stirred at rt for 16 h and then was quenched with aqueous sodium carbonate and extracted three times with methylene chloride. The organic layers were each washed with a portion of brine, dried over sodium sulfate, combined and concentrated. The residue was purified by prep TLC eluting with 10% methanol in methylene chloride and converted to the hydrochioride salt to afford 40 mg of title compound.
Mass spectrum (ESI): m/z 472 (M+l, 100%).
EXAMPLE 65
(R,S)-N- [2-Phenyl-4- [4-(oxazolidin-2-on-3-yl)piperidin- 1-yl] but- 1-yl] -N- methylbenzenesulfonamide hydrochioride salt
Step A: l-Benzyloxycarbonyl-4-(oxazolidin-2-on-3-yl)piperidine
To a solution of 0.53 g (2.0 mmol) of (1- benzyloxycarbonylpiperidin-4-yl)isocyanate from Example 64, Step A in 10 mL of methylene chloride was added 690 mg (2.0 mmol) of 2- chloroethanol and 5 mg (cat) of DMAP. The reaction was stirred under nitrogen at rt for 24 h and then evaporated to dryness to give the crude 2- chloroethylcarbamate intermediate .
The above residue was taken up in 10 mL of DMF under nitrogen and 197 mg (4.93 mmol) of 60% sodium hydride in mineral oil was added. The reaction was stirred at rt for 1 h and then poured into water containing 3 mL of 2 N hydrochloric acid and extracted twice with ether. The organic layers were each washed with a portion of brine, dried over sodium sulfate, combined and concentrated. The residue was purified by FCC eluting with 70% ethyl acetate/hexanes to afford 533 mg of title compound. iH NMR (400 MHz, CDCI3): δ 1.55 (m, 2H), 1.76 (br d, J = 10, 2H), 2.83 (m, 2H), 3.46 (t, J = 8, 2H), 3.87 (m, IH), 4.27 (m, 2H), 4.31 (t, J = 8, 2H), 5.10 (s, 2H), 7.35 (m, 5H).
Step B: 4-(Oxazolidin-2-on-3-yl)piperidine
Using essentially the same procedure as in Example 64, Step D, 525 mg (1.72 mmol) of l-benzyloxycarbonyl-4-(oxazolidin-2-on-3- yl)piperidine from Step A was hydrogenated to afford 250 mg of the title compound.
Step C: (R,S)-N-[2-Phenyl-4-[4-(oxazolidin-2-on-3-yl)piperidin-l- yll but- 1-yll -N-methylbenzenesulfonamide hydrochioride salt
Using essentially the same procedure as in Example 1, Step
C, the piperidine derivative from Step B was utilized to reductively alkylate (R,S)-N-(2-phenyl-4-oxobut-l-yl)-N-methylbenzenesulfonamide to provide the title compound. Mass spectrum (ESI): m/z 472 (M+l, 100%).
EXAMPLE 66
(R,S)-N-[2-Phenyl-4-(4-methoxycarbonyl(ethylamino)piperidin-l-yl)but-l- yl] -N-methylbenzenesulfonamide hydrochioride salt
Step A: l-Benzyloxycarbonyl-4-(methoxycarbonylamino)piperidine
To a solution of 1.0 g (3.9 mmol) of (1-benzyloxycarbonyl- piperidin-4-yl)isocyanate from Example 64, Step A in 10 mL of methanol was added 5 mg (cat) of DMAP. The reaction was stirred under nitrogen at rt for 24 h and then poured into water containing 2 mL of 2 N hydrochloric acid and was extracted twice with ethyl acetate. The organic layers were each washed with a portion of brine, dried over sodium sulfate, combined and concentrated to give 1.4 g of the crude title compound which can be used directly in subsequent reactions. iH NMR (400 MHz, CDCI3): δ 1.32 (m, 2H), 1.92 (br d, J = 10, 4H), 2.91 (v br t, 2H), 3.66 (br s, 3H + IH), 4.10 (m, 2H), 4.58 (br s, IH), 5.09 (s, 2H), .7.33 (m, 5H).
Step B: l-Benzyloxycarbonyl-4-Imethoxycarbonyl(ethylamino)]- piperidine
To 82 mg (0.28 mmol) of l-benzyloxycarbonyl-4- (methoxycarbonylamino)piperidine from Step A and 0.045 mL (0.56 mmol) of ethyl iodide in 4 mL of DMF under nitrogen was added 22 mg (0.56 mmol) of 60% sodium hydride in mineral oil. The reaction was stirred at rt for 1 h and was then poured into water containing 1 mL of 2 N hydrochloric acid and extracted twice with ether. The organic layers were each washed with a portion of brine, dried over sodium sulfate, combined and concentrated. The residue was purified by FCC eluting with 50% ethyl acetate/hexanes to afford 87 mg of title compound. iH
NMR (400 MHz, CDCI3): δ 1.07 (t, J = 7, 3H), 1.5-1.8 (m, 4H), 2.79 (m, 2H),
3.15 (m, 2H), 3.68 (s, 3H), 4.10 (m, IH), 4.26 (m, 2H), 5.10 (s, 2H), 7.34 (m, 5H).
Step C: 4- [Methoxycarbonyl(ethylamino)1 piperidine
Using essentially the same procedure as in Example 64, Step D, 85 mg (0.27 mmol) of l-benzyloxycarbonyl-4-[methoxycarbonyl- (ethylamino)] piperidine from Step B was hydrogenated to afford 37 mg of the title compound.
Step D: (R,S)-N-[2-Phenyl-4-(4-methoxycarbonyl(ethylamino)- piperidin- 1-yl )but- 1-yl] -N-methylbenzenesulfonamide hydrochioride salt
Using essentially the same procedure as in Example 1, Step C, the piperidine derivative from Step C was utilized to reductively alkylate (R,S)-N-(2-phenyl-4-oxobut-l-yl)-N-methylbenzenesulfonamide to provide the title compound. Mass spectrum (ESI): m/z 488 (M+l, 100%).
EXAMPLE 67 (R,S)-N-[2-Phenyl-4-(4-dimethylaminocarbonylaminopiperidin-l-yl)but-l- yl] -N-methylbenzenesulfonamide
Step A: l-Benzyloxycarbonyl-4-(dimethylaminocarbonylamino)- piperidine
To 0.83 g (3.2 mmol) of (l-benzyloxycarbonylpiperidin-4- yl)isocyanate from Example 64, Step A in 10 mL was added 16 mL (32 mmol) of 2 M dimethylamine in THF. The reaction was stirred under nitrogen at rt for 24 h and then poured into water containing 20 mL of 2 N hydrochloric acid and was extracted twice with ethyl acetate. The organic layers were each washed with a portion of brine, dried over sodium sulfate, combined and concentrated to give 0.95 g of the crude title compound which can be used directly in subsequent reactions. IH NMR (400 MHz, CDCI3): δ 1.25 (m, 2H), 1.95 (br d, J = 10, 2H), 2.86 (br s, 6H + 2H), 3.79 (m, IH), 4.0-4.25 (m, 3H), 5.09 (s, 2H), 7.35 (m, 5H).
Step B: 4-(Dimethylaminocarbonylamino)piperidine
Using essentially the same procedure as in Example 64, Step D, 1.4 g (4.6 mmol) of l-benzyloxycarbonyl-4-
(dimethylaminocarbonylamino)piperidine from Step A was hydrogenated to afford 690 mg of the title compound.
Step C: (R,S)-N-[2-Phenyl-4-(4-dimethylaminocarbonylamino- piperidin-l-yl)but- 1-yl] -N-methylbenzenesulfonamide
Using essentially the same procedure as in Example 1, Step
C, the piperidine derivative from Step C was utilized to reductively alkylate (R,S)-N-(2-phenyl-4-oxobut- l-yl)-N-methylbenzenesulfonamide to provide the title compound. Mass spectrum (ESI): m/z 473 (M+l, 100%).
EXAMPLE 68
(R,S)-N-[2-Phenyl-4-(4-benzyloxycarbonyl(prop-l-ylamino)piperidin-l- vDbut-l-yl] -N-methylbenzenesulfonamide hydrochioride salt Step A: 4-Azido-l-t-butoxycarbonylpiperidine
To a solution of 45.3 g (172 mmol) of 4-bromo-l-t- butoxycarbonylpiperidine in 750 mL of DMF was added 22.3 g (343 mmol) of sodium azide and 2.5 g (17 mmol) of sodiun iodide. The reaction was stirred at rt for 24 h and then at 60 C for 4 h. The mixture was poured into water containing 20 mL of sodium bicarbonate and extracted twice with 1:1 ether :hexanes. The organic layers were each washed with a portion of water and brine, dried over sodium sulfate, combined and concentrated. The residue was purified by FCC eluting with 5 - 10% ethyl acetate/hexanes to afford 39 g of title compound having a trace of elimination biproduct. IH NMR (400 MHz, CDCI3): δ 1.43 (s,9H), 1.52 (m, 2H), 1.85 (m, 2H), 3.07
(m, 2H), 3.55 (m, IH), 3.78 (m, 2H).
Step B: 4-Amino-l-t-butoxycarbonylpiperidine
A solution of 4.05 g (17.9 mmol) of 4-azido-l-t- butoxycarbonylpiperidine from Step A in 50 mL of methanol was hydrogenated with 350 mg of 10% Pd/C under a hydrogen balloon for 16 h when the reaction was complete by TLC (10% ethyl acetate/hexanes).
The catalyst was filtered off and the volatiles removed in vacuo to give 3.5 g of title compound which was used directly in subsequent reactions.
Step C: 4-Benzyloxycarbonylamino-l-t-butoxycarbonylpiperidine To a solution of 1.2 g (6.0 mmol) 4-amino-l-t- butoxycarbonylpiperidine from Step B in 40 mL of methylene chloride was added 3.15 mL (18 mmol) of DIPEA and 1.03 mL (7.2 mmol) of benzyl chloroformate while cooled in an ice bath. After 0.5 h the reaction was quenched with aqueous sodium carbonate and extracted three times with methylene chloride. The organic layers were each washed with a portion of brine, dried over sodium sulfate, combined and concentrated. The residue was purified by FCC eluting with 25% ethyl acetate/hexanes to afford 1.94 g of title compound. IH NMR (400 MHz, CDCI3): δ 1.26 (m, 2H), 1.42 (s, 9H), 1.90 (br d, J = 12, 2H), 2.90 (br t, 2H), 3.58 (m, IH), 4.08 (m, 2H), 4.42 (br s, IH), 5.09 (s, 2H), 7.33 ( , 5H).
Step D: 4-Benzyloxycarbonyl(prop-l-ylamino)-l-t- butoxycarbonylpiperidine
To 110 mg (0.32 mmol) 4-benzyloxycarbonylamino-l-t- butoxycarbonylpiperidine from Step C and 0.16 mL (1.6 mmol) of n- propyl iodide in 2 mL of DMF under nitrogen was added 26 mg (0.65 mmol) of 60% sodium hydride in mineral oil. The reaction was stirred at rt for 16 h and was then poured into water and extracted twice with ether. The organic layers were each washed with a portion of brine, dried over sodium sulfate, combined and concentrated. The residue was purified by FCC eluting with 20% ethyl acetate/hexanes to afford 90 mg of title compound.
Step E: 4-Benzyloxycarbonyl(prop-l-ylamino)piperidine hydrochioride salt
To a solution of 2.4 mmol of HCl in 2 mL of methanol (prepared by the addition of 0.17 mL of acetyl chloride at 0 C and stirring for 10 min) was added 90 mg of 4-benzyloxycarbonyl(prop-l-ylamino)-l-t- butoxycarbonylpiperidine. The mixture was stirred at rt for 16 h at which time the reaction was complete by TLC (20% ethyl acetate/hexanes) and was evaporated to dryness in vacuo to afford 75 mg of the title compound as the hydrochioride salt.
Step F: (R,S)-N-[2-Phenyl-4-(4-benzyloxycarbonyl(prop-l- ylamino)piperidin-l-yl)but-l-yl]-N-methylbenzene- sulfonamide hydrochioride salt Using essentially the same procedure as in Example 1, Step
C, the piperidine derivative from Step E was utilized to reductively alkylate (R,S)-N-(2-phenyl-4-oxobut-l-yl)-N-methylbenzenesulfonamide to provide the title compound. Mass spectrum (NH3/CI): m z 578 (M+l,
100%). The following Examples were prepared following the procedure described in Example 1, Step C but using the appropriate substituted piperidine in the reductive amination step (prepared by analogy to the piperidine derivatives in Examples 64-68).
EXAMPLE 69
(R,S)-N-[2-Phenyl-4-(4-methoxycarbonylaminopiperidin-l-yl)but-l-yl]-
N-methylbenzenesulfonamide Mass spectrum (ESI): m/z 460 (M+l, 100%).
EXAMPLE 70
(R,S)-N-[2-Phenyl-4-(4-aminocarbonylaminopiperidin-l-yl)but-l-yl]-N- methylbenzenesulfonamide
Mass spectrum (ESI): m/z 445 (M+l, 100%).
EXAMPLE 71
(R,S)-N-[2-Phenyl-4-(4-aminopiperidin-l-yl)but-l-yl]-N-methylbenzene- sulfonamide hydrochioride salt
Mass spectrum (ESI): m/z 402 (M+l, 100%).
EXAMPLE 72
(R,S)-N-[2-Phenyl-4-(4-acetylaminopiperidin-l-yl)but-l-yl]-N- methylbenzenesulfonamide hydrochioride salt
Mass spectrum (ESI): m/z 444 (M+l, 100%).
EXAMPLE 73
(R,S)-N-[2-Phenyl-4-(4-isopropylcarbonylaminopiperidin-l-yl)but-l- yll -N-methylbenzenesulfonamide hydrochioride salt
Mass spectrum (ESI): m/z 472 (M+l, 100%).
EXAMPLE 74 (R,S)-N-[2-Phenyl-4-(4-methylsulfonylaminopiperidin-l-yl)but-l-yl]-N- methylbenzenesulfonamide hydrochioride salt
Mass spectrum (ESI): m/z 480 (M+l, 100%).
EXAMPLE 75
(R,S)-N-[2-Phenyl-4-(4-isopropylcarbonyl(ethylamino)piperidin-l- yl)but-l-yl1 -N-methylbenzenesulfonamide hydrochioride salt Mass spectrum (ESI): m/z 500 (M+l, 100%).
EXAMPLE 76
(R,S)-N-[2-Phenyl-4-(4-methylsulfonyKethylamino)piperidin-l-yl)but- 1-yl] -N-methylbenzenesulfonamide hydrochioride salt
Mass spectrum (ESI): m/z 508 (M+l, 100%).
EXAMPLE 77
(R,S)-N-[2-Phenyl-4-(4-t-butoxycarbonylaminopiperidin-l-yl)but-l-yl]-
N-methylbenzenesulfonamide hydrochioride salt
Mass spectrum (ESI): m/z 502 (M+l, 100%).
EXAMPLE 78
(R,S)-N-[2-Phenyl-4-(4-methoxycarbonyl(methylamino)piperidin-l-yl)but-
1-yll -N-methylbenzenesulfonamide hydrochioride salt
Mass spectrum (PB-EI): m/z 474 (M+l), 211 (100%).
EXAMPLE 79
(R,S)-N-[2-Phenyl-4-(4-(pyrrolidin-2-on-l-yl)piperidin-l-yl)but-l-yl]-N- methylbenzenesulfonamide hydrochioride salt
Mass spectrum (PB-EI): m z 470 (M+l), 160 (100%).
EXAMPLE 80 (R,S)-N-[2-Phenyl-4-(4-methoxycarbonyl(cyclobutylmethylami piperidin-l-yl)but- 1-yll -N-methylbenzenesulfonamide hydrochioride salt Mass spectrum (PB-EI): m/z 528 (M+l), 160 (100%).
EXAMPLE 81
(R,S)-N-[2-Phenyl-4-(4-ethoxycarbonyl(ethylamino)piperidin-l-yl)but-l- yl] -N-methylbenzenesulfonamide hydrochioride salt Mass spectrum (PB-EI): m/z 502 (M+l), 160 (100%).
EXAMPLE 82
(R,S)-N-[2-Phenyl-4-(4-isobutyloxycarbonyl(ethylamino)piperidin-l- ylTbut- 1-yl] -N-methylbenzenesulfonamide hydrochioride salt
Mass spectrum (PB-EI): m/z 530 (M+l), 160 (100%).
EXAMPLE 83
(R,S)-N-[2-Phenyl-4-(4-piperidin-2-on-l-ylpiperidin-l-yl)but-l-yl]-N- methylbenzenesulfonamide hydrochioride salt
Mass spectrum (ESI): m/z 484 (M+l), 347 (100%).
EXAMPLE 84
(R,S)-N-[2-Phenyl-4-(4-methoxycarbonyl(benzylamino)piperidin-l-yl)but-
1-yll -N-methylbenzenesulfonamide hydrochioride salt
Mass spectrum (ESI): m/z 550 (M+l, 100%).
EXAMPLE 85
(R,S)-N-[2-Phenyl-4-(4-methoxycarbonyl(prop-l-ylamino)piperidin-l- yPbut- 1-yll -N-methylbenzenesulfonamide hydrochioride salt
Mass spectrum (NH3/CI): m/z 502 (M+l), 118 (100%).
EXAMPLE 86 (R,S)-N-[2-Phenyl-4-(4-methoxycarbonyl(but-l-ylamino)piperidin-l- yPbut- 1-yll -N-methylbenzenesulfonamide hydrochioride salt
Mass spectrum (NH3/CI): m/z 516 (M+l), 132 (100%).
EXAMPLE 87
(R,S)-N-[2-Phenyl-4-(4-methoxycarbonyl(cyclohexylmethylamino)-piper- idin-l-yl)but-l-yl]-N-methylbenzenesulfonamide hydrochioride salt Mass spectrum (NHg/CI): m/z 556 (M+l, 100%).
EXAMPLE 88
(R,S)-N-[2-Phenyl-4-(4-methoxycarbonyl(cyclopropylmethylamino)-piper- i din- 1-yl )but- 1-yll -N-methylbenzenesulfonamide hydrochioride salt Mass spectrum (NHg/CI): m/z 514 (M+l, 100%).
EXAMPLE 89
(R,S)-N-[2-Phenyl-4-(4-methoxycarbonyl(pent-l-ylamino)piperidin-l- yPbut- 1-yl] -N-methylbenzenesulfonamide hydrochioride salt
Mass spectrum (NHg/CI): m/z 530 (M+l, 100%).
EXAMPLE 90
(R,S)-N-[2-Phenyl-4-(4-methoxycarbonyl(pent-l-ylamino)piperidin-l- yPbut- 1-yll -N-methylbenzenesulfonamide hydrochioride salt
Mass spectrum (NH3/CI): m/z 530 (M+l, 100%).
EXAMPLE 91
(R,S)-N-[2-Phenyl-4-(4-benzyloxycarbonyl(methylamino)piperidin-l- yPbut- l-yll -N-methylbenzenesulfonamide hydrochioride salt
Mass spectrum (NH3/CI): m/z 550 (M+l, 100%). EXAMPLE 92
(R,S)-N-[2-Phenyl-4-(4-benzyloxycarbonyl(ethylamino)piperidin-l-yl)b
1-yll -N-methylbenzenesulfonamide hydrochioride salt Mass spectrum (PB-EI): m z 564 (M+l), 160 (100%).
EXAMPLE 93
(R,S)-N-[2-Phenyl-4-(4-benzyloxycarbonyl(but-l-ylamino)piperidin-l- yPbut- 1-yl] -N-methylbenzenesulfonamide hydrochioride salt
Mass spectrum (NHg/CI): m/z 592 (M+l, 100%).
EXAMPLE 94
(R,S)-N-[2-Phenyl-4-(4-benzyloxycarbonyl(pent-l-ylamino)piperidin-l- yPbut-l-yll-N-methylbenzenesulfonamide hydrochioride salt
Mass spectrum (NH3/CI): m/z 606 (M+l, 100%).
EXAMPLE 95
(R,S)-N-[2-Phenyl-4-(4-benzyloxycarbonyl(cyclobutylmethylamino)-piper- idin- l-yl)but- 1-yll -N-methylbenzenesulfonamide hydrochioride salt Mass spectrum (NH3/CI): m/z 604 (M+l, 100%).
EXAMPLE 96
(R,S)-N-[2-Phenyl-4-(4-benzyloxycarbonyl(cyclohexylmethylamino)-piper- idin- l-yl)but- l-yll -N-methylbenzenesulfonamide hydrochioride salt Mass spectrum (NH3/CI): m/z 632 (M+l, 100%).
EXAMPLE 97
(S)-N-[2-(3-Chlorophenyl-4-(4-benzyloxycarbonyl(ethylamino)-piperidin-l- yPbut- 1-yll -N-methylbenzenesulfonamide hydrochioride salt The title compound was prepared using essentially the same procedure as in Example 39, Step C. The piperidine subunit was prepared by analogy to the procedure given in Example 68. Mass spectrum (NH3/CI): m/z 598 (M+l, 100%).
EXAMPLE 98
(R,S)-N-[3-Phenyl-4-(4-phenylpiperidin-l-yl)but-l-yl]-N- methylbenzenesulfonamide hydrochioride salt
Step A: N- [3-Phenyl-4-(4-phenylpiperidin- l-yl)but-2-en- 1-yl] -N- methylbenzenesulfonamide
To 250 mg (0.37 mmol) of N-[4-(4-phenylpiperidin-l-yl)-3- tributylstannylbut-2-en- 1-yl] -N-methylbenzenesulfonamide from Example 21, Step B (isomeric higher Rf product) in 0.5 mL of N- methylpyrrolidinone under argon was added 75 mg (0.55 mmol) of potassium carbonate, 8 mg (2% cat) of dichlorobis(triphenylphosphine)- palladium (II) and 90 mg (0.55 mmol) of bromobenzene. The mixture was heated at 70 C for 24 h, cooled, treated with aqueous sodium fluoride for 10 min, and partitioned between water and ether. The water layer was reextracted with ether and each organic layer was washed with brine, dried over sodium sulfate, combined and concentrated in vacuo. The residue was purified by FCC eluting with 20-25% ethyl acetate/hexanes to give 120 mg of title product as an oil. IH NMR (400 MHz, CDCI3): δ 1.55-1.6 (m, 2H), 2.75 (br d, J = 11, 2H), 2.00
(br dt, J= 2 and 14, 2H), 2.42 (m, IH), 2.78 (s, 3H), 2.93 (br d, J = 11, 2H),
3.33 (s, 2H), 4.05 (d, J = 6.5, 2H), 5.78 (t, J = 6.5, IH), 7.1-7.4 (3 m, 5H), 7.5-
7.65 (m, 3H), 7.84 (dd, J = 1.5 and 7, 2H). Mass spectrum (ESI): m z 461 (M+l , 100%).
Step B: (R,S)-N-[3-Phenyl-4-(4-phenylpiperidin-l-yl)but-l-yl]-N- methylbenzenesulfonamide
A mixture of 90 mg (0.20 mmol) of N-[3-phenyl-4-(4- phenylpiperidin-l-yl)but-2-en-l-yl]-N-methylbenzenesulfonamide from Step A, 12 mg of 20% palladium hydroxide/C (50% water), and 2 drops of acetic acid in 3 mL of methanol was hydrogenated at 40 psi for 24 h. The catalyst was removed by filtration and the filtrate concentrated in vacuo. The residue was purified by prep TLC (50% ethyl acetate/ hexanes) to afford 20 mg of title compound. A major biproduct was cleavage of the 4- phenylpiperidine to give N-(3-phenylbut-l-yl)-N- methylbenzenesulfonamide. iH NMR (400 MHz, CDCI3): δ 1.5-1.8 (m,
5H), 1.95 (br t, J = 11, IH), 2.1-2.25 (2 m, 2H), 2.45 (m, 2H), 2.57 (m, IH), 2.6-2.7 (m, 2H), 2.68 (s, 3H), 2.9 (m, 2H), 3.0-3.2 (2 m, 2H), 7.1-7.3 (m, 5H), 7.45 (m, 2H), 7.54 (m, IH), 7.69 (dd, J = 1.5 and 7, 2H). Mass spectrum (ESI): m/z 463 (M+l, 100%).
EXAMPLE 99
(R,S)-N-Methyl-N-[2-methyl-2-phenyl-4-(4-phenylpiperidin-l-yl)but-l- yllbenzenesulfonamide hydrochioride
Step A: (R.S)-N-Methyl(2.5-dimethyl-2-phenylhex-4-enyl)amine
Methylamine hydrochioride (500 mg, 7.41 mmol), triethylamine (1.00 L, 725 mg, 7.17 mmol), and 3 A molecular sieve pellets (1.05 g) were added to a stirred solution of 2,5-dimethyl-2- phenylhex-4-enal (500 mg, 2.47 mmol) in 5.0 mL of methanol at room temperature. After 1 h, the mixture was cooled in an ice bath and acetic acid (0.29 mL, 0.30 g, 5.1 mmol) was added followed by sodium cyanoborohydride (310 mg, 4.93 mmol). The mixture was allowed to slowly come to room temperature and stirred 16 h before being diluted with ethyl acetate (50 mL) and washed with saturated aqueous sodium bicarbonate (30 mL) and saturated aqueous sodium chloride (30 mL). The aqueous layers were extracted with ethyl acetate (30 mL) and the combined organic layers were dried over sodium sulfate, decanted, and evaporated. The residue was purified by flash column chromatography on silica gel, eluting with 5% methanol in ethyl acetate to give 415 mg the title compound. iH NMR (400 MHz, CD3OD): δ 1.34 (s, 3H), 1.54 (s, 3H),
1.59 (s, 3H), 2.27 (s, 3H), 2.30 (dd, J = 14 and 8, IH), 2.39 (dd, J = 14 and 7.5, IH), 2.66 (d, J = 12, IH), 2.87 (d, J = 12, IH), 4.88 (t, J = 7.5, IH), 7.18 (t, J = 7, IH), 7.28-7.36 (m, 4H). Mass spectrum (NH3/CI): m/z 218 (M+l, 100%).
Step B: (R,S)-N-Methyl-N-(2,5-dimethyl-2-phenylhex-4-en-l- yPbenzenesulfonamide Using essentially the same procedure as in Example 1 (Step
A), (R,S)-N-methyl(2,5-dimethyl-2-phenylhex-4-enyl)amine from Step A above was allowed to react with benzenesulfonyl chloride in THF to give the title compound as a colorless oil. iH NMR (400 MHz, CDCI3): δ 1.42
(s, 3H), 1.59 (s, 6H), 2.09 (s, 3H), 2.33 (dd, J = 15 and 8, IH), 2.50 (dd, J = 15 and 6, IH), 2.94 (d, J = 13, IH), 3.40 (d, J = 13, IH), 4.83 (bt, J = 7, IH), 7.17, t, J = 7, IH), 7.23-7.33 (m, 4H), 7.48 (t, J = 7.5, 2H), 7.55 (t, J = 7.5, IH), 7.72 (d, J = 7.5, 2H). Mass spectrum (NH3/CI): m/z 358 (M+l, 100%).
Step C: (R,S)-N-Methyl-N-(2-methyl-2-phenyl-4-oxobut-l- yPbenzenesulfonamide
To a solution of (R,S)-N-methyl-N-(2,5-dimethyl-2- phenylhex-4-en-l-yl)benzenesulfonamide (300 mg, 0.839 mmol) from Step B in 6.0 mL of acetone, 3.0 mL of t-butanol and 1.5 mL of water was added 0.145 mL (118 mg, 0.012 mmol) of 2.5% osmium tetroxide in t- butanol followed by 433 mg (3.70 mmol) of N-methylmorpholine-N-oxide. The reaction was stirred at room temperature for 18 h and was then quenched with 3 g of aqueous sodium bisulfite and concentrated in vacuo. The residue was partitioned between dichloromethane (20 mL) and water (10 mL). The aqueous layer was extracted with dichloromethane (2 x 20 mL) and the combined organic layers were dried over sodium sulfate, decanted, and evaportated to give the diol intermediate. The above product was dissolved in 9.0 mL of THF and 3.0 mL of water, and treated with 323 mg (1.51 mmol) of sodium periodate. After 2 h, additional sodium periodate (150 mg, 0.70 mmol) was added and the mixture was stirred 1 h longer. Most of the THF was removed in vacuo and the residue was patitioned between ethyl acetate (20 mL) and water (10 mL). The aqueous layer was extracted with ethyl acetate (2 x 20 mL) and the combined organic layers were dried (sodium sulfate), decanted, and evaporated. The residue was re-dissolved in 9.0 mL of THF and 3.0 mL of water, and sodium periodate (450 mg, 2.1 mmol) was added in three equal portions at 1.5 h intervals. The mixture was stirred for 1.5 h after the addition of the last portion, and then worked up as before. Flash column chromatography on silica gel, eluting with 20% ethyl acetate in hexane gave 210 mg of the title compound as a colorless syrup. IH NMR (400 MHz, CDCI3): δ 1.64 (s, 3H), 2.21 (s, 3H), 2.78 (dd, J
= 16 and 2.5, IH), 3.15 (d, J = 13, IH), 3.19 (dd, J = 16 and 2.5, IH), 3.23 (d, J = 13, IH), 7.23-7.28 (m, IH), 7.32-7.40 (m, 4H), 7.52 (t, J = 7.5, 2H), 7.59 (t, J = 7.5, IH), 7.74 (d, J = 7.5, 2H), 9.62 (t, J = 2.5, IH). Mass spectrum (ESI): m/z 332 (M+l, 100%).
Step D: (R,S)-N-Methyl-N-[2-methyl-2-phenyl-4-(4-phenyl-piperidin- l-yl)but-l-yllbenzenesulfonamide hydrochioride Using essentially the same procedure as in Example 1 (Step C), (R,S)-N-methyl-N-(2-methyl-2-phenyl-4-oxobut-l-yl)benzene- sulfonamide from Step C above was allowed to react with 4-phenylpiperidine to give the free amine of the title compound as a colorless film. IH NMR (400 MHz, CD3OD): δ 1.50 (s, 3H), 1.70-1.93 (m, 5H), 2.06-
2.23 (m, 3H), 2.11 (s, 3H), 2.29 (td, J = 12 and 4, IH), 2.40-2.59 (m, 2H), 3.03 (d, J = 14, IH), 3.03-3.15 (m, 2H), 3.41 (d, J = 14, IH), 7.15 (t, J = 7, IH),
7.19-7.29 (m, 5H), 7.34 (t, J = 7.5, 2H), 7.42 (d, J = 8, 2H), 7.57 (t, J = 7.5,
2H), 7.64 (t, J = 7.5, IH), 7.76 (d, J = 8, 2H).
Mass spectrum (ESI): m/z 477 (M+l, 100%). The hydrochioride salt of the title compound was prepared by dissolving the free base in ethanol and adding 1.5 equivalents of aqueous 2 N HCl. Evaporation of the solvent gave the title salt as a white solid.
EXAMPLE 100
(R,S)-N-[4-(4-Benzyloxycarbonyl(ethylamino)piperidin-l-yl)-2-methyl-2- phenylbut- l-yll -N-methylbenzenesulfonamide hydrochioride
Using essentially the same procedure as in Example 1 (Step C), (R,S)-N-methyl-N-(2-methyl-2-phenyl-4-oxobut-l-yl)benzene- sulfonamide (from Example 99, Step B) was allowed to react with 4- benzyloxycarbonyl(ethylamino)piperidine (prepared by analogy to Example 68) to give the free amine of the title compound as a colorless film. IH NMR (400 MHz, CD3OD): δ 1.11 (t, J = 7, 3H), 1.47 (s, 3H), 1.60-
1.70 (m, 2H), 1.72-1.86 (m, 3H), 1.91-2.06 (m, 3H), 2.10 (s, 3H), 2.20 (td, J = 12 and 3, IH), 2.28-2.38 (m, IH), 2.90-3.02 (m, 2H), 3.00 (d, J = 14, IH), 3.24
(t, J = 7, 2H), 3.99 (d, J = 14, IH), 3.78-3.90 (b, IH), 5.11 (s, 2H), 7.21 (t, J =
7, IH), 7.27-7.42 (m, 9H), 7.56 (t, J = 7, 2H), 7.63 (t, J = 7.5, IH), 7.75 (d, J = 7.5, 2H). Mass spectrum (NH3/CI): m/z 578 (M+l, 100%). The hydrochioride salt of the title compound was prepared by dissolving the free base in ethanol and adding 1.5 equivalents of aqueous 2 N HCl. Evaporation of the solvent gave the title salt as a clear glass.
EXAMPLE 101
(R,S)-N-[4-(4-Benzyloxycarbonyl(ethylamino)piperidin-l-yl)-2-ethyl-2- phenylbut- 1-yll -N-methylbenzenesulfonamide hydrochioride
Step A: (R.S)-2-Ethyl-2-phenylpent-4-enenitrile
A solution of 2-phenylpent-4-enenitrile (500 mg, 3.18 mmol) in THF (6.5 mL) was stirred in an ice bath and 1.5 M lithium diisopropylamide monotetrahydrofuran complex in cyclohexane (2.16 mL, 3.23 mmol) was added. After 10 min, the ice bath was removed and the solution was stirred at room temperature for 1 h. The solution was cooled in a dry ice/isopropanol bath and iodoethane (0.280 mL, 546 mg, 3.50 mmol) was added. The reaction was allowed to warm to -20 °C over 30 min, and was then stirred 2 h at room temperature. The mixture was partitioned between ethyl acetate (50 mL) and saturated aqueous ammonium chloride (30 mL). The organic layer was washed with saturated aqueous sodium chloride (30 mL), dried over sodium sulfate, decanted, and evaporated. The residue was purified by flash column chromatography on silica gel, eluting with 5% ether in hexane to give the title compound as 537 mg of yellow oil. IH NMR (400 MHz, CDCI3): δ 0.93 (t, J = 7.5, 3H), 1.94 (dq, J = 14 and 7,
IH), 2.08 (dq, J = 14 and 7, IH), 2.68 (d, J = 7, 2H), 5.12 (d, J = 10, IH), 5.13 (d, J = 16, IH), 5.65 (ddt, J = 16, 10, and 7, IH), 7.28-7.35 (m, IH), 7.35-7.42 (m, 4H).
Step B: (R.S)-2-Ethyl-2-phenylpent-4-enal A solution of 500 mg (2.70 mmol) of (R,S)-2-ethyl-2- phenylpent-4-ene nitrile from Step A in 2.0 mL of ether was cooled in an ice bath and 1.5 M diisobutylaluminum hydride in toluene (2.65 mL, 3.97 mmol) was added. The solution was stirred for 2 h at 0 °C, then quenched by the addition of 15 mL of 2 N aqueous HCl and stirred for 1 h. The mixture was extracted with ether (2 x 50 mL). The combined organic layers were washed with saturated aqueous sodium bicarbonate (50 mL) and saturated aqueous sodium chloride (50 mL), dried over sodium sulfate, decanted, and evaporated to give 410 mg of the title compound. iH NMR (400 MHz, CDCI3): δ 0.80 (t, J = 7.5, 3H), 1.94-2.05 (m, 2H), 2.67 (dd, J = 14 and 7, IH), 2.74 (dd, J = 14 and 7, IH), 5.03 (d, J = 10, IH), 5.07 (d, J = 16, IH), 5.53 (ddt, J = 16, 10, and 7, IH), 7.22 (d, J = 8, 2H), 7.29 (t, J = 8, IH), 7.39 (t, J = 8, 2H).
Step C: (R.S)-N-Methyl(2-ethyl-2-phenylpent-4-enyl)amine Using essentially the same procedure as in Example 99
(Step A), the crude (R,S)-2-ethyl-2-phenylpent-4-enal from Step B above gave the title compound as an amber liquid. iH NMR (400 MHz, CD3OD): δ 0.69 (t, J = 7.5, 3H), 1.74 (q, J = 7.5, 2H), 2.27 (s, 3H), 2.48 (dd, J
= 14 and 7, IH), 2.56 (dd, J = 14 and 7, IH), 2.77 (s, 2H), 5.00 (dm, J = 10, IH), 5.07 dm, J = 16, IH), 5.61 (ddt, J = 16, 10, and 7, IH), 7.16-7.22 (m, IH), 7.30-7.37 (m, 4H). Mass spectrum (ESI): m/z 204 (M+l, 100%).
Step D: (R,S)-N-(2-Ethyl-2-phenylpent-4-enyl)-N-methylbenzene- sulfonamide Using essentially the same procedure as in Example 1 (Step
A), (R,S)-N-methyl(2-ethyl-2-phenylpent-4-enyl)amine from Step A above was allowed to react with benzenesulfonyl chloride in THF to give the title compound as an amber syrup. iH NMR (400 MHz, CDCI3): δ 0.82
(t, J = 7.5, 3H), 1.85 (q, J = 7.5, 2H), 1.94 (s, 3H), 2.59 (dd, J = 14 and 7, IH), 2.73 (dd, J = 14 and 7, IH), 3.08 (d, J = 14, IH), 3.25 (d, J = 14, IH), 5.10 (dm, J = 10, IH), 5.16 (bd, J = 16, IH), 5.89 (ddt, J = 16, 10, and 7, IH), 7.20
(d, J = 7, IH), 7.27-7.36 (m, 4H), 7.51 (t, J = 7, 2H), 7.58 (t, J = 7, IH), 7.73
(d, J = 7, 2H).
Mass spectrum (ESI): m/z 344 (M+l, 33%), 361 (M+NH3+I, 100%).
Step E: (R,S)-N-(2-Ethyl-2-phenyl-4-oxobut-l-yl)-N-methyl- benzenesulfonamide
Using essentially the same procedure as in Example 1 (Step B), (R,S)-N-(2-ethyl-2-phenylpent-4-enyl)-N-methylbenzenesulfonamide from Step D above was oxidized to give the title compound as a syrup. IH NMR (400 MHz, CDCI3): δ 0.79 (t, J = 7.5, 3H), 1.92-2.07 (m, 2H), 2.06
(s, 3H), 2.94 (d, J = 14, IH), 2.96 (dd, J = 17 and 3, IH), 3.22 (bd, J = 17, IH),
3.65 (d, J = 14, IH), 7.22-7.38 (m, 5H), 7.53 (t, J = 7, 2H), 7.60 (t, J = 7, IH),
7.74 (d, J = 7, 2H), 9.92 (dd, J = 3 and 2, IH). Mass spectrum (ESI): m/z 346 (M+l, 85%), 363 (M+NH3+1, 100%).
Step F: (R,S)-N-[4-(4-Benzyloxycarbonyl(ethylamino)piperidin-l-yl)-
2-ethyl-2-phenylbut-l-yl]-N-methylbenzenesulfonamide hydrochioride Using essentially the same procedure as in Example 1 (Step
C), (R,S)-N-(2-ethyl-2-phenyl-4-oxobut-l-yl)-N-methylbenzene- sulfonamide from Step E above was allowed to react with 4- benzyloxycarbonyl(ethylamino)piperidine (prepared by analogy to Example 68) to give the free amine of the title compound as a colorless film. IH NMR (400 MHz, CD3OD): δ 0.87 (t, J = 7, 3H), 1.12 (t, J = 7, 3H),
1.63-2.24 (m, 11H), 1.89 (s, 3H), 2.50-2.60 (m, IH), 3.04 (bd, J = 10, IH), 3.11 (bd, J = 10, IH), 3.16 (d, J = 14, IH), 3.22 (d, J = 14, IH), 3.26 (q, J = 7, 2H), 3.82-3.96 (b, IH), 5.12 (s, 2H), 7.20 (t, J = 7, IH), 7.28-7.42 (m, 4H), 7.58 (t, J = 7, 2H), 7.65 (t, J = 7, IH), 7.74 (d, J = 7, 2H). Mass spectrum (ESI): m/z 592 (M+l, 100%). The hydrochioride salt of the title compound was prepared by dissolving the free base in ethanol and adding 1.5 equivalents of aq. 2 N HCl. Evaporation of the solvent gave the title salt as a white glass. While the invention has been described and illustrated with reference to certain particular embodiments thereof, those skilled in the art will appreciate that various adaptations, changes, modifications, substitutions, deletions, or additions of procedures and protocols may be made without departing from the spirit and scope of the invention. For example, effective dosages other than the particular dosages as set forth herein above may be applicable as a consequence of variations in the responsiveness of the mammal being treated for any of the indications with the compounds of the invention indicated above. Likewise, the specific pharmacological responses observed may vary according to and depending upon the particular active compounds selected or whether there are present pharmaceutical carriers, as well as the type of formulation and mode of administration employed, and such expected variations or differences in the results are contemplated in accordance with the objects and practices of the present invention. It is intended, therefore, that the invention be defined by the scope of the claims which follow and that such claims be interpreted as broadly as is reasonable.

Claims

WHAT IS CLAIMED IS:
A compound of the formula:
Figure imgf000184_0001
wherein: wherein: R1 is selected from a group consisting of:
C3, C4, C5 C6 C7, or C8 linear or branched alkyl, which is unsubstituted or mono, di or tri-substituted, where the substituents are independently selected from:
(a) hydroxy,
(b) Cl or F,
(c) phenyl,
(d) mono, di or tri-substituted phenyl, where the substituents are independently selected from:
(V) phenyl, (2') hydroxy, (3') Ci-3alkyl,
(4') cyano, (5') halogen, and
(6') trifluoromethyl,
(e) Cl-6 alkyl, unsubstituted or substituted with hydroxy,
(f) -NR6CO-R7, wherein R6 is hydrogen or C1.3 alkyl, unsubstituted or substituted with C5-8 cycloalkyl, and R ' is Cl-6 alkyl, benzyl or phenyl which is unsubsituted or substituted with halo, CF3, Ci_3alkyl, or Ci-3alkoxy,
(g) -COR6, (h) -OR6, (i) -NR6S(O)j-R?, where j is 1 or 2,
(j) -NR"S(O)j-heteroaryl, wherein heteroaryl is selected from the group consisting of: (D benzimidazolyl,
(21) benzofuranyl,
(3«) benzoxazolyl,
(4') fur any 1,
(5') imidazolyl,
(6') indolyl,
(71) isooxazolyl,
(8') isothiazolyl,
(9') oxadiazolyl,
(10') oxazolyl,
(ID pyrazinyl,
(12') pyrazolyl,
(13') pyridyl,
(14') pyrimidyl,
(15') pyrrolyl,
(16') quinolyl,
(17') tetrazolyl,
(18') thiadiazolyl,
(19') thiazolyl,
(20') thienyl, and
(21') triazolyl, wherein the heteroaryl is unsubstituted or mono di or tri substituted , where the substituents are independently selected from:
(a') phenyl,
(b1) hydroxy,
(c') oxo,
(d') cyano,
(e') halogen, and
(f) trifluoromethyl;
elected from the group consisting of:
(1) hydrogen,
(2) hydroxy,
(3) Ci-6 alkyl, (4) -O-Ci-6 alkyl,
(5) phenyl,
(6) -N(CH3)-CO-N(H)(CH3),
(7) -N(H)-CO-O-CH3, and (8) -CO-CH3;
R3 is selected from the group consisting of:
(1) Ar,
(2) -(Ci-6 alkyl)-Ar, (3) -(Ci-6 alkyl)-O-(C╬╣_6 alkyl)- Ar, and
(4) -N(R4)-CO-O-(Ci-6 alkyl)-Ar, wherein R4 is selected from hydrogen, Ci-io linear or branched alkyl, and C╬╕-6 alkyl substituted with C3-8 cycloalkyl,
(5) -N(R4)-CO-O-R7;
Ar is selected from the group consisting of:
(1) phenyl,
(2) pyrazinyl,
(3) pyrazolyl, (4) pyridyl,
(5) pyrimidyl, and
(6) thienyl, wherein the Ar is unsubstituted or mono or di-substituted, and the substituents are independently selected from: (a) C1-3 alkyl, unsubstituted or substituted with
(1') oxo, (2') hydroxy, (3*) -OR7, (4') phenyl, and (5') trifluoromethyl,
(b) halogen,
(c) -OC1-6 alkyl,
(d) trifluoromethyl,
(e) -N╬╕2, (f) CONR6-(C╬╣-2 alkyl),
(g) CO2H,
(h) CO2-(Ci-2 alkyl), (i) CH2NR6-(CI-2 alkyl), (j) CH2NH-C(O)-Ci-3alkyl,
(k) CH2NH-C(O)NH2, (1) CH2NH-C(O)NHCi-3alkyl, (m) CH2NH-C(O)N-diC╬╣-3 alkyl), (n) CH2NH-S(O)j-Ci-3alkyl, (o) CH2-heteroaryl, with the heteroaryl is selected from the group consisting of: (1') imidazolyl, (21) oxazolyl, (3') pyridyl, (4') tetrazolyl,
(5') triazolyl, and the heteroaryl is unsubstituted, mono, di or tri- substituted, where the substituents selected from: (a') hydrogen, (b1) Cχ-6 alkyl, branched or unbranched, unsubstituted or mono or di-substituted, the substituents being selected from hydrogen and hydroxy; and pharmaceutically acceptable salts thereof.
2. The compound of Claim 1 wherein:
Rl bears at least one substituent which is selected from:
(a) -NR6CO-R7, wherein R6 is Cl-3 alkyl, unsubstituted or substituted with cyclohexyl, and R7 is Cl-6 alkyl, benzyl or phenyl which is unsubsituted or substituted with halo, CF3, Cl-3alkyl, or Ci-3alkoxy, and
(b) -NR6S(O)j-R7, where j is 1 or 2.
3. The compound of Claim 1 wherein: R1 bears at least one substituent which is:
-NR6S(O)j-R7, wherein R6 is Cl-3 alkyl, unsubstituted or substituted with cyclohexyl, and R7 is Cl-6 alkyl, benzyl or phenyl which is unsubsituted or substituted with halo, CF3, Ci-3alkyl, or Ci-3alkoxy, and where j is 1 or 2.
4. The compound of Claim 1 wherein: R! is selected from the group consisting of: C4, C5, or C6 linear alkyl, which is substituted, where the substituents are independently selected from:
(a) phenyl,
(b) mono, di or tri-substituted phenyl, where the substituents are independently selected from: (l1) hydroxy,
(2') methyl or ethyl, (3') Cl or F, and (4') trifluoromethyl,
(c) Cl-6 alkyl, unsubstituted or substituted with hydroxy, (d) -NR6CO-R7, wherein R6 is methyl, unsubstituted or substituted with cyclohexyl, and R7 is phenyl which is unsubstituted or substituted with Cl, F, CF3, Ci- 3alkyl or Cl-3alkoxy, and (e) -NR6S(O)j-R7, where j is 1 or 2.
5. The compound of Claim 1 wherein:
R1 is C4 linear alkyl, which is substituted, where the substituents are independently selected from: (a) phenyl, (b) mono, di or tri-substituted phenyl, where the substituents are independently selected from:
(l1) hydroxy,
(2') methyl or ethyl,
(3') Cl or F, and (4') trifluoromethyl,
(O Cl-6 alkyl, unsubstituted or substituted with hydroxy, and
(d) -NR6S(O)j-R7, where R6 is methyl, unsubstituted or substituted with cyclohexyl, and R7 is phenyl which is unsubstituted or substituted with Cl, F, CF3, Ci- 3alkyl or Ci-3alkoxy, and j is 1 or 2.
6. The compound of Claim 1 wherein: ! is selected from the group consisting of:
Figure imgf000189_0001
Figure imgf000189_0002
7. The compound of Claim 1 wherein: R1 is selected from the group consisting of:
Figure imgf000189_0003
Figure imgf000190_0001
8. The compound of Claim 1 wherein: R2 is selected from the group consisting of: (1) hydrogen,
(2) hydroxy, and
(3) phenyl.
9. The compound of Claim 1 wherein: R2 is hydrogen.
10. The compound of Claim 1 wherein: R3 is selected from:
(1) Ar,
(2) -N(R )-CO-0-(Cl-6 alkyl)-Ar, wherein R is selected from hydrogen, Cl-10 linear or branched alkyl, and C╬╕-6 alkyl substituted with C3-8 cycloalkyl.
11. The compound of Claim 1 wherein: R3 is -N(R4)-CO-O-(Ci-6 alkyl)-Ar, wherein R is selected from hydrogen, Ci-io linear or branched alkyl, and C╬╕-6 alkyl substituted with C3-8 cycloalkyl.
12. The compound of Claim 1 wherein: R3 is selected from:
(1) phenyl, and
(2) -N(R4)-CO-O-(C I-6 alkyD-phenyl, wherein R4 is selected from hydrogen, Cl-10 linear or branched alkyl, and C╬╕-6 alkyl substituted with C3-8 cycloalkyl.
13. The compound of Claim 1 wherein:
R3 is:
-N(R4)-CO-O-(CH2)-phenyl, wherein R4 is selected from hydrogen, Cl-6 linear or branched alkyl, and CH2 substituted with C3-8 cycloalkyl.
14. The compound of Claim 1 wherein:
-N(R4)-CO-O-(CH2)-phenyl, wherein R4 is selected from hydrogen and Cl-6 alkyl.
15. A compound which is selected from the group consisting of:
Figure imgf000191_0001
Figure imgf000191_0002
Figure imgf000192_0001
Figure imgf000192_0002
Figure imgf000193_0001
Figure imgf000193_0002
Figure imgf000193_0003
Figure imgf000193_0004
-191-
Figure imgf000194_0001
Figure imgf000194_0002
Figure imgf000195_0001
Figure imgf000195_0002
Figure imgf000195_0003
Figure imgf000195_0004
Figure imgf000196_0001
Figure imgf000196_0002
Figure imgf000196_0003
Figure imgf000196_0004
Figure imgf000197_0001
Figure imgf000197_0002
Figure imgf000197_0003
-195
Figure imgf000198_0001
Figure imgf000198_0002
Figure imgf000198_0003
Figure imgf000199_0001
Figure imgf000199_0002
Figure imgf000199_0003
Figure imgf000199_0004
Figure imgf000200_0001
Figure imgf000200_0002
Figure imgf000201_0001
Figure imgf000201_0002
Figure imgf000201_0003
Figure imgf000202_0001
Figure imgf000202_0002
Figure imgf000202_0003
Figure imgf000203_0001
Figure imgf000203_0002
Figure imgf000203_0003
Figure imgf000204_0001
Figure imgf000204_0002
Figure imgf000204_0003
Figure imgf000205_0001
Figure imgf000205_0002
Figure imgf000205_0003
Figure imgf000205_0004
Figure imgf000206_0001
Figure imgf000206_0002
Figure imgf000206_0003
Figure imgf000207_0001
Figure imgf000207_0002
Figure imgf000207_0003
Figure imgf000208_0001
Figure imgf000208_0002
-206
Figure imgf000209_0001
Figure imgf000209_0002
Figure imgf000210_0001
Figure imgf000210_0002
-208
Figure imgf000211_0001
Figure imgf000212_0001
Figure imgf000212_0002
Figure imgf000212_0003
Figure imgf000212_0004
Figure imgf000213_0001
Figure imgf000213_0002
-211-
Figure imgf000214_0001
Figure imgf000214_0002
Figure imgf000214_0003
Figure imgf000214_0004
Figure imgf000215_0001
Figure imgf000215_0002
Figure imgf000215_0003
Figure imgf000215_0004
Figure imgf000216_0001
Figure imgf000216_0002
Figure imgf000216_0003
Figure imgf000216_0004
-214-
Figure imgf000217_0001
Figure imgf000217_0002
Figure imgf000217_0003
Figure imgf000218_0001
Figure imgf000218_0002
Figure imgf000218_0003
Figure imgf000218_0004
Figure imgf000219_0001
Figure imgf000219_0002
Figure imgf000219_0003
Figure imgf000220_0001
Figure imgf000220_0002
Figure imgf000220_0003
Figure imgf000220_0004
Figure imgf000221_0001
Figure imgf000221_0002
Figure imgf000221_0003
Figure imgf000222_0001
Figure imgf000222_0002
Figure imgf000222_0003
220
Figure imgf000223_0001
Figure imgf000223_0002
Figure imgf000224_0001
Figure imgf000224_0002
Figure imgf000224_0003
222-
Figure imgf000225_0001
Figure imgf000225_0002
Figure imgf000225_0003
Figure imgf000226_0001
Figure imgf000226_0002
Figure imgf000226_0003
Figure imgf000227_0001
Figure imgf000227_0002
Figure imgf000227_0003
Figure imgf000227_0004
Figure imgf000228_0001
Figure imgf000228_0002
Figure imgf000228_0003
Figure imgf000229_0001
Figure imgf000229_0002
Figure imgf000229_0003
Figure imgf000229_0004
Figure imgf000230_0001
Figure imgf000230_0002
Figure imgf000230_0003
Figure imgf000231_0001
Figure imgf000231_0002
Figure imgf000231_0003
Figure imgf000231_0004
Figure imgf000232_0001
Figure imgf000232_0002
Figure imgf000232_0003
Figure imgf000233_0001
Figure imgf000233_0002
Figure imgf000233_0003
Figure imgf000234_0001
Figure imgf000234_0002
Figure imgf000234_0003
232-
Figure imgf000235_0001
Figure imgf000235_0002
Figure imgf000235_0003
Figure imgf000235_0004
Figure imgf000236_0001
Figure imgf000236_0002
Figure imgf000236_0003
Figure imgf000236_0004
Figure imgf000237_0001
Figure imgf000237_0002
Figure imgf000237_0003
Figure imgf000237_0004
Figure imgf000238_0001
Figure imgf000239_0001
Figure imgf000240_0001
Figure imgf000241_0001
Figure imgf000242_0001
Figure imgf000242_0002
Figure imgf000242_0003
Figure imgf000243_0001
Figure imgf000243_0002
Figure imgf000243_0003
Figure imgf000243_0004
cn
Figure imgf000244_0001
Figure imgf000245_0001
Figure imgf000245_0002
Figure imgf000245_0003
Figure imgf000245_0004
cn
Figure imgf000246_0001
Figure imgf000247_0001
Figure imgf000247_0002
Figure imgf000248_0001
cn
Figure imgf000249_0001
Figure imgf000250_0001
PhCH
Figure imgf000250_0002
Figure imgf000250_0003
Figure imgf000250_0004
Figure imgf000250_0005
Figure imgf000251_0001
Figure imgf000252_0001
Figure imgf000252_0002
Figure imgf000252_0003
Figure imgf000253_0001
Figure imgf000254_0001
Figure imgf000255_0001
Figure imgf000255_0002
Figure imgf000256_0001
< ^
Figure imgf000256_0002
r^
Figure imgf000257_0001
Figure imgf000257_0002
^
Figure imgf000258_0001
Figure imgf000258_0002
Figure imgf000259_0001
Figure imgf000259_0002
Figure imgf000259_0003
Figure imgf000260_0001
Figure imgf000260_0002
and pharmaceutically acceptable salts thereof.
16. A compound which is selected from the group consisting of:
(R,S)-N-[2-Phenyl-4-(4-phenylpiperidin- 1-yl )but- 1-yl] -N-methylbenzene- sulfonamide;
(R,S)-N-[2-Phenyl-4-(4-benzylpiperidin-l-yl)but-l-yl]-N-methylbenzene- sulfonamide;
(R,S)-N-[2-Phenyl-4-(4-dimethylaminocarbonyl-4-phenylpiperidin-l- yl)but- 1 -yl] -N-methylbenzenesulfonamide ;
(R,S)-N-[2-Phenyl-4-(4-aminocarbonyl-4-phenylpiperidin-l-yl)but-l-yl]- N-methylbenzenesulfonamide;
(R,S)-N-[2-Phenyl-4-(4-hydroxymethyl-4-phenylpiperidin-l-yl)but-l-yl]- N-methylbenzenesulfonamide;
(R,S)-N-[2-Phenyl-4-(4-methoxycarbonyl-4-phenylpiperidin-l-yl)but-l- yl] -N-methylbenzenesulfonamide;
(R,S)-N-[2-Phenyl-4-(piperidin-l-yl)but- 1-yl] -N-methylbenzenesulfonamide;
(R,S)-N-[2-Phenyl-4-(4-pentylaminocarbonylpiperidin-l-yl)but-l-yl]-N- methylbenzenesulfonamide;
(R,S)-N-[2-Phenyl-4-(4-isopropylaminocarbonylpiperidin-l-yl)but-l-yl]- N-methylbenzenesulfonamide;
(R,S)-N-[2-Phenyl-4-(4-methylaminocarbonylmethylene-4-phenyl- piperidin-l-yl)but-l-yl]-N-methylbenzenesulfonamide;
(R,S)-N-[2-Phenyl-4-(4-methylaminocarbonyl(methylamino)methylene-4- phenylpiperidin-l-yl)but-l-yl]-N-methylbenzenesulfonamide; (R,S)-N-[2-Phenyl-4-(4-methoxycarbonylaminomethylene-4- phenylpiperidin-l-yl)but-l-yl]-N-methylbenzenesulfonamide;
(R,S)-N- [2-Phenyl-4-(4-methylaminocarbonylaminomethylene-4- phenylpiperi din- l-yl)but- 1-yl] -N-methylbenzenesulfonamide ;
(R,S)-N-[2-Phenyl-4-(4-(2-methyl)phenylpiperidin-l-yl)but-l-yl]-N- methylbenzenesulfonamide;
(R,S)-N-[2-Phenyl-4-(4-morpholinocarbonylpiperidin-l-yl)but-l-yl]-N- methylbenzenesulfonamide;
(R,S)-N-[2-(2-Chlorophenyl)-4-(4-phenylpiperidin-l-yl)but-l-yl]-N- methylbenzenesulfonamide;
(R,S)-N-[2-(2-Thienyl)-4-(4-phenylpiperidin-l-yl)but-l-yl]-N- methylbenzenesulfonamide;
(R,S)-N-[2-(3-Thienyl)-4-(4-phenylpiperidin-l-yl)but-l-yl]-N- methylbenzenesulfonamide;
(R,S)-N-[2-(3-Thienyl)-4-(4-benzylpiperidin-l-yl)but-l-yl]-N-methyl- benzenesulfonamide;
(R,S)-N-[2-Cyclohexyl-4-(4-phenylpiperidin-l-yl)but- 1-yl] -N-methylbenzenesulfonamide;
(R,S)-N-[2-(3,5-Dichlorophenyl)-4-(4-phenylpiperidin-l-yl)but-l-yl]-N- methylbenzenesulfonamide;
(R,S)-N-[2-(3-Methylphenyl)-4-(4-phenylpiperidin-l-yl)but-l-yl]-N-methyl- benzenesulfonamide; (R,S)-N-[2-(3-Ethylphenyl)-4-(4-phenylpiperidin-l-yl)but-l-yl]-N-methyl- benzenesulfonamide;
(R,S)-N-[2-(3-Carboethoxyphenyl)-4-(4-phenylpiperidin-l-yl)but-l-yl]-N- methylbenzenesulfonamide;
(R,S)-N-[2-(3-Fluorophenyl)-4-(4-phenylpiperidin-l-yl)but-l-yl]-N- methylbenzenesulfonamide;
(R,S)-N-[2-(3-Methoxyphenyl)-4-(4-phenylpiperidin-l-yl)but-l-yl]-N- methylbenzenesulfonamide;
(R,S)-N- [2-(3 ,4-Difluorophenyl)-4-(4-phenylpiperidin- l-yl)but- 1-yl] -N- methylbenzenesulfonamide;
(R,S)-N-[2-(3-Biphenyl)-4-(4-phenylpiperidin-l-yl)but-l-yl]-N- methylbenzenesulfonamide;
(R,S)-N- [2-(3-Pyridyl)-4-(4-phenylpiperidin- 1 -yl)but- 1 -yl] -N- methylbenzenesulfonamide;
(R,S)-N-[2-(Naphthalen-2-yl)-4-(4-phenylpiperidin-l-yl)b ut-l-yl]-N- methylbenzenesulfonamide;
(R,S)-N-[2-(4-Methylphenyl)-4-(4-phenylpiperidin-l-yl)but-l-yl]-N- methylbenzenesulfonamide;
(R,S)-N-[2-(2-Pyridyl)-4-(4-phenylpiperidin-l-yl)but-l-yl]-N- methylbenzenesulfonamide;
(R,S)-N-[2-(3-Fluoro-4-methylphenyl)-4-(4-phenylpiperidin-l-yl)but-l- yl] -N-methylbenzenesulfonamide;
(R,S)-N-[2-(3,4-Dimethylphenyl)-4-(4-phenylpiperidin-l-yl)but-l-yl]- N-methylbenzenesulfonamide; (R,S)-N-[2-(3,5-Dimethylphenyl)-4-(4-phenylpiperidin-l-yl)but-l-yl]- N-methylbenzenesulfonamide;
(R,S)-N-[2-(4-Methoxyphenyl)-4-(4-phenylpiperidin-l-yl)but-l-yl]-N- methylbenzenesulfonamide;
(R,S)-N-[2-(3-Trifluoromethylphenyl)-4-(4-phenylpiperidin-l-yl)but-l- yl] -N-methylbenzenesulfonamide;
(R,S)-N-[2-(3-Methyl-4-fluorophenyl)-4-(4-phenylpiperidin-l-yl)but-l- yl] -N-methylbenzenesulfonamide;
(S)-N-[2-(3-Chlorophenyl)-4-(4-phenylpiperidin-l-yl)but-l-yl]-N- methylbenzenesulfonamide;
(S)-N-[4-(4-Benzylpiperidin-l-yl)-2-(3-chlorophenyl)but-l-yl]-N- methylbenzenesulfonamide;
(S)-N-[4-(4-(3-Phenylprop-l-yl)piperidin-l-yl)-2-(3-chlorophenyl)but- l-yl]-N-methylbenzenesulfonamide;
(S)-N-[2-(3-Chlorophenyl)-4-(4-t-butylpiperidin-l-yl)but-l-yl]-N- methylbenzenesulfonamide;
(S)-N-[2-(3-Chlorophenyl)-4-(4-(cis-octahydro-2H-benzimidazol-2-on-l- yl)piperidin-l-yl)but-l-yl]-N-methylbenzenesulfonamide;
(S)-N-[2-(3-Chlorophenyl)-4-(4-(l,2,3,4-tetrahydro-2H-quinazolin-2-on-l- yl)piperidin-l-yl)but-l-yl]-N-methylbenzenesulfonamide;
(S)-N-[2-(3-Chlorophenyl)-4-(3-phenylpiperidin-l-yl)but-l-yl]-N- methylbenzenesulfonamide;
(S)-N-[2-(3-Chlorophenyl)-4-(4-hydroxy-4-phenylpiperidin-l-yl)but-l-yl]- N-methylbenzenesulfonamide;
(S)-N-[2-(3-Chlorophenyl)-4-(4-(2,3-dihydro-2H-benzimidazol-2-on-l- yl)piperidin-l-yl)but-l-yl]-N-methylbenzenesulfonamide;
(S)-N-[2-(3-Chlorophenyl)-4-[4,4-diphenylpiperidin-l-yl]-butyl}-N- methylbenzenesulfonamide;
(S)-N-[4-[4-(4-Chlorophenyl)-4-hydroxypiperidin-l-yl]-2-(3-chlorophenyl)- but-l-yl]-N-methylbenzenesulfonamide;
(S)-N-[4-(4-Acetyl-4-phenylpiperidin-l-yl)-2-(3-chlorophenyl)but-l-yl]-N- methylbenzenesulfonamide;
(S)-N-[4-[4-(4-Chloro-3-trifluoromethylphenyl)-4-hydroxypiperidin-l-yl]-2- (3-chlorophenyl)but-l-yl] -N-methylbenzenesulfonamide;
(S)-N-[2-(3-Chlorophenyl)-4-[4-(2-methoxycarbonylphenyl)piperidin-l-yl]- but-l-yl]-N-methylbenzenesulfonamide;
(S)-N-[2-(3-Chlorophenyl)-4-[4-hydroxy-4-(3-trifluoromethyl)phenyl-piper- idin-l-yl]-but-l-yl]-N-methylbenzenesulfonamide;
(S)-N-[2-(3-Chlorophenyl)-4-[4-(4-fluorophenyl)-4-hydroxypiperidin-l- yl] but- 1-yl] -N-methylbenzenesulfonamide;
(S)-N- [2-(3-Chlorophenyl)-4- [4-(2-oxo-4H-benzo [d] [ 1 ,3] oxazin- l-yl)piper- idin- 1-yl] but- 1-yl] -N-methylbenzenesulfonamide;
(S)-N- [2-(3-Chlorophenyl)-4- [4-(2-oxo-3H-benzo [d] [ 1 ,4] oxazin- l-yl)piper- idin- 1-yl] but- 1-yl] -N-methylbenzenesulfonamide ;
(S)-N-[4-(4-Benzoylpiperidin-l-yl)-2-(3-chlorophenyl)but-l-yl]-N- methylbenzenesulfonamide; (S)-N-[2-(3-Chlorophenyl)-4-[4-(2-methoxy)phenylpiperidin-l-yl]but-l- yl] -N-methylbenzenesulfonamide;
(S)-N-[2-(3-Chlorophenyl)-4-(4-piperidin-l-ylpiperidin-l-yl)but-l-yl]-N- methylbenzenesulfonamide;
(S)-N-[2-(3,4-Methylenedioxyphenyl)-4-(4-phenylpiperidin-l-yl)but-l- yl] -N-methylbenzenesulfonamide;
(S)-N-[2-(4-Fluorophenyl)-4-(4-phenylpiperidin-l-yl)but-l-yl]-N- methylbenzenesulfonamide;
(S)-N-[2-(3,4-Dichlorophenyl)-4-(4-phenylpiperidin-l-yl)-but-l-yl]-N- ethylbenzenesulfonamide;
(R,S)-N-[2-Phenyl-4-(4-phenylpiperidin-l-yl)but-l-yl]-N-methylphenyl- acetamide;
(R,S)-N-[2-Phenyl-4-[4-acetyl(ethylamino)piperidin-l-yl]but-l-yl]-N- methylbenzenesulfonamide;
(R,S)-N- [2-Phenyl-4- [4-(oxazolidin-2-on-3-yl)piperidin- 1-yl] but- 1-yl] -N- methylbenzenesulfonamide;
(R,S)-N-[2-Phenyl-4-(4-methoxycarbonyl(ethylamino)piperidin-l-yl)but-l- yl] -N-methylbenzenesulfonamide;
(R,S)-N-[2-Phenyl-4-(4-dimethylaminocarbonylaminopiperidin-l-yl)but-l- yl] -N-methylbenzenesulfonamide;
(R,S)-N-[2-Phenyl-4-(4-benzyloxycarbonyl(prop-l-ylamino)piperidin-l- yl)but- 1-yl] -N-methylbenzenesulfonamide;
(R,S)-N-[2-Phenyl-4-(4-methoxycarbonylaminopiperidin-l-yl)but-l-yl]- N-methylbenzenesulfonamide; (R,S)-N-[2-Phenyl-4-(4-aminocarbonylaminopiperidin-l-yl)but-l-yl]-N- methylbenzenesulfonamide;
(R,S)-N-[2-Phenyl-4-(4-aminopiperidin- 1-yl )but- 1-yl] -N-methylbenzenesulfonamide;
(R,S)-N-[2-Phenyl-4-(4-acetylaminopiperidin-l-yl)but-l-yl]-N- methylbenzenesulfonamide;
(R,S)-N-[2-Phenyl-4-(4-isoρropylcarbonylaminopiperidin-l-yl)but-l- yl] -N-methylbenzenesulfonamide;
(R,S)-N-[2-Phenyl-4-(4-methylsulfonylaminopiperidin-l-yl)but-l-yl]-N- methylbenzenesulfonamide;
(R,S)-N-[2-Phenyl-4-(4-isopropylcarbonyl(ethylamino)piperidin-l- yl)but-l-yl]-N-methylbenzenesulfonamide;
(R,S)-N-[2-Phenyl-4-(4-methylsulfonyl(ethylamino)piperidin-l-yl)but- l-yl]-N-methylbenzenesulfonamide;
(R,S)-N-[2-Phenyl-4-(4-t-butoxycarbonylaminopiperidin-l-yl)but-l-yl]- N-methylbenzenesulfonamide;
(R,S)-N-[2-Phenyl-4-(4-methoxycarbonyl(methylamino)piperidin-l-yl)but- l-yl]-N-methylbenzenesulfonamide;
(R,S)-N-[2-Phenyl-4-(4-(pyrrolidin-2-on-l-yl)piperidin-l-yl)but-l-yl]-N- methylbenzenesulfonamide;
(R,S)-N-[2-Phenyl-4-(4-methoxycarbonyl(cyclobutylmethylamino)- piperidin-l-yl)but-l-yl]-N-methylbenzenesulfonamide; (R,S)-N-[2-Phenyl-4-(4-ethoxycarbonyl(ethylamino)piperidin-l-yl)but-l- yl] -N-methylbenzenesulfonamide;
(R,S)-N-[2-Phenyl-4-(4-isobutyloxycarbonyl(ethylamino)piperidin-l- yl)but-l-yl]-N-methylbenzenesulfonamide;
(R,S)-N-[2-Phenyl-4-(4-piperidin-2-on-l-ylpiperidin-l-yl)but-l-yl]-N- methylbenzenesulfonamide;
(R,S)-N-[2-Phenyl-4-(4-methoxycarbonyl(benzylamino)piperidin-l-yl)but- 1-yl] -N-methylbenzenesulfonamide;
(R,S)-N-[2-Phenyl-4-(4-methoxycarbonyl(prop-l-ylamino)piperidin-l- yl)but-l-yl]-N-methylbenzenesulfonamide;
(R,S)-N-[2-Phenyl-4-(4-methoxycarbonyl(but-l-ylamino)piperidin-l- yl)but-l-yl]-N-methylbenzenesulfonamide;
(R,S)-N-[2-Phenyl-4-(4-methoxycarbonyl(cyclohexylmethylamino)-piper- idin- 1 -yl)but- 1-yl] -N-methylbenzenesulfonamide ;
(R,S)-N-[2-Phenyl-4-(4-methoxycarbonyl(cyclopropylmethylamino)-piper- idin-l-yl)but-l-yl]-N-methylbenzenesulfonamide;
(R,S)-N-[2-Phenyl-4-(4-methoxycarbonyl(pent-l-ylamino)piperidin-l- yl)but-l-yl]-N-methylbenzenesulfonamide;
(R,S)-N-[2-Phenyl-4-(4-benzyloxycarbonyl(methylamino)piperidin-l- yl)but-l-yl]-N-methylbenzenesulfonamide;
(R,S)-N-[2-Phenyl-4-(4-benzyloxycarbonyl(ethylamino)piperidin-l-yl)but- 1-yl] -N-methylbenzenesulfonamide;
(R,S)-N-[2-Phenyl-4-(4-benzyloxycarbonyl(but-l-ylamino)piperidin-l- yl)but- 1-yl] -N-methylbenzenesulfonamide; (R,S)-N-[2-Phenyl-4-(4-benzyloxycarbonyl(pent-l-ylamino)piperidin-l- yl)but-l-yl]-N-methylbenzenesulfonamide;
(R,S)-N-[2-Phenyl-4-(4-benzyloxycarbonyl(cyclobutylmethylamino)-piper- idin-l-yl)but- 1-yl] -N-methylbenzenesulfonamide;
(R,S)-N-[2-Phenyl-4-(4-benzyloxycarbonyl(cyclohexylmethylamino)-piper- idin-l-yl)but-l-yl]-N-methylbenzenesulfonamide;
(S)-N-[2-(3-Chlorophenyl-4-(4-benzyloxycarbonyl(ethylamino)-piperidin-l- yl)but-l-yl]-N-methylbenzenesulfonamide;
(R,S)-N-[3-Phenyl-4-(4-phenylpiperidin-l-yl)but-l-yl]-N- methylbenzenesulfonamide;
(R,S)-N-Methyl-N-[2-methyl-2-phenyl-4-(4-phenylpiperidin-l-yl)but-l- yl]benzenesulfonamide;
(R,S)-N-[4-(4-Benzyloxycarbonyl(ethylamino)piperidin-l-yl)-2-methyl-2- phenylbut-1-yl] -N-methylbenzenesulfonamide; and
(R,S)-N-[4-(4-Benzyloxycarbonyl(ethylamino)piperidin-l-yl)-2-ethyl-2- phenylbut- 1-yl] -N-methylbenzenesulfonamide;
and pharmaceutically acceptable salts thereof.
17. A pharmaceutical composition which comprises an inert carrier and a compound of Claim 1.
18. A method for the modulation of chemokine receptor activity in a mammal comprising the administration of an effective amount of a compound of formula I:
Figure imgf000270_0001
I
wherein:
R1 is selected from a group consisting of: linear or branched Cl-8 alkyl, linear or branched C2-8 alkenyl, wherein the Cl-8 alkyl or C2-8 alkenyl is optionally mono, di, tri or tetra substituted, where the substituents are independently selected from:
(a) hydroxy,
(b) oxo, (c) cyano,
(d) halogen which is selected from F, Cl, Br, and I,
(e) trifluoromethyl,
(f) phenyl
(g) mono, di or tri-substituted phenyl, where the substituents are independently selected from:
(D phenyl, (2') hydroxy, (31) Ci-3alkyl,
(4') cyano, (5') halogen,
(6') trifluoromethyl,
(7') -NR╬▓COR?,
Figure imgf000270_0002
(9') -NR6CONHR7, (10') -NR6S(O)jR7, wherein j is 1 or 2,
(11') -CONR6R7. (12') -COR6, (13') -CO2R6, (14') -OR6,
(15') -S(O)kR6, wherein k is 0, 1 or 2, (h) Cl-6 alkyl, unsubstituted or substituted with hydroxy,
(i) -NR6R7,
Figure imgf000271_0001
(1) -NR6CONHR7, (m) -NR6S(O)j-R7,
(n) -CONR6R7,
(o) -COR6,
(p) -CO2R6,
(q) -OCOR6, (r) -CN,
(s) -OR6, (t) -S(O)kR6, (u) -NR6CO-heteroaryl, (v) -NR6S(O)j-heteroaryl, and (w) heteroaryl, wherein heteroaryl is selected from the group consisting of:
(1') benzimidazolyl,
(2') benzofuranyl,
(3') benzoxazolyl, (4') furanyl,
(5') imidazolyl,
(6') indolyl,
(7') isooxazolyl,
(8') isothiazolyl, (9') oxadiazolyl,
(10') oxazolyl,
(ID pyrazinyl,
(12') pyrazolyl,
(13') pyridyl, (14') pyrimidyl, (15') pyrrolyl, (16') quinolyl, (17') tetrazolyl, (18*) thiadiazolyl,
(19') thiazolyl, (20') thienyl, and (21') triazolyl, wherein the heteroaryl is unsubstituted or mono di or tri- substituted, where the substituents are independently selected from:
(a") phenyl, (b") hydroxy, (c") oxo, (d") cyano,
(e") halogen, and (f) trifluoromethyl; elected from the group consisting of: (1) hydrogen, (2) hydroxy,
(3) Ci-6 alkyl,
(4) substituted Cl-6 alkyl, where the substituents are independently selected from:
(a) phenyl, (b) hydroxy,
(c) oxo,
(d) halogen,
(e) trifluoromethyl,
(f) -N(R4)(R5), wherein R4 and R5 are independently selected from hydrogen, Cl-10 linear or branched alkyl, and C╬╕-6 alkyl substituted with C3-8 cycloalkyl,
(g) -N(R4)-CO-O-(R5), and
(h) -N(R4')-CO-N(R4)(R5). wherein R ' is selected from the definitions of R4, (5) -O-C1-6 alkyl, and (6) phenyl; R3 is selected from the group consisting of:
(1) Ar,
(2) -N(R4)-CO-O-(Ci-6 alkyl)-Ar, (3) -N(R )-CO-O-R7,
(4) -(Cl-6 alkyl)-Ar,
(5) -(Cl-6 alkyl)-O-(C╬╣_6 alkyl)-Ar, and
(6) -(Cl-6 alkyl)-O-(Cl-6 alkyl)-Ar; Ar is selected from the group consisting of: (1) phenyl,
(2) pyridyl,
(3) pyrimidyl,
(4) naphthyl,
(5) furyl, (6) pyrryl,
(7) thienyl,
(8) isothiazolyl,
(9) imidazolyl,
(10) benzimidazolyl, (11) tetrazolyl,
(12) pyrazinyl,
(13) quinolyl,
(14) isoquinolyl,
(15) benzofuryl, (16) isobenzofuryl,
(17) benzothienyl,
(18) pyrazolyl,
(19) indolyl,
(20) isoindolyl, (21) purinyl,
(22) isoxazolyl,
(23) thiazolyl,
(24) oxazolyl,
(25) triazinyl, and (26) benzthiazolyl, (27) benzoxazolyl,
(28) imidazopyrazinyl,
(29) triazolopyrazinyl,
(30) naphthyridinyl, (31) furopyridinyl,
(32) thiopyranopyrimidyl and the 5-oxide and 5-dioxide thereof,
(33) pyridazinyl,
(34) quinazolinyl,
(35) pteridinyl, (36) triazolopyrimidyl,
(37) triazolopyrazinyl,
(38) thiapurinyl,
(39) oxapurinyl, and
(40) deazapurinyl, wherein Ar items (1) to (40) are unsubstituted or mono or di-substituted, where the substituents are independently selected from:
(a) Cl-3 alkyl, unsubstituted or substituted with a substituent selected from:
(1') oxo, (2') hydroxy,
(3') -OR7,
(4') phenyl,
(5') trifluoromethyl, and
(6') phenyl or mono, di or tri-substituted phenyl, where the substituents are independently selected from: hydroxy, cyano, halogen, and trifluoromethyl,
(b) halogen,
(c) -OCl-6 alkyl, (d) trifluoromethyl,
(e) hydroxy,
( ) -N02,
(g) -(CH2)pS(O)k-(Ci-6 alkyl), wherein p is 0, 1 or 2, (h) -(CH2)pS(O)j-NH2, (i) -(CH2)pS(O)j-NH(Ci-6 alkyl), (j) -(CH2)pS(O)j-NHR6,
(k) -(CH2)pS(O)j-NR6-(Ci-6 alkyl),
(1) -(CH2)pCONH2,
(m) -(CH2)pCONH-(Ci-6 alkyl),
(n) -(CH2)pCONHR6,
(o) -(CH2)pCONR6R7,
(P) -(CH2)pCO2H,
(q) -(CH2)pC02-(C╬╣-6 alkyl),
(r) -(CH2)PNR6R7,
(s) -(CH2)pNH-C(O)-Ci-6alkyl,
(t) -(CH2)pNH-C(O)-NH2,
(u) -(CH2)pNH-C(O)-NHCi-6alkyl,
(v) -(CH2)pNH-C(O)-N(C╬╣-6 alkyl)2,
(w) -(CH2)pNH-S(O)k-C╬╣_6alkyl,
(x) -(CH2)pN(Ci-3alkyl)-C(O)-N(diC╬╣-6 alkyl),
(y) -(CH2)p-heteroaryl, -C(O)-heteroaryl or
-(CH2)p-O-heteroaryl , wherein the heteroaryl is selected from the group consisting of:
(1') benzimidazolyl,
(2') benzofuranyl,
(3') benzoxazolyl,
(4') furanyl,
(5') imidazolyl,
(6') indolyl,
(7') isooxazolyl,
(8') isothiazolyl,
(9') oxadiazolyl,
(10') oxazolyl,
(11') pyrazinyl,
(12') pyrazolyl,
(13') pyridyl or oxopyridyl,
(14') pyrimidyl,
(15') pyrrolyl,
(16') quinolyl, (17') tetrazolyl,
(18') thiadiazolyl,
(19') thiazolyl,
(20') thienyl, and
(21') triazolyl, wherein the heteroaryl group of items (1') to (21') is unsubstituted, or mono, di or tri-substituted, where the substituents are selected from:
(a') hydrogen,
(b') Cl-6 alkyl, branched or unbranched, unsubstituted or mono or di-substituted, where the substituents are selected from hydrogen and hydroxy,
(c') hydroxy,
(d') oxo,
(e1) -OR6,
(f) halogen,
(g') trifluoromethyl,
(h') nitro,
(i') cyano,
(j') -NHR6,
(k') -NR6R7,
(D -NHCOR6,
(m') -NR6COR7,
(n') -NHCO2R6,
(o') -NR6CO2R7,
(P') -NHS(O)jR6,
(q') -NR6S(O)jR7,
(r') -CONR6R7,
(s') -COR6,
(f) -CO2R6, and
(u') -S(O)jR6; elected from the group consisting of:
(1) hydrogen,
(2) Cl-6 alkyl, (3) substituted Ci-6 alkyl, where the substituents are independently selected from:
(a) phenyl,
(b) hydroxy, (c) oxo,
(d) cyano,
(e) halogen,
(f) trifluoromethyl, and
(g) C5-8 cycloalkyl, (4) phenyl,
(5) mono, di or tri-substituted phenyl, where the substituents are independently selected from:
(a) hydroxy,
(b) Ci-3alkyl, (c) cyano,
(d) halogen, and
(e) trifluoromethyl; selected from the group consisting of: (1) hydrogen, (2) Cl-6 alkyl or C5-8 cycloalkyl,
(3) substituted Cl-6 alkyl or C5-8 cycloalkyl, where the substituents are independently selected from:
(a) phenyl,
(b) mono, di or tri-substituted phenyl, where the substituent is independently selected from:
(D hydroxy,
(3') cyano,
(4') halogen,
(5') trifluoromethyl, and
(6') Ci-3alkyloxy,
(b) hydroxy,
(c) oxo,
(d) cyano, (e) halogen, and
(f) trifluoromethyl,
(4) phenyl,
(5) mono, di or tri-substituted phenyl, where the substituents are independently selected from:
(a) hydroxy,
(b) Cl-3alkyl,
(c) cyano,
(d) halogen, and (e) trifluoromethyl; or R6 and R7 may be joined together to form a 5-, 6-, or 7- membered monocyclic saturated ring containing 1 or 2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, and in which the ring is unsubstituted or mono or di-substituted, the substituents independently selected from:
(1) hydroxy,
(2) oxo,
(3) cyano, (4) halogen,
(5) trifluoromethyl, m is an integer selected from 0, 1 and 2, n is an integer selected from 0, 1 and 2, and pharmaceutically acceptable salts thereof.
19. A method for the modulation of chemokine receptor activity in a mammal comprising the administration of an effective amount of the compound of Claim 1.
20. A method for preventing infection by HIV, treating infection by HIV, delaying of the onset of AIDS, or treating AIDS comprising the administration to a patient of an effective amount of the compound of Claim 1.
PCT/US1998/014990 1997-07-25 1998-07-21 Cyclic amine modulators of chemokine receptor activity WO1999004794A1 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
CA002296314A CA2296314A1 (en) 1997-07-25 1998-07-21 Cyclic amine modulators of chemokine receptor activity
EP98936920A EP1003514A4 (en) 1997-07-25 1998-07-21 Cyclic amine modulators of chemokine receptor activity
JP50994999A JP2002510327A (en) 1997-07-25 1998-07-21 Cyclic amine chemokine receptor activity modulator
AU85760/98A AU8576098A (en) 1997-07-25 1998-07-21 Cyclic amine modulators of chemokine receptor activity

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US5375497P 1997-07-25 1997-07-25
US60/053,754 1997-07-25
GBGB9800958.2A GB9800958D0 (en) 1998-01-16 1998-01-16 Cyclic amine modulators of chemokine activity
GB9800958.2 1998-01-16

Publications (1)

Publication Number Publication Date
WO1999004794A1 true WO1999004794A1 (en) 1999-02-04

Family

ID=26312958

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1998/014990 WO1999004794A1 (en) 1997-07-25 1998-07-21 Cyclic amine modulators of chemokine receptor activity

Country Status (5)

Country Link
EP (1) EP1003514A4 (en)
JP (1) JP2002510327A (en)
AU (1) AU8576098A (en)
CA (1) CA2296314A1 (en)
WO (1) WO1999004794A1 (en)

Cited By (98)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000029377A1 (en) * 1998-11-17 2000-05-25 F. Hoffmann-La Roche Ag 4-aroyl-piperidin-ccr-3 receptor antagonists iii
EP1013276A1 (en) * 1998-12-23 2000-06-28 Pfizer Inc. Aminoazacycloalkanes as CCR5 modulators
WO2000038680A1 (en) * 1998-12-23 2000-07-06 Pfizer Limited Azabicycloalkanes as ccr5 modulators
WO2000039125A1 (en) * 1998-12-23 2000-07-06 Pfizer Limited Piperidines as ccr5 modulators
WO2000056729A1 (en) * 1999-03-24 2000-09-28 Anormed Inc. Chemokine recpetor binding heterocyclic compounds
EP1050307A1 (en) * 1999-05-06 2000-11-08 Applied Research Systems ARS Holding N.V. CCR4 antagonists in sepsis
WO2000066558A1 (en) * 1999-05-04 2000-11-09 Schering Corporation Piperazine derivatives useful as ccr5 antagonists
WO2000066559A1 (en) * 1999-05-04 2000-11-09 Schering Corporation Piperidine derivatives useful as ccr5 antagonists
WO2000076972A1 (en) * 1999-06-11 2000-12-21 Merck & Co., Inc. N-cyclopentyl modulators of chemokine receptor activity
WO2001014333A1 (en) * 1999-08-24 2001-03-01 Astrazeneca Uk Limited Substituted piperidine compounds useful as modulators of chemokine receptor activity
WO2001066525A1 (en) * 2000-03-10 2001-09-13 Astrazeneca Ab New ccr5 modulators: benzimidazoles or benzotriazoles
WO2001087839A1 (en) * 2000-05-17 2001-11-22 Astrazeneca Ab Pharmaceutically active piperidine derivatives, in particular as modulators of chemokine receptor activity
WO2001090106A2 (en) * 2000-05-26 2001-11-29 Pfizer Limited Tryasolyl tropane derivatives as ccr5 modulators
WO2001092227A1 (en) * 2000-05-31 2001-12-06 Astrazeneca Ab Chemical compounds
US6331545B1 (en) 1998-12-18 2001-12-18 Soo S. Ko Heterocycyclic piperidines as modulators of chemokine receptor activity
WO2002004420A1 (en) * 2000-07-12 2002-01-17 Novartis Ag Piperidine coumpounds for use as ccr-3 inhibitors
EP1180513A1 (en) * 1999-04-28 2002-02-20 Takeda Chemical Industries, Ltd. Cyclic amide compounds, process for the preparation of the same and uses thereof
US6358979B1 (en) 1999-06-11 2002-03-19 Merck & Co., Inc. N-cyclopentyl modulators of chemokine receptor activity
US6387930B1 (en) 1999-05-04 2002-05-14 Schering Corporation Piperidine derivatives useful as CCR5 antagonists
US6391865B1 (en) 1999-05-04 2002-05-21 Schering Corporation Piperazine derivatives useful as CCR5 antagonists
US6432981B1 (en) 1999-06-11 2002-08-13 Merck & Co., Inc. Cyclopentyl modulators of chemokine receptor activity
WO2002079186A2 (en) * 2001-03-30 2002-10-10 F. Hoffmann-La Roche Ag Aminopiperidine derivatives as modulators of chemokine receptor activity
US6472410B1 (en) 1999-06-11 2002-10-29 Merck & Co., Inc. N-cyclopentyl modulators of chemokine receptor activity
US6486180B1 (en) 1998-12-18 2002-11-26 Bristol-Myers Squibb Pharma Company N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
US6492400B1 (en) 1998-12-18 2002-12-10 Bristol-Myers Squibb Pharma Company N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
US6500844B1 (en) 1999-06-11 2002-12-31 Merck & Co., Inc. Cyclopentyl modulators of chemokine receptor activity
US6506777B1 (en) 1999-06-11 2003-01-14 Merck & Co., Inc. Cyclopentyl modulators of chemokine receptor activity
US6511826B2 (en) 1995-06-06 2003-01-28 Human Genome Sciences, Inc. Polynucleotides encoding human G-protein chemokine receptor (CCR5) HDGNR10
US6525070B2 (en) 2000-04-08 2003-02-25 Astrazeneca Ab Bipiperidine derivatives as modulators of CCR3 activity and as H1 antagonists
US6538002B1 (en) 1999-06-11 2003-03-25 Merck & Co., Inc. Cyclopentyl modulators of chemokine receptor activity
US6562978B1 (en) 1999-10-01 2003-05-13 Takeda Chemical Industries, Ltd. Cyclic amine compounds as CCR5 antagonists
WO2003077907A1 (en) * 2002-03-15 2003-09-25 Novartis Ag Azetidine derivatives as ccr-3 receptor antagonists
US6627629B2 (en) 2000-06-30 2003-09-30 Bristol-Myers Squibb Pharma N-ureidoheterocycloalkyl-piperidines as modulators of chemokine receptor activity
US6656953B2 (en) 2000-12-06 2003-12-02 Sepracor Inc. 4,4-Disubstituted piperidines, and methods of use thereof
US6667314B2 (en) 2000-05-26 2003-12-23 Pfizer, Inc. Tropane derivatives useful in therapy
US6689765B2 (en) 1999-05-04 2004-02-10 Schering Corporation Piperazine derivatives useful as CCR5 antagonists
US6720325B2 (en) 2001-03-29 2004-04-13 Schering Corporation CCR5 antagonists useful for treating aids
US6743594B1 (en) 1995-06-06 2004-06-01 Human Genome Sciences, Inc. Methods of screening using human G-protein chemokine receptor HDGNR10 (CCR5)
US6750348B1 (en) 1999-03-24 2004-06-15 Anormed, Inc. Chemokine receptor binding heterocyclic compounds
WO2004054974A2 (en) * 2002-12-13 2004-07-01 Smithkline Beecham Corporation Piperidine derivatives as ccr5 antagonists
US6787650B1 (en) 1999-10-05 2004-09-07 Takeda Chemical Industries, Ltd. Urea compounds, process for producing the same and use thereof
US6919356B2 (en) 2002-09-26 2005-07-19 Bristol Myers Squibb Company N-substituted heterocyclic amines as modulators of chemokine receptor activity
WO2005073192A1 (en) * 2004-02-02 2005-08-11 Astrazeneca Ab Novel piperidines as chemokine modulators (ccr)
US6949643B2 (en) 2001-04-12 2005-09-27 Astrazeneca Ab Thiazolopytimidines and their use as modulators of chemokine receptor activity
US6958343B2 (en) 2000-02-11 2005-10-25 Astrazeneca, Ab Thiazolopyrimidines and their use as modulators of chemokine receptor activity
US6958350B2 (en) 2001-02-19 2005-10-25 Astrazeneca Ab Chemical compounds
US6958344B2 (en) 2000-02-11 2005-10-25 Astrazeneca Ab Pyrimidine compounds and their use as modulators of chemokine receptor activity
US6960602B2 (en) 2001-03-22 2005-11-01 Astrazeneca Ab Piperidine derivatives as modulators of chemokine receptors
US6974869B2 (en) 2001-09-18 2005-12-13 Bristol-Myers Squibb Pharma Company Piperizinones as modulators of chemokine receptor activity
US6992091B2 (en) 2002-09-12 2006-01-31 Bristol-Myers Squibb Company N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
US7071193B2 (en) 2000-10-20 2006-07-04 Astrazeneca Ab 7-amino-2-alkylthiopteridin-4-yl-amines for the treatment of chemokine-related diseases
US7144903B2 (en) 2001-05-23 2006-12-05 Amgen Inc. CCR4 antagonists
WO2006129679A1 (en) 2005-05-31 2006-12-07 Ono Pharmaceutical Co., Ltd. Spiropiperidine compound and medicinal use thereof
US7186718B2 (en) 2001-08-22 2007-03-06 Astrazeneca Ab Piperidinyl-morpholinyl derivatives as modulators of chemokine receptor activity
US7192973B2 (en) 2001-11-15 2007-03-20 Astrazeneca Ab Piperidine derivatives and their use as modulators of chemokine receptor activity (especially CCR5)
WO2007049771A1 (en) 2005-10-28 2007-05-03 Ono Pharmaceutical Co., Ltd. Compound containing basic group and use thereof
WO2007058322A1 (en) 2005-11-18 2007-05-24 Ono Pharmaceutical Co., Ltd. Basic group-containing compound and use thereof
US7238691B2 (en) 2001-09-18 2007-07-03 Astrazeneca Ab Piperidine derivatives and their use as modulators of chemokine (especially CCR3) activity
US7262204B2 (en) 2000-10-11 2007-08-28 Amgen Inc. Modulation of CCR4 function
US7265227B2 (en) 2001-07-23 2007-09-04 Astrazeneca Ab Piperidine derivatives useful as modulators of chemokine receptor activity
WO2007105637A1 (en) 2006-03-10 2007-09-20 Ono Pharmaceutical Co., Ltd. Nitrogenated heterocyclic derivative, and pharmaceutical agent comprising the derivative as active ingredient
CN100343240C (en) * 2002-03-29 2007-10-17 先灵公司 Stereoselective alkylation of chiral 2-methyl-4-protected piperazines
US7294636B2 (en) 2003-05-09 2007-11-13 Astrazeneca Ab Chemical compounds
WO2007132846A1 (en) 2006-05-16 2007-11-22 Ono Pharmaceutical Co., Ltd. Compound having acidic group which may be protected, and use thereof
US7304077B2 (en) 2000-09-04 2007-12-04 Astrazeneca Ab Chemical compounds
US7307090B2 (en) 2001-07-02 2007-12-11 Astrazeneca Ab Piperidine derivatives useful as modulators of chemokine receptor activity
WO2008016006A1 (en) 2006-07-31 2008-02-07 Ono Pharmaceutical Co., Ltd. Compound having cyclic group bound thereto through spiro binding and use thereof
US7482363B2 (en) 2002-03-19 2009-01-27 Astrazeneca Ab Piperidine derivatives useful as modulators of chemokine receptor activity
US7485732B2 (en) 2003-06-11 2009-02-03 Merck & Co., Inc. Substituted 3-alkyl and 3-alkenyl azetidine derivatives
US7495013B2 (en) 2003-04-01 2009-02-24 Astrazeneca Ab Chemical compounds
US7517989B2 (en) 2002-03-19 2009-04-14 Astrazeneca Ab Piperidine derivatives useful as modulators of chemokine receptor activity
US7579342B2 (en) 2000-02-23 2009-08-25 Astrazeneca Pteridine compounds for the treatment of psoriasis
US7585867B2 (en) 2002-09-20 2009-09-08 Astrazeneca Ab Substituted thiazolo[4,5-d]pyrimidin-2(3H)-one
US7615555B2 (en) 2004-04-23 2009-11-10 Astrazeneca Ab Piperidine derivatives as modulators of chemokine receptor CCR5
US7709500B2 (en) 2002-02-18 2010-05-04 Astrazeneca Ab Chemical compounds
US7790883B2 (en) 2003-12-05 2010-09-07 Astrazeneca Ab Process for the preparation of thiazolopyrimidines
WO2011011652A1 (en) 2009-07-24 2011-01-27 Glaxosmithkline Llc Therapeutic compounds
US7906652B2 (en) 2005-11-28 2011-03-15 Merck Sharp & Dohme Corp. Heterocycle-substituted 3-alkyl azetidine derivatives
EP2364982A1 (en) 2003-04-18 2011-09-14 ONO Pharmaceutical Co., Ltd. Spiro-piperidine compounds as chemokine receptor antagonists and medicinal use thereof
EP2385040A1 (en) 2003-03-14 2011-11-09 ONO Pharmaceutical Co., Ltd. Nitrogen-containing heterocyclic derivatives and drugs containing the same as the active ingredient
US8143261B2 (en) 1999-10-01 2012-03-27 Astrazeneca Ab Thiazolo (4,5-D) pyrimidine compounds
US8314127B2 (en) 2005-07-21 2012-11-20 Astrazeneca Ab Piperidine derivatives
EP2546234A1 (en) 2004-09-13 2013-01-16 Ono Pharmaceutical Co., Ltd. Nitrogeneous heterocyclic derivative and medicine containing the same as an active ingredient
WO2013024022A1 (en) 2011-08-12 2013-02-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for treatment of pulmonary hypertension
US8778967B2 (en) 2001-12-21 2014-07-15 Genzyme Corporation Chemokine receptor binding heterocyclic compounds with enhanced efficacy
US9206186B2 (en) 2003-03-24 2015-12-08 Axikin Pharmaceuticals, Inc. 2-phenoxy- and 2-phenylsulfonamide derivatives with CCR3 antagonistic activity for the treatment of inflammatory or immunological disorders
US10117931B2 (en) 2009-04-28 2018-11-06 Kameran Lashkari Methods for treatment of age-related macular degeneration
CN110483490A (en) * 2019-08-29 2019-11-22 苏州汉德创宏生化科技有限公司 A kind of synthetic method of 3- (piperidin-4-yl) oxazolidine -2- ketone and its salt
US10548889B1 (en) 2018-08-31 2020-02-04 X4 Pharmaceuticals, Inc. Compositions of CXCR4 inhibitors and methods of preparation and use
US10610527B2 (en) 2015-12-22 2020-04-07 X4 Pharmaceuticals, Inc. Methods for treating immunodeficiency disease
US10633336B2 (en) 2014-12-19 2020-04-28 The Broad Institute, Inc. Dopamine D2 receptor ligands
US10752588B2 (en) 2014-12-19 2020-08-25 The Broad Institute, Inc. Dopamine D2 receptor ligands
US10759796B2 (en) 2016-06-21 2020-09-01 X4 Pharmaceuticals, Inc. CXCR4 inhibitors and uses thereof
US10953003B2 (en) 2015-12-14 2021-03-23 X4 Pharmaceuticals, Inc. Methods for treating cancer
US10988465B2 (en) 2016-06-21 2021-04-27 X4 Pharmaceuticals, Inc. CXCR4 inhibitors and uses thereof
US11332470B2 (en) 2016-06-21 2022-05-17 X4 Pharmaceuticals, Inc. CXCR4 inhibitors and uses thereof
US11337969B2 (en) 2016-04-08 2022-05-24 X4 Pharmaceuticals, Inc. Methods for treating cancer
US11357742B2 (en) 2015-12-14 2022-06-14 X4 Pharmaceuticals, Inc. Methods for treating cancer

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1558250A4 (en) * 2002-10-30 2006-11-02 Merck & Co Inc Gamma-aminoamide modulators of chemokine receptor activity
CA2534550A1 (en) * 2003-09-15 2005-03-24 Novartis Ag 1, 3-disubstituted azetidine derivatives for use as ccr-3 receptor antagonists in the treatment of inflammatory and allergic diseases
WO2006138350A2 (en) * 2005-06-15 2006-12-28 Anormed Inc. Chemokine receptor binding compounds

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5434158A (en) * 1994-04-26 1995-07-18 Merck & Co., Inc. Spiro-substituted azacycles as neurokinin-3 antagonists
WO1996024582A1 (en) * 1995-02-10 1996-08-15 Zeneca Limited 5-(4-subst.-piperidinyl-1)-3-aryl-pentanoic acid derivatives as tachykinin receptor antagonist
US5576333A (en) * 1992-11-03 1996-11-19 Zeneca Limited Carboxamide derivatives
US5789422A (en) * 1996-10-28 1998-08-04 Schering Corporation Substituted arylalkylamines as neurokinin antagonists

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9100505D0 (en) * 1991-01-10 1991-02-20 Shell Int Research Piperidine derivatives
GB9310713D0 (en) * 1993-05-24 1993-07-07 Zeneca Ltd Aryl substituted heterocycles
FR2719311B1 (en) * 1994-03-18 1998-06-26 Sanofi Sa Compounds that are selective antagonists of the human NK3 receptor and their use as drugs and diagnostic tools.
EP0883613A1 (en) * 1996-02-09 1998-12-16 Smithkline Beecham Plc Sulfonamide derivatives as 5ht7 receptor antagonists
IL125658A0 (en) * 1997-08-18 1999-04-11 Hoffmann La Roche Ccr-3 receptor antagonists

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5576333A (en) * 1992-11-03 1996-11-19 Zeneca Limited Carboxamide derivatives
US5434158A (en) * 1994-04-26 1995-07-18 Merck & Co., Inc. Spiro-substituted azacycles as neurokinin-3 antagonists
WO1996024582A1 (en) * 1995-02-10 1996-08-15 Zeneca Limited 5-(4-subst.-piperidinyl-1)-3-aryl-pentanoic acid derivatives as tachykinin receptor antagonist
US5789422A (en) * 1996-10-28 1998-08-04 Schering Corporation Substituted arylalkylamines as neurokinin antagonists

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
Chemical Abstracts Service (C A S); 1 January 1900 (1900-01-01), XP002912835, Database accession no. 127-5325 *
Chemical Abstracts Service (C A S); 1 January 1900 (1900-01-01), XP002912836, Database accession no. 111-146934 *
CHEMICAL ABSTRACTS, 1 January 1900, Columbus, Ohio, US; abstract no. 108-68302, XP002912830 *
CHEMICAL ABSTRACTS, 1 January 1900, Columbus, Ohio, US; abstract no. 115-182801, XP002912833 *
CHEMICAL ABSTRACTS, 1 January 1900, Columbus, Ohio, US; abstract no. 117-191696, XP002912831 *
CHEMICAL ABSTRACTS, 1 January 1900, Columbus, Ohio, US; abstract no. 122-205210, XP002912832 *
HIRSCHMANN R: "PEPTIDE RELATED RESEARCH AS A VEHICLE TOWARDS CHEMICAL AND BIOLOGICAL UNDERSTANDING", BOOKS OF ABSTRACTS. DIVISION OF MEDICINAL CHEMISTRY, XX, XX, 13 April 1997 (1997-04-13), XX, pages COMPLETE, XP002912834 *
See also references of EP1003514A4 *

Cited By (169)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6743594B1 (en) 1995-06-06 2004-06-01 Human Genome Sciences, Inc. Methods of screening using human G-protein chemokine receptor HDGNR10 (CCR5)
US6511826B2 (en) 1995-06-06 2003-01-28 Human Genome Sciences, Inc. Polynucleotides encoding human G-protein chemokine receptor (CCR5) HDGNR10
US6759519B2 (en) 1995-06-06 2004-07-06 Human Genome Sciences, Inc. Antibodies to human G-protein chemokine receptor HDGNR10 (CCR5receptor)
US6800729B2 (en) 1995-06-06 2004-10-05 Human Genome Sciences, Inc. Human G-Protein chemokine receptor HDGNR10 (CCR5 receptor)
ES2160525A1 (en) * 1998-11-17 2001-11-01 Hoffmann La Roche 4-aroyl-piperidin-ccr-3 receptor antagonists iii
WO2000029377A1 (en) * 1998-11-17 2000-05-25 F. Hoffmann-La Roche Ag 4-aroyl-piperidin-ccr-3 receptor antagonists iii
US6759411B2 (en) 1998-12-18 2004-07-06 Bristol-Myers Squibb Pharma Company Heterocyclic piperidines as modulators of chemokine receptor activity
US6331545B1 (en) 1998-12-18 2001-12-18 Soo S. Ko Heterocycyclic piperidines as modulators of chemokine receptor activity
US7312222B2 (en) 1998-12-18 2007-12-25 Bristol-Myers Squibb Pharma Company Heterocyclic piperidines as modulators of chemokine receptor activity
US6486180B1 (en) 1998-12-18 2002-11-26 Bristol-Myers Squibb Pharma Company N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
US6875776B2 (en) 1998-12-18 2005-04-05 Bristol-Myers Squibb Pharma Company N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
US6492400B1 (en) 1998-12-18 2002-12-10 Bristol-Myers Squibb Pharma Company N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
US6780857B2 (en) 1998-12-18 2004-08-24 Bristol-Myers Squibb Pharma Company N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
WO2000039125A1 (en) * 1998-12-23 2000-07-06 Pfizer Limited Piperidines as ccr5 modulators
US7041667B1 (en) 1998-12-23 2006-05-09 Pfizer, Inc. CCR5 modulators
US7217714B1 (en) 1998-12-23 2007-05-15 Agouron Pharmaceuticals, Inc. CCR5 modulators
WO2000038680A1 (en) * 1998-12-23 2000-07-06 Pfizer Limited Azabicycloalkanes as ccr5 modulators
HRP20010468B1 (en) * 1998-12-23 2012-06-30 Pfizer Inc. Azabicycloalkanes as ccr5 modulators
US6586430B1 (en) 1998-12-23 2003-07-01 Pfizer Inc. CCR5 modulators
AP1697A (en) * 1998-12-23 2006-12-22 Pfizer Azabicycloalkanes as CCR5 modulators.
EP1013276A1 (en) * 1998-12-23 2000-06-28 Pfizer Inc. Aminoazacycloalkanes as CCR5 modulators
WO2000056729A1 (en) * 1999-03-24 2000-09-28 Anormed Inc. Chemokine recpetor binding heterocyclic compounds
US6750348B1 (en) 1999-03-24 2004-06-15 Anormed, Inc. Chemokine receptor binding heterocyclic compounds
US7629337B2 (en) 1999-03-24 2009-12-08 Genzyme Corporation Chemokine receptor binding heterocyclic compounds
US7183273B2 (en) 1999-03-24 2007-02-27 Anormed, Inc. Chemokine receptor binding heterocyclic compounds
EP1180513A1 (en) * 1999-04-28 2002-02-20 Takeda Chemical Industries, Ltd. Cyclic amide compounds, process for the preparation of the same and uses thereof
EP1180513A4 (en) * 1999-04-28 2002-07-10 Takeda Chemical Industries Ltd Cyclic amide compounds, process for the preparation of the same and uses thereof
US6689765B2 (en) 1999-05-04 2004-02-10 Schering Corporation Piperazine derivatives useful as CCR5 antagonists
US8114879B2 (en) 1999-05-04 2012-02-14 Schering Corporation Piperazine derivatives useful as CCR5 antagonists
WO2000066558A1 (en) * 1999-05-04 2000-11-09 Schering Corporation Piperazine derivatives useful as ccr5 antagonists
JP2011219493A (en) * 1999-05-04 2011-11-04 Schering Corp Piperazine derivative useful as ccr5 antagonist
WO2000066559A1 (en) * 1999-05-04 2000-11-09 Schering Corporation Piperidine derivatives useful as ccr5 antagonists
EP1659111A3 (en) * 1999-05-04 2007-05-09 Schering Corporation Piperidine derivatives useful as ccr5 antagonists
EP1659111A2 (en) * 1999-05-04 2006-05-24 Schering Corporation Piperidine derivatives useful as ccr5 antagonists
US6387930B1 (en) 1999-05-04 2002-05-14 Schering Corporation Piperidine derivatives useful as CCR5 antagonists
CZ301161B6 (en) * 1999-05-04 2009-11-18 Schering Corporation Piperidinopiperidyl derivative usable as CCR5 antagonist and pharmaceutical composition in which the derivative is comprised
EP1632479A3 (en) * 1999-05-04 2007-05-09 Schering Corporation Piperazine derivatives useful as ccr5 antagonists
US7384944B2 (en) 1999-05-04 2008-06-10 Schering Corporation Piperazine derivatives useful as CCR5 antagonists
US6391865B1 (en) 1999-05-04 2002-05-21 Schering Corporation Piperazine derivatives useful as CCR5 antagonists
US6602885B2 (en) 1999-05-04 2003-08-05 Schering Corporation Piperidine derivatives useful as CCR5 antagonists
EP1050307A1 (en) * 1999-05-06 2000-11-08 Applied Research Systems ARS Holding N.V. CCR4 antagonists in sepsis
WO2000067791A1 (en) * 1999-05-06 2000-11-16 Glaxo Group Limited Ccr4 antagonists in sepsis
US6358979B1 (en) 1999-06-11 2002-03-19 Merck & Co., Inc. N-cyclopentyl modulators of chemokine receptor activity
US6432981B1 (en) 1999-06-11 2002-08-13 Merck & Co., Inc. Cyclopentyl modulators of chemokine receptor activity
WO2000076972A1 (en) * 1999-06-11 2000-12-21 Merck & Co., Inc. N-cyclopentyl modulators of chemokine receptor activity
JP4688381B2 (en) * 1999-06-11 2011-05-25 メルク・シャープ・エンド・ドーム・コーポレイション N-cyclopentyl modulator of chemokine receptor activity
US6472410B1 (en) 1999-06-11 2002-10-29 Merck & Co., Inc. N-cyclopentyl modulators of chemokine receptor activity
US6593346B2 (en) 1999-06-11 2003-07-15 Merck & Co. Inc. N-cyclopentyl modulators of chemokine receptor activity
AU772321B2 (en) * 1999-06-11 2004-04-22 Merck Sharp & Dohme Corp. N-cyclopentyl modulators of chemokine receptor activity
US6500844B1 (en) 1999-06-11 2002-12-31 Merck & Co., Inc. Cyclopentyl modulators of chemokine receptor activity
US6538002B1 (en) 1999-06-11 2003-03-25 Merck & Co., Inc. Cyclopentyl modulators of chemokine receptor activity
US6506777B1 (en) 1999-06-11 2003-01-14 Merck & Co., Inc. Cyclopentyl modulators of chemokine receptor activity
JP2003502315A (en) * 1999-06-11 2003-01-21 メルク エンド カムパニー インコーポレーテッド N-cyclopentyl modulator of chemokine receptor activity
US6903085B1 (en) 1999-08-24 2005-06-07 Astrazeneca, Ab Substituted piperidine compounds useful as modulators of chemokine receptor activity
WO2001014333A1 (en) * 1999-08-24 2001-03-01 Astrazeneca Uk Limited Substituted piperidine compounds useful as modulators of chemokine receptor activity
US6562978B1 (en) 1999-10-01 2003-05-13 Takeda Chemical Industries, Ltd. Cyclic amine compounds as CCR5 antagonists
US8143261B2 (en) 1999-10-01 2012-03-27 Astrazeneca Ab Thiazolo (4,5-D) pyrimidine compounds
US7348324B2 (en) 1999-10-01 2008-03-25 Takeda Pharmaceutical Company Limited Cyclic amine compounds as CCR5 antagonists
US6787650B1 (en) 1999-10-05 2004-09-07 Takeda Chemical Industries, Ltd. Urea compounds, process for producing the same and use thereof
US6958344B2 (en) 2000-02-11 2005-10-25 Astrazeneca Ab Pyrimidine compounds and their use as modulators of chemokine receptor activity
US6958343B2 (en) 2000-02-11 2005-10-25 Astrazeneca, Ab Thiazolopyrimidines and their use as modulators of chemokine receptor activity
US7579342B2 (en) 2000-02-23 2009-08-25 Astrazeneca Pteridine compounds for the treatment of psoriasis
US6989393B2 (en) 2000-03-10 2006-01-24 Astrazeneca Ab Ccr5 modulators benzimidazoles or benzotriazoles
WO2001066525A1 (en) * 2000-03-10 2001-09-13 Astrazeneca Ab New ccr5 modulators: benzimidazoles or benzotriazoles
US6525070B2 (en) 2000-04-08 2003-02-25 Astrazeneca Ab Bipiperidine derivatives as modulators of CCR3 activity and as H1 antagonists
US7179922B2 (en) 2000-04-08 2007-02-20 Astrazeneca Ab Chemical compounds
US6903115B2 (en) 2000-04-08 2005-06-07 Astrazeneca Ab Bipiperidine compounds
US7238811B2 (en) 2000-04-08 2007-07-03 Astrazeneca Ab Chemical compounds
JP2003533510A (en) * 2000-05-17 2003-11-11 アストラゼネカ・アクチエボラーグ Pharmaceutically active piperidine derivatives, especially as modulators of chemokine receptor activity
WO2001087839A1 (en) * 2000-05-17 2001-11-22 Astrazeneca Ab Pharmaceutically active piperidine derivatives, in particular as modulators of chemokine receptor activity
EA005382B1 (en) * 2000-05-26 2005-02-24 Пфайзер Инк. Tropane derivatives useful in therapy
WO2001090106A3 (en) * 2000-05-26 2002-03-28 Pfizer Ltd Tryasolyl tropane derivatives as ccr5 modulators
CN100355753C (en) * 2000-05-26 2007-12-19 辉瑞大药厂 Tropan derivatives useful in therapy, method for obtaining thereof and intermediate compounds
HRP20020938B1 (en) * 2000-05-26 2011-05-31 Pfizer Inc. Tropane derivatives useful in therapy
WO2001090106A2 (en) * 2000-05-26 2001-11-29 Pfizer Limited Tryasolyl tropane derivatives as ccr5 modulators
EP1526134A2 (en) * 2000-05-26 2005-04-27 Pfizer Limited Triazolyl tropane derivatives as ccr5 modulators
US7368460B2 (en) 2000-05-26 2008-05-06 Pfizer, Inc. Tropane derivatives useful in therapy
US7576097B2 (en) 2000-05-26 2009-08-18 Pfizer, Inc. Tropane derivatives useful in therapy
US6667314B2 (en) 2000-05-26 2003-12-23 Pfizer, Inc. Tropane derivatives useful in therapy
EP1990341A1 (en) * 2000-05-26 2008-11-12 Pfizer Inc. Triazolyl tropane derivatives as CCR5 modulators
EP1526134A3 (en) * 2000-05-26 2006-11-29 Pfizer Limited Triazolyl tropane derivatives as ccr5 modulators
US7348341B2 (en) 2000-05-31 2008-03-25 Astrazeneca Ab Chemical compounds
WO2001092227A1 (en) * 2000-05-31 2001-12-06 Astrazeneca Ab Chemical compounds
US6627629B2 (en) 2000-06-30 2003-09-30 Bristol-Myers Squibb Pharma N-ureidoheterocycloalkyl-piperidines as modulators of chemokine receptor activity
US6949546B2 (en) 2000-06-30 2005-09-27 Bristol-Myers Squibb Pharma Company N-ureidoheterocycloalkyl-piperidines as modulators of chemokine receptor activity
WO2002004420A1 (en) * 2000-07-12 2002-01-17 Novartis Ag Piperidine coumpounds for use as ccr-3 inhibitors
US6670379B2 (en) 2000-07-12 2003-12-30 Novartis Ag Piperidine compounds for use as ccr-3 inhibitors
US7304077B2 (en) 2000-09-04 2007-12-04 Astrazeneca Ab Chemical compounds
US7262204B2 (en) 2000-10-11 2007-08-28 Amgen Inc. Modulation of CCR4 function
US7071193B2 (en) 2000-10-20 2006-07-04 Astrazeneca Ab 7-amino-2-alkylthiopteridin-4-yl-amines for the treatment of chemokine-related diseases
US7217823B2 (en) 2000-12-06 2007-05-15 Sepracor Inc. 4,4-Disubstituted piperidines, and methods of use thereof
US6656953B2 (en) 2000-12-06 2003-12-02 Sepracor Inc. 4,4-Disubstituted piperidines, and methods of use thereof
US6958350B2 (en) 2001-02-19 2005-10-25 Astrazeneca Ab Chemical compounds
US6960602B2 (en) 2001-03-22 2005-11-01 Astrazeneca Ab Piperidine derivatives as modulators of chemokine receptors
US6900211B2 (en) 2001-03-29 2005-05-31 Schering Corporation CCR5 antagonists useful for treating aids
US7008946B2 (en) 2001-03-29 2006-03-07 Schering Corporation CCR5 antagonists useful for treating AIDS
US6720325B2 (en) 2001-03-29 2004-04-13 Schering Corporation CCR5 antagonists useful for treating aids
US7098213B2 (en) 2001-03-29 2006-08-29 Schering Corporation CCR5 antagonists useful for treating AIDS
US7060701B2 (en) 2001-03-29 2006-06-13 Schering Corporation CCR5 antagonists useful for treating AIDS
WO2002079186A2 (en) * 2001-03-30 2002-10-10 F. Hoffmann-La Roche Ag Aminopiperidine derivatives as modulators of chemokine receptor activity
WO2002079186A3 (en) * 2001-03-30 2003-05-01 Hoffmann La Roche Aminopiperidine derivatives as modulators of chemokine receptor activity
US6949643B2 (en) 2001-04-12 2005-09-27 Astrazeneca Ab Thiazolopytimidines and their use as modulators of chemokine receptor activity
US7144903B2 (en) 2001-05-23 2006-12-05 Amgen Inc. CCR4 antagonists
US7307090B2 (en) 2001-07-02 2007-12-11 Astrazeneca Ab Piperidine derivatives useful as modulators of chemokine receptor activity
US7265227B2 (en) 2001-07-23 2007-09-04 Astrazeneca Ab Piperidine derivatives useful as modulators of chemokine receptor activity
US7186718B2 (en) 2001-08-22 2007-03-06 Astrazeneca Ab Piperidinyl-morpholinyl derivatives as modulators of chemokine receptor activity
US7514430B2 (en) 2001-09-18 2009-04-07 Bristol-Myers Squibb Pharma Company Piperizinones as modulators of chemokine receptor activity
US7238691B2 (en) 2001-09-18 2007-07-03 Astrazeneca Ab Piperidine derivatives and their use as modulators of chemokine (especially CCR3) activity
US6974869B2 (en) 2001-09-18 2005-12-13 Bristol-Myers Squibb Pharma Company Piperizinones as modulators of chemokine receptor activity
US7192973B2 (en) 2001-11-15 2007-03-20 Astrazeneca Ab Piperidine derivatives and their use as modulators of chemokine receptor activity (especially CCR5)
US8778967B2 (en) 2001-12-21 2014-07-15 Genzyme Corporation Chemokine receptor binding heterocyclic compounds with enhanced efficacy
US10322111B2 (en) 2001-12-21 2019-06-18 Genzyme Corporation Chemokine receptor binding heterocyclic compounds with enhanced efficacy
US7709500B2 (en) 2002-02-18 2010-05-04 Astrazeneca Ab Chemical compounds
US7288537B2 (en) 2002-03-15 2007-10-30 Novartis Ag Azetidine derivatives as CCR-3 receptor antagonists
KR100706270B1 (en) * 2002-03-15 2007-04-11 노파르티스 아게 Azetidine derivatives as ???-3 receptor antagonists
JP2009102325A (en) * 2002-03-15 2009-05-14 Novartis Ag Azetidine derivative as ccr-3 receptor antagonist
AU2003227072B2 (en) * 2002-03-15 2006-08-10 Novartis Ag Azetidine derivatives as CCR-3 receptor antagonists
WO2003077907A1 (en) * 2002-03-15 2003-09-25 Novartis Ag Azetidine derivatives as ccr-3 receptor antagonists
US7482363B2 (en) 2002-03-19 2009-01-27 Astrazeneca Ab Piperidine derivatives useful as modulators of chemokine receptor activity
US7517989B2 (en) 2002-03-19 2009-04-14 Astrazeneca Ab Piperidine derivatives useful as modulators of chemokine receptor activity
CN100343240C (en) * 2002-03-29 2007-10-17 先灵公司 Stereoselective alkylation of chiral 2-methyl-4-protected piperazines
US6992091B2 (en) 2002-09-12 2006-01-31 Bristol-Myers Squibb Company N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
US7585867B2 (en) 2002-09-20 2009-09-08 Astrazeneca Ab Substituted thiazolo[4,5-d]pyrimidin-2(3H)-one
US6919356B2 (en) 2002-09-26 2005-07-19 Bristol Myers Squibb Company N-substituted heterocyclic amines as modulators of chemokine receptor activity
WO2004054974A3 (en) * 2002-12-13 2004-09-02 Smithkline Beecham Corp Piperidine derivatives as ccr5 antagonists
WO2004054974A2 (en) * 2002-12-13 2004-07-01 Smithkline Beecham Corporation Piperidine derivatives as ccr5 antagonists
US7645771B2 (en) 2002-12-13 2010-01-12 Smithkline Beecham Corp. CCR5 antagonists as therapeutic agents
EP2385040A1 (en) 2003-03-14 2011-11-09 ONO Pharmaceutical Co., Ltd. Nitrogen-containing heterocyclic derivatives and drugs containing the same as the active ingredient
US9206186B2 (en) 2003-03-24 2015-12-08 Axikin Pharmaceuticals, Inc. 2-phenoxy- and 2-phenylsulfonamide derivatives with CCR3 antagonistic activity for the treatment of inflammatory or immunological disorders
US7495013B2 (en) 2003-04-01 2009-02-24 Astrazeneca Ab Chemical compounds
EP2364982A1 (en) 2003-04-18 2011-09-14 ONO Pharmaceutical Co., Ltd. Spiro-piperidine compounds as chemokine receptor antagonists and medicinal use thereof
US7294636B2 (en) 2003-05-09 2007-11-13 Astrazeneca Ab Chemical compounds
US7485732B2 (en) 2003-06-11 2009-02-03 Merck & Co., Inc. Substituted 3-alkyl and 3-alkenyl azetidine derivatives
US7906503B2 (en) 2003-06-11 2011-03-15 Merck Sharp & Dohme Corp. Substituted 3-alkyl and 3-alkenyl azetidine derivatives
US7790883B2 (en) 2003-12-05 2010-09-07 Astrazeneca Ab Process for the preparation of thiazolopyrimidines
WO2005073192A1 (en) * 2004-02-02 2005-08-11 Astrazeneca Ab Novel piperidines as chemokine modulators (ccr)
US7956070B2 (en) 2004-02-02 2011-06-07 Astrazeneca Ab Piperidines as chemokine modulators (CCR)
US7615555B2 (en) 2004-04-23 2009-11-10 Astrazeneca Ab Piperidine derivatives as modulators of chemokine receptor CCR5
EP2546234A1 (en) 2004-09-13 2013-01-16 Ono Pharmaceutical Co., Ltd. Nitrogeneous heterocyclic derivative and medicine containing the same as an active ingredient
WO2006129679A1 (en) 2005-05-31 2006-12-07 Ono Pharmaceutical Co., Ltd. Spiropiperidine compound and medicinal use thereof
US8314127B2 (en) 2005-07-21 2012-11-20 Astrazeneca Ab Piperidine derivatives
WO2007049771A1 (en) 2005-10-28 2007-05-03 Ono Pharmaceutical Co., Ltd. Compound containing basic group and use thereof
EP2657235A1 (en) 2005-10-28 2013-10-30 Ono Pharmaceutical Co., Ltd. Compound containing basic group and use thereof
WO2007058322A1 (en) 2005-11-18 2007-05-24 Ono Pharmaceutical Co., Ltd. Basic group-containing compound and use thereof
US7906652B2 (en) 2005-11-28 2011-03-15 Merck Sharp & Dohme Corp. Heterocycle-substituted 3-alkyl azetidine derivatives
WO2007105637A1 (en) 2006-03-10 2007-09-20 Ono Pharmaceutical Co., Ltd. Nitrogenated heterocyclic derivative, and pharmaceutical agent comprising the derivative as active ingredient
WO2007132846A1 (en) 2006-05-16 2007-11-22 Ono Pharmaceutical Co., Ltd. Compound having acidic group which may be protected, and use thereof
WO2008016006A1 (en) 2006-07-31 2008-02-07 Ono Pharmaceutical Co., Ltd. Compound having cyclic group bound thereto through spiro binding and use thereof
US10117931B2 (en) 2009-04-28 2018-11-06 Kameran Lashkari Methods for treatment of age-related macular degeneration
WO2011011652A1 (en) 2009-07-24 2011-01-27 Glaxosmithkline Llc Therapeutic compounds
US8592395B2 (en) 2009-07-24 2013-11-26 Glaxosmithkline Llc Therapeutic compounds
WO2013024022A1 (en) 2011-08-12 2013-02-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for treatment of pulmonary hypertension
US11498896B2 (en) 2014-12-19 2022-11-15 The Broad Institute, Inc. Dopamine D2 receptor ligands
US10633336B2 (en) 2014-12-19 2020-04-28 The Broad Institute, Inc. Dopamine D2 receptor ligands
US10752588B2 (en) 2014-12-19 2020-08-25 The Broad Institute, Inc. Dopamine D2 receptor ligands
US11357742B2 (en) 2015-12-14 2022-06-14 X4 Pharmaceuticals, Inc. Methods for treating cancer
US10953003B2 (en) 2015-12-14 2021-03-23 X4 Pharmaceuticals, Inc. Methods for treating cancer
US11219621B2 (en) 2015-12-22 2022-01-11 X4 Pharmaceuticals, Inc. Methods for treating immunodeficiency disease
US10610527B2 (en) 2015-12-22 2020-04-07 X4 Pharmaceuticals, Inc. Methods for treating immunodeficiency disease
US11337969B2 (en) 2016-04-08 2022-05-24 X4 Pharmaceuticals, Inc. Methods for treating cancer
US10988465B2 (en) 2016-06-21 2021-04-27 X4 Pharmaceuticals, Inc. CXCR4 inhibitors and uses thereof
US11306088B2 (en) 2016-06-21 2022-04-19 X4 Pharmaceuticals, Inc. CXCR4 inhibitors and uses thereof
US11332470B2 (en) 2016-06-21 2022-05-17 X4 Pharmaceuticals, Inc. CXCR4 inhibitors and uses thereof
US10759796B2 (en) 2016-06-21 2020-09-01 X4 Pharmaceuticals, Inc. CXCR4 inhibitors and uses thereof
US11780837B2 (en) 2016-06-21 2023-10-10 X4 Pharmaceuticals, Inc. CXCR4 inhibitors and uses thereof
US11045461B2 (en) 2018-08-31 2021-06-29 X4 Pharmaceuticals, Inc. Compositions of CXCR4 inhibitors and methods of preparation and use
US10548889B1 (en) 2018-08-31 2020-02-04 X4 Pharmaceuticals, Inc. Compositions of CXCR4 inhibitors and methods of preparation and use
US11672793B2 (en) 2018-08-31 2023-06-13 X4 Pharmaceuticals, Inc. Compositions of CXCR4 inhibitors and methods of preparation and use
CN110483490A (en) * 2019-08-29 2019-11-22 苏州汉德创宏生化科技有限公司 A kind of synthetic method of 3- (piperidin-4-yl) oxazolidine -2- ketone and its salt

Also Published As

Publication number Publication date
CA2296314A1 (en) 1999-02-04
AU8576098A (en) 1999-02-16
EP1003514A1 (en) 2000-05-31
JP2002510327A (en) 2002-04-02
EP1003514A4 (en) 2000-10-11

Similar Documents

Publication Publication Date Title
US6136827A (en) Cyclic amine modulations of chemokine receptor activity
EP1003514A1 (en) Cyclic amine modulators of chemokine receptor activity
US6166037A (en) Pyrrolidine and piperidine modulators of chemokine receptor activity
US6140349A (en) Cyclic amine modulators of chemokine receptor activity
EP1052992A1 (en) Cyclic amine modulators of chemokine receptor activity
US6013644A (en) Spiro-substituted azacycles as modulators of chemokine receptor activity
US6303593B1 (en) 3-thienyl and 3-furanyl pyrrolidine modulators of chemokine receptor activity
EP1009405A1 (en) Pyrrolidine and piperidine modulators of chemokine receptor activity
US5962462A (en) Spiro-substituted azacycles as modulators of chemokine receptor activity
US6362201B1 (en) 3-cyclopropyl and 3-cyclobutyl pyrrolidine modulators of chemokine receptor activity
US6124319A (en) 3,3-disubstituted piperidines as modulators of chemokine receptor activity
US6489354B1 (en) 3-alkyl substituted pyrrolidine modulators of chemokine receptor activity
WO1998025604A1 (en) Spiro-substituted azacycles as modulators of chemokine receptor activity
US6432981B1 (en) Cyclopentyl modulators of chemokine receptor activity
WO1998025617A1 (en) Substituted aryl piperazines as modulators of chemokine receptor activity
WO1998025605A1 (en) Spiro-substituted azacycles as modulators of chemokine receptor activity
CA2278309A1 (en) 3,3-disubstituted piperidines as modulators of chemokine receptor activity
US6372764B1 (en) Pyrrolidine modulators of chemokine receptor activity
US6511994B2 (en) Modulators of CCR5 chemokine receptor activity
US6506777B1 (en) Cyclopentyl modulators of chemokine receptor activity
US6500844B1 (en) Cyclopentyl modulators of chemokine receptor activity
US6472410B1 (en) N-cyclopentyl modulators of chemokine receptor activity
US6538002B1 (en) Cyclopentyl modulators of chemokine receptor activity
EP1192133B1 (en) N-cyclopentyl modulators of chemokine receptor activity
US6455548B2 (en) 4-alkyl piperidinyl pyrrolidine modulators of chemokine receptor activity

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AL AM AU AZ BA BB BG BR BY CA CN CU CZ EE GE HR HU ID IL IS JP KG KR KZ LC LK LR LT LV MD MG MK MN MX NO NZ PL RO RU SG SI SK SL TJ TM TR TT UA US UZ VN YU

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 1998936920

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2296314

Country of ref document: CA

Ref country code: CA

Ref document number: 2296314

Kind code of ref document: A

Format of ref document f/p: F

NENP Non-entry into the national phase

Ref country code: KR

WWE Wipo information: entry into national phase

Ref document number: 85760/98

Country of ref document: AU

WWP Wipo information: published in national office

Ref document number: 1998936920

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1998936920

Country of ref document: EP